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The role of CD38 expression on NAD levels and cell physiology in a leukaemia model 
Zainab Nejim Al-Abady 
Abstract 
CD38 is a transmembrane glycoprotein with both ADP-ribosyl cyclase/cyclic ADP-ribose 
hydrolase activities; it is also known as a cell surface receptor. CD38 utilizes NAD(P) as a 
substrate to produce the second messengers, Nicotinic acid adenine dinucleotide phosphate 
(NAADP) and Cyclic adenosine diphosphate ribose (cADPR). CD38 has been implicated in 
several diseases. For instance, in chronic lymphocytic leukemia (CLL), it is known as a poor 
prognostic marker and as a disease modifier. Also, abundant data are available on the receptor 
functions of CD38 in CLL. However, the aim of the work described in this thesis was to 
investigate the enzymatic functions of CD38 in leukemia. The work also addresses the question 
of why CD38+ subset leukemia patients are characterised by poor outcome. 
It has been postulated that CD38 is the major NADase in cells, and that knocking it down 
increases NAD levels significantly. Thus, it was hypothesized that NAD levels might be 
depleted and result in detrimental consequences on cell physiology when CD38 is significantly 
expressed. Also, it was suggested that a similar linkage might be also present in leukemia, 
contributing to poor outcome. To test this hypothesis, a human leukaemia cell line (HL60) was 
used as a convenient model that differentiates into CD38+ cells when stimulated using all-trans 
retinoic acid (ATRA). It is shown that CD38 is expressed extracellularly and intracellularly in 
the differentiated cells, as evaluated by qPCR, FACS, Western blotting and the NGD 
cyclization assay. However, one of the major consequences of the early expression of CD38 (at 
3 h) was a substantial depletion of intracellular NAD+ levels that was apparent by 4 h after 
treatment with ATRA. These novel data suggest a major role for CD38 as a main regulator of 
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NAD during the differentiation. The main role of CD38 in degradation of NAD was confirmed 
by using a CD38 inhibitor (kuromanin). Interestingly, the drop in NAD+ levels during the 
differentiation was reversed after treatment with kuromanin. Furthermore, the CD38 
homologue, CD157, and other NAD-consuming enzymes (PARP and SIRT) were all 
investigated, and it was found that there are no substantial roles of all these enzymes on the 
NAD+ degradation during the differentiation. In contrast, qPCR results for NAD-biosynthesis 
enzymes during the differentiation process showed a significant rise in indolamine 2,3-
dioxygenase (IDO) mRNA expression, with lesser increases in nicotinamide nucleotide 
adenyltransferase (NMNAT) and nicotinamide phosphoribosyl transferase (NAMPT) mRNA 
levels. 
The consequences of low NAD levels on cell metabolism were also assessed; the results show a 
reduction in lactate production and glutathione levels with an elevation of TBARS levels. 
However, the NAD+:NADH ratio remained relatively constant. Moreover, the effects of low 
NAD levels on DNA repair and cell death were also investigated in response to DNA damage 
caused by UVB. Preliminary findings show that, in CD38+ cells, there is a resistance to 
apoptotic cell death. Additionally, CD38 expression was also investigated in leukaemia cells, 
and was found to be regulated in response to hypoxic environment, or the change in NAD+ 
levels following FK866, kuromanin and NAD+ application. Altogether, these studies raise the 
possibility that the impact of CD38 enzymatic function on NAD levels and the negative 
consequences on NAD(P)-dependent processes might play an important role in the poor 
prognosis in CD38+ leukemia patients. 
  
vi 
 
Table of Contents 
Copyright Statement ........................................................................................................................... ii 
Dedication .......................................................................................................................................... iii 
Abstract .............................................................................................................................................. iv 
List of Figures .................................................................................................................................. xiii 
List of Tables .................................................................................................................................. xxii 
Abbreviations ................................................................................................................................. xxiii 
Author’s Declaration ...................................................................................................................... xxxi 
Publications .................................................................................................................................... xxxi 
Platform presentations ................................................................................................................... xxxi 
Poster presentations ....................................................................................................................... xxxi 
Workshop ...................................................................................................................................... xxxii 
Acknowledgements ...................................................................................................................... xxxiii 
CHAPTER 1 ........................................................................................................................................1 
GENERAL INTRODUCTION ............................................................................................................1 
1. GENERAL INTRODUCTION ........................................................................................................2 
1.1 Nicotinamide adenine dinucleotide (NAD) ...............................................................................2 
1.2 Members of the ADP-ribosyl cyclase family .............................................................................7 
1.3 Distribution of CD38 .................................................................................................................8 
vii 
 
1.4 CD38 (the type-II & -III glycoprotein) and cyclase crystal structures ....................................10 
1.5 CD38 as a cell surface receptor................................................................................................14 
1.6 CD38 as active enzyme ............................................................................................................17 
1.7 The interdependence between CD38 enzymatic and receptor functions .................................21 
1.8 Visualization of the cyclization reaction (enzyme-NAD interaction) ......................................22 
1.9 The Second Messengers (cADPR and NAADP) .....................................................................24 
1.10 Role of CD38/second messengers in pathophysiological conditions.....................................26 
1.10.1 CD38 and obesity ............................................................................................................26 
1.10.2 CD38 and diabetes ..........................................................................................................29 
1.10.3 CD38 and Chronic Lymphocyte Leukaemia (CLL) .......................................................31 
1.11 The HL60 cell line and induction of differentiation ..............................................................42 
1.12 CD38 and HL60 differentiation .............................................................................................44 
1.13 The strengths of the HL60 model ..........................................................................................45 
1.14 Objectives of the study ...........................................................................................................46 
CHAPTER 2 ......................................................................................................................................48 
GENERAL MATERIALS & METHODS .........................................................................................48 
2. Materials and Methods ...................................................................................................................49 
2.1 Materials ..................................................................................................................................49 
2.2 Culture of HL60 and RAJI cells ..............................................................................................49 
viii 
 
2.3 HL60 and all-trans retinoic acid (cell differentiation) .............................................................50 
2.4 NBT differentiation assay ........................................................................................................51 
2.5 Assessment of viability ............................................................................................................51 
2.6 Cell proliferation assay (MTT) ................................................................................................51 
2.7 mRNA isolation and Quantitative Real-Time PCR .................................................................52 
2.8 Assessment of CD38 expression during HL60 differentiation by western blotting ................55 
2.8.1 Plasma membrane and whole cell lysate preparation........................................................55 
2.8.2 Preparation of Nuclear Extract ..........................................................................................55 
2.8.3 Determination of protein concentration ............................................................................56 
2.8.4 Western blot assessment of protein expression .................................................................56 
2.9 NAD
+
 assays ............................................................................................................................58 
2.9.1 Glucose 6-phosphate dehydrogenase (G6PDH)/diaphorase cycling assay .......................58 
2.9.2 Alcohol dehydrogenase cycling assays .............................................................................58 
CHAPTER 3 ......................................................................................................................................65 
THE EFFECT OF CD38 EXPRESSION ON NAD LEVELS IN HUMAN LEUKEMIA CELLS ..65 
3.1 Introduction ..................................................................................................................................66 
3.2 Material and methods ...................................................................................................................68 
3.2.1 Materials ...............................................................................................................................68 
3.2.2 Culture of the MCF-7 cell line ..............................................................................................68 
ix 
 
3.2.3 Measurement of the cyclase activity of CD38 ......................................................................68 
3.2.4 Detection of surface and intracellular CD38 during HL60 differentiation by fluorescence-
activated cell sorter (FACS) ...........................................................................................................69 
3.2.4.1 Flow cytometry for extracellular staining ......................................................................69 
3.2.4.2 Flow cytometry for intracellular staining .......................................................................71 
3.2.5 Co-culture of differentiating cells with MCF-7 cells and measurement of cell proliferation 
by MTT assay ................................................................................................................................71 
3.2.6 Determination of intracellular NAD levels in cells treated with CD38, PARP and Sirtuin 
inhibitors ........................................................................................................................................72 
3.2.7 Statistical analysis .................................................................................................................72 
3.3 Results ..........................................................................................................................................73 
3.3.1 ATRA-induced HL60 mature granulocyte cell differentiation and inhibited cell proliferation
 .......................................................................................................................................................73 
3.3.2 ATRA-induced HL60 differentiation is accompanied by CD38 induction ..........................77 
3.3.2.1 Measuement of CD38 mRNA expression by qPCR ......................................................77 
3.3.2.2 Surface and whole cell lysate CD38 cyclase activity during HL60 differentiation .......79 
3.3.2.3 Analysis of intracellular and extracellular CD38 by FACS ...........................................82 
3.3.2.4 CD38 Western blots for whole cell lysate and nuclear extract ......................................87 
3.3.3 Effect of CD38 expression on NAD levels during HL60 differentiation .............................92 
3.3.4 Kuromanin inhibited NAD-cyclization activity of CD38 and elevated NAD levels, but 
PARP and sirtuin inhibitors had no effect on NAD levels during the differentiation ...................97 
x 
 
3.3.5 Evaluation of the NAD biosynthesis enzymes during ATRA-induced HL60 differentiation
 .....................................................................................................................................................108 
3.3.6 CD38 and cell proliferation.................................................................................................112 
3.4 Discussion ..................................................................................................................................114 
CHAPTER 4 ....................................................................................................................................123 
EFFECT OF LOWERED NAD LEVELS ON CELL PHYSIOLOGY ...........................................123 
4.1 Introduction ................................................................................................................................124 
4.2 Materials and methods ...............................................................................................................126 
4.2.1 Materials .............................................................................................................................126 
4.2.2 Measurement of the NAD
+
: NADH ratio ............................................................................126 
4.2.3 Determination of total glutathione by the enzymatic recycling assay ................................126 
4.2.4 Thiobarbituric Acid Reactive Substance assay ...................................................................128 
4.2.5 Lactate assay .......................................................................................................................130 
4.2.6 Glucose challenge ...............................................................................................................131 
4.2.7 Statistical analysis ...............................................................................................................131 
4.3 Results ........................................................................................................................................132 
4.3.1 NAD
+
:NADH ratio during HL60 differentiation ................................................................132 
4.3.2 Effect of low intracellular NAD levels on lactate levels before and after glucose application 
and during cell differentiation ......................................................................................................134 
4.3.3 TBARS production during ATRA-induced HL60 differentiation ......................................138 
xi 
 
4.3.4 Total glutathione levels .......................................................................................................140 
4.4 Discussion ..................................................................................................................................142 
CHAPTER 5 ....................................................................................................................................150 
REGULATION OF CD38 EXPRESSION ......................................................................................150 
5.1 Introduction ................................................................................................................................151 
5.2 Materials and methods ...............................................................................................................153 
5.2.1 Materials .............................................................................................................................153 
5.2.2 Evaluation of CD38 expression in differentiating cells after treatment with kuromanin ...153 
5.2.3 Determination of the effects of addition of FK866 or NAD on intracellular NAD levels, cell 
proliferation and CD38 expression in cell lines ...........................................................................153 
5.2.4 Oxygen exposure protocol ..................................................................................................154 
5.2.5 Statistical analysis ...............................................................................................................155 
5.3 Results ........................................................................................................................................156 
5.3.1 Effect of elevated NAD
+
 levels on CD38 expression after kuromanin treatment ...............156 
5.3.2 Manipulation of intracellular NAD
+
 levels by NAD application or using FK866 ..............158 
5.3.4 Effects of hypoxia and hyperoxia conditions on CD38 expression in leukaemia cell lines166 
5.4 Discussion ..................................................................................................................................173 
CHAPTER 6 ....................................................................................................................................181 
EFFECT OF LOW NAD LEVELS ON THE DNA DAMAGE AND CELL DEATH ...................181 
xii 
 
6.1 Introduction ................................................................................................................................182 
6.2 Material and methods .................................................................................................................184 
6.2.1 Materials .............................................................................................................................184 
6.2.2 Comet assay and quantification of DNA damage ...............................................................184 
6.2.3 Validation of the comet assay under in vitro conditions using hydrogen peroxide ............186 
6.2.4 UVB radiation of differentiated cells and induction of apoptosis .......................................186 
6.2.5 Halo-Comet assay ...............................................................................................................187 
6.2.6 Wright-Giemsa staining method .........................................................................................187 
6.2.7 Statistical analysis ...............................................................................................................188 
6.3 Results ........................................................................................................................................189 
6.3.1 Effect of cellular NAD levels on UVB-induce DNA damage ............................................189 
6.3.2 Effect of UVB on PAR production in CD38
+
/
-
 cells ...........................................................198 
6.3.3 Effect of UVB-induced DNA damage on apoptotic cell death in CD38
+ 
and CD38
- 
cells .200 
6.4 Discussion ..................................................................................................................................204 
CHAPTER 7 ....................................................................................................................................210 
GENERAL DISCUSSION ..............................................................................................................210 
7.1 Discussion ..................................................................................................................................211 
7.2 Future studies .............................................................................................................................217 
REFERENCES ................................................................................................................................222 
xiii 
 
Appendices .......................................................................................................................................252 
 
List of Figures 
Chapter 1 
Figure 1.1 The structures of the nicotinamide nucleotides, NAD, NADP and NADH........................3 
Figure 1.2 NAD metabolism represented by the biosynthesis pathways (the de novo pathway and 
salvage pathway), in addition to a network of NAD-consuming enzymes included (CD38, PARP, 
and sirtuins). NAD is shuttling between its oxidized form NAD
+
 and the reduced form NADH. The 
electrons bound by NADH can be transferred to the electron transport chain (ETC) of mitochondria. 
The reaction catalyzed by NAD kinase (NADK) links NAD to the redox pair of NADP
+
 and 
NADPH (adapted from Wilhelm and Hirrlinger, 2012). .....................................................................6 
Figure 1.3 Structures of ADP-ribosyl cyclase and CD38. (A) The Aplysia ADP-ribosyl cyclase is a 
homo-dimer and the surfaces of the two monomers are coloured differently. Transparent grey 
revealing the secondary structures underneath. The colour code is: helix-red, β-sheet-yellow, coil-
grey. The NAD molecules bound at the active sites are rendered using sticks. Colour code is: 
nitrogen-blue, oxygen-red, phosphorus-yellow, carbon-green. The letter C indicates the carboxyl 
end (adapted from Lee, 2012). (B) CD38 structure shows its membrane interaction. (C) The overall 
structure of human CD38. The N-terminal structures (in the red circle) and the C-terminal structure 
circled in blue (adapted from Liu et al., 2005). .................................................................................11 
Figure 1.4 Schematic representation of different types of integral membrane proteins as follows (a) 
type-1 transmembrane, (b) type-2 transmembrane, (c) multipass transmembrane, (d) lipid-chain 
anchored membrane, and (e) GPI-anchored membrane (modified from Cai and Chou, 2006). ........12 
Figure 1.5 Simplified diagram representing monomeric, dimeric and oligomeric forms of CD38. 
Cleavage of the surface membrane form gives rise to p39 (soluble), its dimeric form is p78 and 
p190 represents a tetramer of the membrane form (modified from Ferrero and Malavasi, 1999). ....13 
Figure 1.6 Schematic representation of CD38 (A) cyclase and hydrolase reactions by using β-NAD 
as substrate (Modified from Zhang et al., 2011). (B) Base exchange reaction in the presence of β-
NAD with the pH optimum of 4 (modified from Yamasaki et al., 2005). .........................................20 
Figure 1.7 Visualization of the ara-2’FNAD cyclization reaction catalyzed by the cyclase. Adapted 
from Lee (2012). ................................................................................................................................24 
xiv 
 
Figure 1.8 The crucial role of CD38 deficiency in preventing the development of obesity through 
activation of SIRT/PGC1α following NAD elevation. ......................................................................28 
Figure 1.9 Simple diagram showing the role of CD38 activities and its products in protection 
against diabetes. .................................................................................................................................31 
Figure 1.10 Hypothetical model of the interactions between CLL cells and distinct environments, 
suggesting a role for CD38 in the pathogenesis of CLL.  CD38
+
 CLL cells (grey) are more sensitive 
to CXCL12 signals, with a higher propensity to home to lymphoid tissues than the CD38
-
 (orange). 
CLL lymphocytes in LN (PCs) come into contact with nurse-like (NLC) cells, follicular dendritic 
(FDC) cells, stromal cells, endothelial cells (EC), mesenchymal, and T cells. The presence of these 
environments, in addition to the cytokines and toll-like receptors (TLR) lead to CLL cell 
proliferation and disease progression; these events are more apparent in the CD38
+
 subsets (adapted 
from Malavasi et al., 2011). ...............................................................................................................35 
Figure 1.11 Potential applications of CD38 as a therapeutic target (adapted from Deaglio et al., 
2008). .................................................................................................................................................40 
Chapter 2 
Figure 2.1 Diagram illustrating HL60 differentiation by ATRA over 5 days. ...................................50 
Figure 2.2  The principle of enzymatic cycling reaction for the colorimetric determination of NAD
+
.
 ...........................................................................................................................................................59 
Figure 2.3 A simple diagram for nucleotides extraction and assay illustrating NAD
+
  extraction by 
HCl and NADH extraction by NaOH. ...............................................................................................60 
Figure 2. 4 (A) The NAD cycling assay. NAD (5-60 µM) extracted with HCl. The mixture was 
equilibrated in the dark at 25ºC for up to 30 min (r=0.99). (B) The NAD(H) cycling assay. NADH 
(5-30 µM) extracted with NaOH.  The mixture was equilibrated in the dark at 25ºC for up to 30 min 
(r=0.99). Change in absorbance is recorded at 565 nm. Data are means ± SEM, n=3. .....................62 
Figure 2. 5 Intracellular NAD levels determined in HL60 cells with cell density (0.24-0.98 × 10
6 
cells ml
-1
) and incubation time 30 min. Data are means ± SEM, n = 3 (7 measurements). ...............64 
 
 
xv 
 
Chapter 3 
Figure 3.1 cells were gated and cell debris was gated out based on forward scatter (FSC) and side 
scatter (SSC) profiles as shown in the SSC-FSC dot plot, to analyse data by using WinMDI 2.8 
software and to calculate mean fluorescence index. ..........................................................................70 
Figure 3.2 The NBT reduction ability of ATRA treated HL60 cells for 5 days comparing to 
untreated HL60 cells (as control). Data are means ± SEM, n = 3 (3-5 measurements per replicate). * 
denotes significant difference from the control, P < 0.05. .................................................................75 
Figure 3.3 Morphology of undifferentiated (control) and differentiated HL60 cells. Differentiation 
was induced using ATRA for 5 days. Cytospin slide preparations of cell culture suspensions were 
stained with Wright-Giemsa stain and examined using light microscopy (×1000 magnification). 
Scale bar: 30 µm. ...............................................................................................................................75 
Figure 3.4 Effect of ATRA-induced HL60 differentiation over 5 days on cell vitality (MTT assay) 
as compared to the untreated control (HL60). Data are means ± SEM, n = 3 (3 measurements per 
replicate). * denotes significant difference from the control (HL60), P < 0.05. ................................76 
Figure 3.5 Time-course analysis of CD38 mRNA induction in HL60 cells treated with ATRA over 
5 days differentiation showing the increase in CD38 expression, but not in CD157 expression 
comparing to untreated control (HL60). Data are means ± SEM, n = 3 (4-7 measurements per 
replicate). * denotes a significant difference from the control (HL60), P < 0.05. .............................78 
Figure 3.6 Time courses of measuring of CD38 cyclase activity in whole cell lysate (solid line) and 
in live cells (dashed line) in HL60 cells during differentiation using ATRA over 24 hours 
comparing to untreated control (100%). Data are means ± SEM, n = 3 (1 measurement per 
replicate). * denotes significant difference from the untreated control (HL60), P < 0.05. ................80 
Figure 3.7 Time course of CD38 cyclase activity in HL60 cells treated with ATRA over 5 days 
comparing to each untreated control (HL60). Data are means ± SEM, n = 3 (3 measurements per 
replicate). * denotes significant difference from the appropriate control (P < 0.05). ........................81 
Figure 3.8 Expression of CD38 in HL60 cells treated with ATRA, analyzed by FACS after staining 
with CD38 antibody (HIT2-PE) and expressed as mean fluorescence index (MFI) comparing to 
untreated HL60 cells (as control). (A) Extracellular CD38 expression from 10-120 hours of 
differentiation and (B) Total CD38 expression at 10, 18, and 24 h of differentiation. Data are means 
± SEM, n = 3 (1 measurement per replicate). * denotes significant difference from the control (P < 
0.05). ..................................................................................................................................................84 
xvi 
 
Figure 3.9 Expression of extracellular CD38 (red histograms) versus intracellular CD38 (blue 
histograms) in RAJI cells (positive control), and undifferentiated HL60 cells (negative control), in 
comparison with the Isotype control (IgG)-stained cells shown in the black histograms. Cells were 
stained with PE-labeled anti-CD38 mAb and analyzed by FACS. Data are representative of three 
independent experiments. ..................................................................................................................85 
Figure 3.10  Expression of extracellular CD38 (red Histogram) versus intracellular CD38 (blue 
Histogram) in the time course of ATRA-induced HL60 differentiation, in comparison with the 
Isotype control (IgG) stained cells shown in the black histograms. Cells were stained with PE-
labelled anti-CD38 mAb and analyzed by FACS. Data are representative of three independent 
experiments. .......................................................................................................................................86 
Figure 3.11 Time-course of ATRA treatment of HL60 cells over 5 days showing (A) Western blot 
of differentiating cells for CD38 showing the 45 kDa band corresponding to membrane CD38 under 
reducing, denaturing conditions and 12% SDS-PAGE. 100 µg of protein/ well were used each 
experiment with 1:500 primary antibody dilution (data represent 1 of the 3 separated experiments) 
(B) The luminescence intensity of CD38 single band 45 kDa. Data are means ± SEM, n = 3 (1 
measurements per replicate). * denotes significant difference from the untreated control (HL60), P 
< 0.05. ................................................................................................................................................88 
Figure 3.12 Time course of ATRA treatment of HL60 cells over 3 days showing (A) western 
blotting of nuclear CD38 under reducing and denaturing conditions. A 12% SDS-PAGE gel with 60 
µg of protein/well was used in each experiment (gel shown representative of 3 experiments) (B) 
CD38 expression in the nuclear fraction was measured as the rate of cGDPR production from NGD. 
Data are means ± SEM, n = 3 (1 measurements per replicate). No significant differences in activity 
during differentiation and comparing to untreated control (HL60) were found (P ˃ 0.05). ..............90 
Figure 3.13 The effect of different ATRA concentrations (0, 10 nM and 1 µM) on the NAD assay, 
at a range of NAD concentrations (0.97, 1.95, 19.5 and 195 µM). Data are means ± SEM, n = 3 (3 
measurements per replicate). * denotes significant difference from the appropriate untreated control 
(P < 0.05). ..........................................................................................................................................93 
Figure 3.14 The decline in intracellular NAD levels during HL60 differentiation estimated over 5 
days of differentiation and compared to untreated control (HL60). Data are means ± SEM, n = 3 (3 - 
7 measurements per replicate). * denotes significant difference from the control (100% HL60), P < 
0.05. ...................................................................................................................................................95 
Figure 3.15 The decline in intracellular NAD levels (solid line), concomitant with CD38 mRNA 
induction (dashed line) during HL60 differentiation estimated over 5 days of differentiation and 
compared to untreated control (HL60). Data are means ± SEM, n = 3 (3 - 7 measurements per 
replicate). ...........................................................................................................................................96 
xvii 
 
Figure 3.16 (A) CD38 cyclase activity in HL60 and RAJI cells as expressed as initial rate. (B) 
Intracellular NAD levels in HL60 and RAJI cells as expressed as pmol/10
6
 cells. Data are means ± 
SEM, n = 2-3 (3-5 measurements per replicate). * denotes significant difference between group 
(Student’s t test, P < 0.05). .................................................................................................................98 
Figure 3.17 Intracellular NAD levels in RAJI and HL60 cells treated with kuromanin (8 µM) for up 
to 2 h comparing to appropriate untreated control (RAJI or HL60 cells). Data are means ± SEM, n = 
3 (4-5 measurements per replicate), P ˃ 0.05. .................................................................................100 
Figure 3.18 Effect of treatment with kuromanin up to 30 µM on (A) intracellular NAD levels in 
RAJI cells over 6 h comparing to untreated control (100% RAJI cells), and (B) the vitality (MTT 
assay) of RAJI cells when incubated for up to 48 h with kuromanin comparing to untreated control 
(100% RAJI cells). Data are means ± SEM, n = 3 (3-6 measurements per replicate).* denotes 
significant difference from the untreated RAJI cells (P < 0.05). .....................................................101 
Figure 3.19 The effect of treatment with kuromanin up to 30 µM on NBT reduction by ATRA 
treated HL60 cells for 4 days comparing to untreated HL60 cells (control). Data are means ± SEM, 
n = 3 (4-6 measurements per replicate). * denotes significant difference from the control (P < 0.05).
 .........................................................................................................................................................103 
Figure 3.20 Effect of treatment with 10 µM kuromanin on intracellular NAD levels of differentiated 
cell up to 6 h comparing to differentiated cells without kuromanin treatment (as control). Data are 
means ± SEM, n = 3 (4 measurements per replicate). * denotes significant difference from the 
control (differentiated cells), P < 0.05. ............................................................................................104 
Figure 3.21 Intracellular NAD levels were investigated in differentiated cells for 3 days with ATRA 
after treatment with (A) PARP inhibitor (4-amino-1,8-naphthalimide) up to 30 µM or (B)  sirtuin 
inhibitor (sirtinol) up to 30 µM. Data are means ± SEM, n = 3 (3 measurements per replicate). No 
significant differences in NAD levels were found between differentiated cells with or without 
inhibitor, P ˃ 0.05. ...........................................................................................................................107 
Figure 3.22 Time course of ATRA-induced differentiation of HL60 cells over 5 days showing the 
increase in IDO expression comparing to untreated HL60 cells (as control). Data are means ± SEM, 
n = 3 (3-6 measurements per replicate). * denotes significant difference from the control (P < 0.05).
 .........................................................................................................................................................110 
Figure 3.23 Time courses of ATRA-induced differentiation of HL60 cells over 5 days showing (A) 
NMNAT expression (B) NAMPT expression and were compared to untreated HL60 cells (as 
control). Data are means ± SEM, n = 3 (3-4 measurements per replicate). * denotes significant 
difference from the control (P < 0.05). ............................................................................................111 
xviii 
 
Figure 3.24 The effects of 1 day culture of differentiated cells (3 days) with MCF-7 cells on cell 
proliferation (MTT assay) as compared to the differentiating cells for 3 days (as control). Data are 
means ± SEM, n = 3 (8 measurements per replicate). * denotes significant difference from the 
control (P < 0.05). ............................................................................................................................113 
 Chapter 4 
Figure 4.1 Principle of the total glutathione assay. GSH produce GSSTNB in the presence of 
DTNB. GSSG or the mix (GSSTNB) converted again to GSH in the presence of glutathione 
reductase (GR) and NADPH. ...........................................................................................................127 
Figure 4.2 Standard curve of (0-100µM) 1,1,3,3-tetraethoxypropane, was used to estimate of 
TBARS levels for each sample. Change in absorbance is recorded at 532 nm. ..............................129 
Figure 4.3 Simple diagram showing lactate production from glycolysis as product of lactic 
fermentation. ....................................................................................................................................130 
Figure 4.4 Time course of ATRA induced differentiation of HL60 cells over 5 days comparing to 
HL60 (as control), showing (A) intracellular NAD levels (B) intracellular NADH levels (C) the 
NAD
+
: NADH ratio. Data are means ± SEM, n = 2 (3-6 measurements per replicate). ..................133 
Figure 4.5 Lactate production expressed as nmol/10
6 
cells during the time course of ATRA-induced 
differentiation of HL60 cells over 5 days compared to untreated HL60 cells (control). Data are 
means ± SEM, n = 4 (3 measurements per replicate). * denotes a significant difference from the 
appropriate control, P < 0.05. ...........................................................................................................135 
Figure 4.6 Lactate production expressed as nmol/10
6 
cells after incubation of HL60 cells or 1 day-
differentiated cells (either treated or not treated with 100 µM NAD) for 1 h with 25 mM glucose 
and compared to appropriate untreated control. Data are means ± SEM, n = 3 (5 measurements per 
replicate), p˃ 0.05. ...........................................................................................................................137 
Figure 4.7 Lipid peroxidation as evaluated by TBARS levels during the time course of HL60 
differentiation over 5 days comparing to untreated HL60 cells (control). Data are means ± SEM, n = 
3 (3 measurements per replicate). * denotes a significant difference from each appropriate control, P 
< 0.05. ..............................................................................................................................................139 
Figure 4.8 Time course of ATRA-induced HL60 differentiation over 5 days showing the increase in 
total glutathione levels after day 1 of differentiation but not after 3 and 5 days comparing to 
untreated HL60 cells (control). Data are means ± SEM, n = 4 (4 measurements per replicate). * 
denotes a significant difference from the control (HL60), P < 0.05. ...............................................141 
xix 
 
Figure 4.9 Simple diagram representing generation of NADP
+
 from NAD and NADPH from 
NADP
+
. Adapted from Pollak et al. (2007). ....................................................................................147 
Figure 4.10 The consequences of lowered intracellular NAD levels on cell metabolism. This 
diagram describes the role of CD38 expression as a determinant of NAD- mediated cell survival, 
leading to either apoptosis in differentiated HL60 cells or anti-apoptotic effects in CD38
+
 leukemia 
cells. .................................................................................................................................................149 
 Chapter 5 
Figure 5.1 (A) boxes and (B) Oxygen cylinders used in normoxia, hypoxia and hyperoxia 
experiments. .....................................................................................................................................155 
Figure 5.2 Effect of kuromanin (30 µM) on CD38 expression during the time course of 
differentiation of HL60 cells with 1 µM ATRA up to 24 h comparing to differentiated cells without 
treatment (as control). Data are means ± SEM, n = 3 (3 measurements per replicate), * denotes a 
significant difference from each control, P < 0.05. ..........................................................................157 
Figure 5.3 Effect of treatment with NAD
+
 (0-100 µM) for 1 day on RAJI and HL60 cells comparing 
to untreated control (100%). (A) Intracellular NAD
+
 levels and (B) cell vitality (as determined by 
MTT assay). Data are means ± SEM, n = 3 (3-4 measurements per replicate). * denotes a significant 
difference from the control (HL60 or RAJI cells without treatments), P < 0.05. ............................159 
Figure 5.4 Effect of treatment with FK866 for 1 day on RAJI and HL60 cells comparing to 
untreated control (100%).. (A) Intracellular NAD levels and (B) cell vitality (as determined by MTT 
assay). Data are means ± SEM, n = 3 (3-4 measurements per replicate). * denotes a significant 
difference from the control (HL60 or RAJI cells without treatments), P < 0.05. ............................161 
Figure 5.5 Effect of treatment with 100 nM FK866 and 100 µM NAD
+
 on CD38 expression after 1 
day incubation comparing to the control (untreated HL60 and RAJI cells) in (A) HL60 cells, and 
(B) RAJI cells. Data are means ± SEM, n = 3 (3 measurements per replicate). * denotes a 
significant difference from the control (RAJI cells without treatments), P < 0.05. .........................163 
Figure 5.6 Effect of treatment with 100 nM FK866 and 100 µM NAD
+
 on CD38 expression after 1 
day incubation in differentiating cells (ATRA treated cells) up to 24 h comparing to HL60 and 
ATRA treated cells without FK866 or NAD.  Data are means ± SEM, n = 3 (3 measurements per 
replicate). * denotes a significant difference from the appropriate control (differentiated cells 
without treatments), P < 0.05. ..........................................................................................................165 
xx 
 
Figure 5.7 CD38 expression in RAJI cells exposed to hypoxia (2% O2) and incubated for 30 min 
and 90 min compared to the untreated control (normoxia). Data are means ± SEM, n = 3 (3 
measurements per replicate), no significant differences between groups were found (P >0.05). ....167 
Figure 5.8 CD38 expression in HL60 cells exposed to hypoxia (2% O2) and incubated for 30 min, 
90 min and 6 h compared to the control (normoxia), hypoxia (5% O2), and hyperoxia (95% O2). 
Data are means ± SEM, n = 3 (3 measurements per replicate). * denotes a significant difference 
from the control (HL60 cells without treatments), P < 0.05. ...........................................................168 
Figure 5.9 Effect of hypoxia (2% O2) after 30 min incubation in both HL60 and RAJI cells on (A) 
lactate production, n = 3 (2 measurements per replicate), and (B) cell vitality (MTT assay) 
comparing to each untreated control (normoxia), n=2 (3 measurements per replicate). Data are 
means ± SEM.* denotes a significant difference from the related control (HL60 or RAJI cells 
without treatment), P < 0.05. ...........................................................................................................170 
Figure 5.10 Effect of hypoxia (2% O2) after 30 min incubation both in HL60 and RAJI cells on 
intracellular NAD
+
 levels comparable to the untreated control (normoxia). Data are means ± SEM, n 
= 3 (2 measurements per replicate). * denotes a significant difference from the control (HL60 cells 
without treatments), P < 0.05. ..........................................................................................................172 
Figure 5.11 Schematic diagram showing how NAD levels might regulate CD38 expression through 
multiple suggested mechanisms. For instance, elevated NAD levels following kuromanin and NAD
+
 
application might inhibit CD38 mRNA expression. Alternatively, depletion of NAD by using 
FK866 might also inhibit CD38 mRNA expression, while decreased NAD levels under hypoxia 
might upregulate CD38 expression. .................................................................................................178 
Figure 5.12 CD38 regulations in different cell types by hormones, cytokines, and retinoic acid and 
the associated increase in ADP ribosyl cyclase activity. In addition to decreasing cADPR hydrolase 
activity under hypoxia and the consequences of cADPR accumulation, adapted from Kotlikoff et al. 
(2004). ..............................................................................................................................................179 
Chapter 6 
Figure 6.1 Schematic representation of the comet assay describing slide preparation, cell lysis, 
electrophoresis, visualisation and scoring steps (adapted from Tice et al., 2000). ..........................185 
Figure 6.2 DNA damage expressed as percentage tail DNA in HL60 (solid line) and 1 day 
differentiated HL60 cells (dashed line) following 10 min in vitro incubation with different 
concentrations of H2O2 (1-300 μM). Data are means ± SEM, n = 1 (100 measurements). .............190 
xxi 
 
Figure 6.3 Spectrum of the twin-tube UV lamp with a maximum emission in the UVB region (310 
nm). The lamp was used to irradiate the cells to induce DNA damage. The data represent a single 
measurement. ...................................................................................................................................192 
Figure 6.4 DNA damage expressed as percentage tail DNA in undifferentiated HL60 cells, 
differentiated HL60 cells (3 days) and RAJI cells following the irradiation with 1.6 kJ m
-2
 UVB. 
Data are means ± SEM, n = 3 (100 measurements per replicate). * denotes significant difference 
from the appropriate untreated control (P < 0.05)............................................................................193 
Figure 6.5 Representative comet images of undifferentiated HL60, 3 days differentiated HL60 cells 
and RAJI cells, which were exposed to UVB-induced DNA damage (1.6 kJ m
-2
). Cells were stained 
with ethidium bromide before visualization. Magnification = ×200. Scale bars: 50 μm. ................195 
Figure 6.6 DNA repair of UVB-induced DNA damage (1.6 kJ m-2). Following HL60, ATRA-
induced HL60 differentiation (3 days) and RAJI cell irradiation, the percentage of DNA damage 
was assessed after recovery times of 45 min, 90 min and 6 hours. Data are means ± SEM, n = 3 
(100 measurements per replicate). * denotes significant difference from the appropriate control (P < 
0.05). ................................................................................................................................................196 
Figure 6.7 Cell viability following UVB-induced DNA damaged (1.6 kJ m-2) in HL60, ATRA-
induced differentiated HL60 and RAJI cells as assessed by trypan blue exclusion over a recovery 
time of 45 min, 90 min and 6 h, n = 1 (4 measurements). ...............................................................197 
Figure 6.8 Western blotting analysis for poly ADP-ribose polymer expression under (A) normal 
conditions,  represented by HL60 cells treated for 3 days with ATRA compared to the controls 
(RAJI and undifferentiated HL60 cells), and (B) PAR production after UVB exposure from 0-6 h 
for 50 µg cell lysate under reducing conditions and 12% SDS PAGE (Chapter 2, section 2.8.4). The 
figure represents one of two separate cultures. ................................................................................199 
Figure 6.9 Photomicrographs showing HL60, 3 day- differentiated HL60 cells and RAJI cells 
stained with Wright-Giemsa stain before, and after irradiation (0-6 h). Cells exhibit features typical 
of apoptosis after UVB-irradiation. Original magnification х100. Scale bars: 50 µm. ...................202 
Figure 6.10 Photomicrographs processed during the halo assay showing HL60, 3 day differentiated 
HL60 cells and RAJI cells stained with ethidium bromide as controls or after UVB irradiation (0-6 
h). Original magnification х 400. Scale bars: 50 µm. ......................................................................203 
Figure 6.11 The effects of CD38 expression on NAD depletion and the role of NAD as a metabolic 
link between DNA damage induced by different stimuli or in cancer, and the resistance to cell death 
via a reduction in ATP levels. ..........................................................................................................208 
xxii 
 
Chapter 7 
Figure 7.1 Schematic diagram representing the third hypothesis for the functional role of CD38 
enzymatic functions mediated by NAD, combining with its receptor functions in inducing cell 
proliferation and poor prognosis in CD38
+
 leukemia patients. ........................................................213 
List of Tables 
Table 2.1 Primers used for qPCR experiments, the size and product was shown for each primer. ...54 
xxiii 
 
Abbreviations 
Abbreviation Glossary 
9-cis RA 9-cis retinoic acid  
ADH  Alcohol Dehydrogenase  
ADPR  Adenosine diphosphate ribose 
ADPRP ADP-ribose 2’- phosphate  
ALDH  Aldehyde dehydrogenase  
AML  Acute myeloblastic leukaemia 
ANOVA Analysis of variance  
APL  Acute promyelocytic leukaemia 
ARTs  ADP-ribose transferases  
ATL  Adult T-cell leukemia-lymphoma  
ATO  Arsenic trioxide  
ATP  Adenosine triphosphate  
ATRA  All trans retinoic acid  
BCR  B-cell–receptor  
BER  Base excision repair  
BM  Bone marrow 
xxiv 
 
BSA  Bovine serum albumin  
BST-1  Bone marrow stromal cell antigen 1 
cADPR Cyclic adenosine diphosphate ribose 
CAMs  Coronary arterial myocytes  
CCD  Charge-coupled device  
CCL19 CC ligand 19  
cGDPR Cyclic guanosine diphosphate ribose 
CICR  Ca
2+-
induced Ca
2+
 release  
cIDPR  Cyclic inosine diphosphate ribose  
CLL  Chronic lymphocyte leukaemia  
CNT  Concentrative nucleoside transporters  
CPD  Cyclobutane pyrimidine dimer  
CtBP  C-terminal binding protein  
CX43  Connexin-43  
CXCL12 CXC ligand 12  
CXCR4 CXC receptor 4  
DC  Dendritic cells  
DMSO  Dimethylsulfoxide 
xxv 
 
ECL  Electro generated chemiluminescence  
ECCAC European collection of cell culture 
eNAMPT Extracellular NAMPT  
ENT  Equilibrative nucleoside transporters  
ER  Endoplasmic reticulum  
ETC  Electron transport chain  
FACS  Fluorescence-activated cell sorter  
FCS  Fetal Calf Serum  
FDC  Follicular dendritic cells 
FKBP  FK506-binding protein  
FSC  Forward scatter  
G6P-DH Glucose 6-phosphate dehydrogenase  
GM-CSF Granulocyte-macrophage colony-stimulating factor  
GSH  Reduced glutathione 
HAE  4-hydroxyalkenals  
HASM  Human airway smooth muscle  
HEB  Hypertonic extraction buffer  
HIF  Hypoxia inducible factors  
xxvi 
 
HL60  Human leukaemia cells  
HLA  Human leukocyte antigen 
HLB  Hypotonic lysis buffer  
HMW  High molecular weight  
HPV  Hypoxic pulmonary vasoconstriction 
HRP  Horseradish Peroxidase  
IDO  Indoleamine 2, 3-dioxygenase  
IDP  Isocitrate dehydrogenase  
IFN  Interferons  
IgV  Immunoglobulin variable  
IL  Interleukin  
IP3  Inositol trisphosphate  
KO  Knock out  
LDH  Lactate dehydrogenase  
LN  Lymphoid nodes  
LPS  Lipopolysaccharide  
mAbs  Monoclonal antibodies  
MAPK  Mitogen-activated protein kinase  
xxvii 
 
MDA  Malondialdehyde  
ME  Malic enzyme  
MFI  Mean fluorescence index  
MMPs  Matrix metalloproteinases  
MPT  Mitochondrial permeability transition  
MTT  3-(4, 5-dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide  
NA  Nicotinic acid  
NAADP Nicotinic acid adenine dinucleotide phosphate 
NAD  Nicotinamide adeninedinucleotide  
NADase NAD glycohydrolase  
NADK  NAD kinase  
NADP  Nicotinamide adeninedinucleotide phosphate 
NADs  NAD synthetase 
Nam  Nicotinamide 
NaMN  Nicotinic acid mononucleotide 
NAMPT Nicotinamide phosphoribosyltransferase 
NAPRT Nicotinic acid phosphoribosyl transferase  
NBT  Nitroblue tetrazolium  
xxviii 
 
NER  Nucleotide excision repair  
NGD  Nicotinamide guanine dinucleotide  
NHD  Nicotinamide hypoxanthine dinucleotide  
NIDDM Non-insulin dependent diabetes  
NK  Natural killer cells  
NLC  Nurse-like cells 
NMNAT Nicotinamide mononucleotide adenylyltransferase  
NOD  Non-obese diabetic  
NOX4  NAD(P)H oxidase  
NRK  Nicotinamide riboside kinase 
NuT  Nucleoside transporter  
PAGE  Polyacrylamide gel electrophoresis  
PAR  Poly ADP-ribose   
PARPs  Poly-ADP-ribose-polymerases  
PBS  Phosphate buffered saline  
PCs  Proliferation centre  
PE  Phycoerythrin  
PECAM-1 Platelet endothelial cell adhesion molecule-1  
xxix 
 
PES  Phenazine ethosulfate  
PGC-1α  Peroxisome proliferator-activated receptor δ co-activator-1  
PI3-K  Phosphoinositide 3-kinase 
PMA  Phorbol 12-myristate 13-acetate  
PML  Promyelocytic leukemia 
PVDF  Polyvinylidine difluoride  
QPCR  Quantitative polymerase chain reaction 
RAR  Retinoic acid receptor  
RARE  Retinoic acid response element  
RAS  Retinoic acid syndrome 
ROS  Reactive oxygen species 
RPMI  Roswell Park Memorial Institute  
RXR  Retinoid x receptor  
RyR  Ryanodine receptor  
SAP  Saponin and PBS 
SDS  Sodium dodecyl sulphate  
SSBR  Single strand break repair 
SSC  Side scatter  
xxx 
 
TBA  Thiobarbituric acid  
TBARS Thiobarbituric acid reactive substances  
TBS  Tris-buffered saline  
TCA  Tricarboxylic acid cycle 
TCR  T-cell receptor  
TGase  Transglutaminase 
TLR  Toll-like receptors  
TNB  5-thio-2-nitrobenzoate  
TNF-α  Tumor necrosis factor-α  
TPCs  Two-pore channels  
TRPM2 Transient receptor potential cation channel member 2  
TTBS  TBS-Tween   
ZAP-70 Zeta1-associated protein of 70 kDa 
  
xxxi 
 
Author’s Declaration 
At no time during the registration for the degree of Doctor of Philosophy has the author 
been registered for any other University award without prior agreement of the Graduate 
Committee. This study was financed with the aid of Ministry of the Higher Education and 
Scientific Research/Iraq. Relevant scientific seminars and conferences were attended at 
which work was presented and papers have been prepared for publication: 
Publications 
Z.N. Al-Abady et al., Large changes in NAD levels associated with CD38 expression 
during HL-60 cell differentiation, Biochem. Biophys. Res. Commun. (2013), 
http://dx.doi.org/10.1016/j.bbrc.2013.10.170 (published) 
Platform presentations 
Role of CD38 in disease. University of Plymouth, Plymouth, UK, March 2010 
CD38 in human leukaemia cells. University of Plymouth, Plymouth, UK, March 2012 
Poster presentations 
Enzymatic activity of CD38 comparative to NAD levels in leukemia cells. Centre for 
Research in Translational Biomedicine, research day. University of Plymouth, Plymouth, 
UK, Aprill, 2011 
CD38 expression regulates NAD(H) levels during HL-60 differentiation. The Postgraduate 
Society Annual Conference, University of Plymouth, Plymouth, UK, June, 2012. Also were 
presented by colleagues at FASEB Summer Research Conference, Lucca, Italy, September, 
2011. 
The forgotten role of CD38: is enzymatic activity important in CLL pathophysiology. 
Centre for Research in Translational Biomedicine, research day. University of Plymouth, 
Plymouth, UK, July, 2012. 
xxxii 
 
CD38 Expression Regulates NAD(H) Levels in Human Leukemia Cells. International 
conference, 16th BIENNIAL meeting. London, UK, September 2012. 
Workshop 
Practical Techniques in molecular biology workshop, 16-19 July, 2012, Plymouth 
University. 
 
 
Word count of main body of thesis: (42,266 words)  
 
 
 
Signed ----------------------------  
 
Date ------------------------------- 
  
xxxiii 
 
Acknowledgements 
The work presented here would not have been possible were it not for the support of a 
number of people. Firstly, I would like to express my sincere gratitude to my supervisors, 
Dr. Richard Billington for his kind support and advice throughout the duration of this 
research even in his very busy time and Dr. John Moody; for his contributions of time, 
ideas, and support during these studies. 
 Besides my supervisors, I would also like to extend my thanks to all my colleagues in the 
School of Biomedical and Biological Sciences, who answered my request for help 
especially Dr. Wondwossen Abate. Appreciation also goes out to technical colleagues, 
especially William Vevers and Michele Kierman. Further, I am grateful to the Ministry of 
the Higher Education and Scientific Research, Republic of Iraq for giving me this 
opportunity for graduate studies and for their financial support. 
Above all, I must acknowledge my husband Abass Al-Shabany without his love, 
encouragement and editing assistance, I would not have finished this thesis. I cannot forget 
also to express my loving thanks to my daughter Ayiat and my sons; Haider and Abdu-
Allah; they have missed and lost a lot due to my research. My Mum, Dad, Sisters and 
Brothers were all behind me throughout this journey. Their prayers and emotional support 
were with me especially during the difficult times. 
1 
CHAPTER 1 
GENERAL INTRODUCTION 
  
2 
1. GENERAL INTRODUCTION 
1.1 Nicotinamide adenine dinucleotide (NAD) 
Nicotinamide adenine dinucleotide (NAD) and its phosphorylated form, NADP (Fig 1.1) were 
first discovered by Harden and Young (1906); NAD and NADP have long been known to be 
essential co-enzymes in some of the most fundamental redox reactions of basic metabolism, such 
as glycolysis, the tricarboxylic acid (TCA/Krebs’) cycle and the pentose phosphate pathway 
(Mathew et al., 2000; Ziegler, 2000). The oxidized and reduced forms of NAD (NAD
+
 and 
NADH, respectively) regulate glycolysis by acting as cofactors for the glycolytic enzyme 
glyceraldehyde-3-phosphate dehydrogenase. NAD(H) also mediates important energy 
metabolism-related reactions, such as the lactate dehydrogenase-catalyzed lactate-pyruvate 
conversion in the cytosol (Stryer, 1995; Berger et al., 2004). Generally, NADH is the substrate of 
over 300 cellular dehydrogenases, including those located in the inner mitochondrial membrane 
that catalyzes the transfer of electrons from NADH to coenzyme Q during oxidative 
phosphorylation (Li and Chen, 2002). Hence NAD(H) is essential for the synthesis of ATP 
(Stryer, 1995; Berger et al., 2004). Moreover, beyond the function of NAD in energy 
metabolism, its phosphorylated form (NADP
+
) has important functions in the cellular antioxidant 
capacity through its role as a precursor for synthesizing the major reducing molecule NADPH; 
the latter provides several cell protective functions (Stryer, 1995; Pollak et al., 2007). 
 
 
3 
Figure 1.1 The structures of the nicotinamide nucleotides, NAD, NADP and NADH. 
Interestingly, NAD has other important functions, as a signalling molecule, via acting as 
substrate for several NAD-consuming enzymes. These enzymes are represented by the 
CD38/CD157 system, poly-ADP-ribose-polymerases (PARPs), mono-ADP-ribose transferases 
(ARTs) and sirtuins (NAD-dependent protein deacetylases) in cells. NAD mediates post-
translational protein modification by serving as substrate for the ADP-ribosylation reaction (via 
ARTs; Koch-Nolte et al., 2008). It also controls DNA repair (via PARP; Kim et al., 2005). This 
group of enzymes uses NAD as a substrate to catalyze the addition of a polymer of ADP-ribose 
to the protein. Further, NAD mediates gene silencing and longevity (via sirtuins; Michan and 
Sinclair, 2007). These enzymes catalyse the deacylation of proteins, in which the acetyl group is 
transferred from the protein to the ADP-ribose portion of NAD, releasing the nicotinamide group 
from NAD in the process. Additionally, in the late 1980s, NAD(P) was discovered to be a key 
substrate in producing two novel Ca
2+
 messengers; cADPR and NAADP (Lee et al., 1989; Lee 
4 
and Aarhus, 1995). These messengers are involved in a wide range of biological functions. Thus, 
NAD mediates Ca
2+
-signalling (via CD38/CD157; Malavasi et al., 2008). In fact, extracellular 
and intracellular NAD levels may be regulated by CD38; EC 3.2.2.6 (Adebanjo et al., 1999), 
which has been defined both as an ectoenzyme and as a receptor molecule (Howard et al., 1993; 
Malavasi et al., 1994). 
Extracellular NAD
+
 as a signalling molecule for CD38 and ARTs has additional functions. It 
may work like a cytokine, deriving rapid and functional responses through binding to specific 
purinergic type 2 receptors. It may also induce cell proliferation, migration, chemotaxis and 
apoptosis. For example, NAD
+
 activates the purinergic receptor P2Y11, which results in cell 
activation in human granulocytes (Moreschi et al., 2006). In human monocytes, NAD
+
 binds 
different receptors such as P2X1, P2X4, and P2X7, which trigger Ca
2+
 influx (Klein et al., 
2009). Furthermore, NAD
+
 induces cell proliferation, migration and release of prostaglandin E2 
and cytokines in mesenchymal stem cells (Fruscione  et al., 2011). NAD
+
 is involved in 
immunoregulation through the extracellular enzymatic network that control NAD
+
 levels, which 
may be responsible for providing an essential second signal for chemotaxis through the two 
intracellular Ca
2+
 mobilizers, cADPR and ADPR (Berridge, 1993; Meszaros et al., 1993; Perraud 
et al., 2001). Furthermore, the mechanism to control regulator T lymphocytes cells is mediated 
through the immunomodulatory functions of NAD
+
 that are mainly linked to the activation of 
ART enzymes. This can be done by transferring the ADP moiety of NAD
+
 to specific amino 
acids in target proteins; P2X7 receptor (Koch-Nolte et al., 2008), which causes activation 
signalling, leading to apoptotic cell death (Adriouch et al., 2001; Seman et al., 2003).  
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In contrast, while several NAD-dependent enzymes catalyse consumption of NAD in cells, 
resynthesis of NAD is necessary to maintain the functions of a wide variety of these enzymes. 
Thus, cellular NAD is synthesized either via a de novo pathway from tryptophan or via one of 
two possible recycling pathways: from nicotinic acid (NAc) or nicotinamide (NAM); vitamin PP, 
or niacin (Fig. 1.2; Magni et al., 2004), and from nicotinamide riboside (NR; Bieganowski and 
Brenner, 2004).  
There are two important enzymes, nicotinamide phosphoribosyltransferase (NAMPT) and 
nicotinamide mononucleotide adenylyltransferase (NMNAT), that constitute an NAD salvage 
recycling pathway in mammalian cells  (Rongvaux et al., 2003). Specifically, NAMPT catalyzes 
the conversion of NAM to nicotinamide mononucleotide (NMN), and localizes to both the 
cytosol and nucleus (Rongvaux et al., 2002). NMN produced from NAM (via NAMPT) or from 
NR (via nicotinamide riboside kinase (NRK)) is further converted into NAD by NMNAT. NAD 
can be also synthesized from NAc, by nicotinic acid phosphoribosyl transferase (NAPRT), in 
addition to other enzymes such as NAD synthetase (NADs) via the intermediate nicotinic acid 
mononucleotide (NaMN; Wilhelm and Hirrlinger, 2012).  In the nucleus, NAMPT and NMNAT 
have been observed to produce NAD as a substrate for NAD-dependent enzymes, including 
SIRT1 and PARP1 (Zhang et al., 2009a). On the other hand there are three different enzymes 
that catabolise tryptophan in the endogenous de novo pathway, including tryptophan dioxygenase 
(TDO), indoleamine 2,3-dioxygenase (IDO) and indoleamine 2,3-dioxygenase-2; IDO2 (Ball et 
al., 2009). Specifically, IDO activity is inducible in multiple cell types (Mellor and Munn, 2004), 
and it is chronically activated in many cancer patients (Schroecksnadel et al., 2007). 
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Figure 1.2 NAD metabolism represented by the biosynthesis pathways (the de novo pathway and salvage 
pathway), in addition to a network of NAD-consuming enzymes included (CD38, PARP, and sirtuins). 
NAD is shuttling between its oxidized form NAD
+
 and the reduced form NADH. The electrons bound by 
NADH can be transferred to the electron transport chain (ETC) of mitochondria. The reaction catalyzed 
by NAD kinase (NADK) links NAD to the redox pair of NADP
+
 and NADPH (adapted from Wilhelm 
and Hirrlinger, 2012). 
In humans, the distribution of NAD
+
 levels in plasma and tissue is different; the concentration of 
NAD
+
 in human plasma ranges between 10 and 50 nM (De Flora et al., 2004). NAD
+
 levels may 
depend on the balance between the opposing processes of dinucleotide release from cells and its 
enzymatic degradation (De Flora et al., 2004). However, NAD
+
 levels in specific tissue regions 
may be significantly higher than those in plasma, such as during inflammation (Scheuplein et al., 
2009). Investigation of cellular NAD
+ 
and NADH levels in response to different environmental 
stimuli has been an important subject of several studies. For instance, the intracellular 
NAD
+
/NADH ratio reflects the cellular metabolic status and redox state. It has been reported that 
under oxidative stress some cell types (for example, erythrocytes) increase their intracellular 
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NADH/NAD
+
 ratio or the NADH level, in order to resist possible oxidative damage (Liang et al., 
2007; Ying, 2007). However, the change in nucleotide (NAD(H)) levels has also been linked to 
several diseases, such as sickle cell disease (Zerez et al., 1990), neoplasia and ischaemia 
(Lohmann et al., 1989), several age-associated diseases such as diabetes, cancers and 
neurodegenerative diseases; Parkinson’s disease (Soriano et al., 2001; Greenamyre et al., 2001; 
Zhang et al., 2002; Lin and Guarente 2003). Notably, several studies suggest that the change in 
NAD levels might modulate protein activities, and have an effect on cell functions (Ying, 2006; 
2008). For instance, an augmentation of intracellular NAD
+
 levels following CD38 knock out 
leads to SIRT activation with positive consequences on cell physiology (Barbosa et al., 2007). 
One possible explanation is that CD38, as a member of the cyclase family, appears to be a major 
NAD consuming enzyme in cells. Thus, CD38 limits the availability of NAD to all other 
consumers. 
1.2 Members of the ADP-ribosyl cyclase family 
As mentioned above, NAD
+
 is a substrate in the production of a novel Ca
2+
 messenger, cyclic 
ADP-ribose (cADPR; Lee et al., 1989). Generally, cADPR is produced from NAD
+
 by ADP-
ribosyl cyclase activity, and there are three main members of the ADP-ribosyl cyclase family. 
The first ADP-ribosyl cyclase was described in the ovotestis of a marine invertebrate, the sea 
slug (Aplysia california). The ADP-ribosyl cyclase from Aplysia is a soluble protein with a 
molecular weight of ~30 kDa. It generates cADPR as the predominant product of its enzymatic 
activity (Clapper et al., 1987; Lee et al., 1989). The second member of the ADP-riboysl cyclase 
family is CD38, which is the mammalian homologue of the Aplysia cyclase, with a single chain 
of 45 kDa (Mehta et al., 1996; Ortolan et al., 2002). CD38 was discovered by Reinherz et al. 
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(1980), while working on T lymphocytes by using the monoclonal antibody OKT10, and it was 
known then as a surface antigen (T10; Katz et al., 1983). Several years later, T10 came to be 
known as ‘cluster of differentiation 38’ (CD38; Pallesen and Plesner, 1987). The third member 
of the cyclase family is CD157, a mammalian homologue of CD38, with a crystal structure that 
shows a high degree of structural homology with CD38 and the Aplysia cyclase as well 
(Yamamoto-Katayama et al., 2002). CD157 is a 42-45 kDa surface molecule, identified as a 
bone marrow stromal cell antigen-1 (BST-1), also known as Mo-5 (Kaisho et al., 1994). Each of 
the CD38 and CD157 glycoproteins has a polypeptide core of 280-300 amino acids (Liu et al., 
2005). 
In addition to the well-known members of the ADP-ribosyl cyclase family, recent reports 
indicate the presence of CD38- and CD157-independent ADP-ribosyl cyclases. The next addition 
to the ADP-ribosyl cyclase family is an NAD(P)-catabolising enzyme from Schistosoma 
mansoni (SmNACE; Kuhn et al., 2006). 
1.3 Distribution of CD38 
CD38 is distributed in a number of human and non-human tissues. It has been detected on the 
sarcolemma in skeletal and heart muscle, in addition to CD38 localization in the human brain 
(Mizuguchi et al., 1995; Fernandez et al., 1998). The CD38 molecule has been also found at 
various locations, including the normal prostatic epithelial cells (Kramer et al., 1995); pancreatic 
islet cells (Koguma et al., 1994; Mallone et al., 2002); cornea (Sizzano et al., 2007); the kidney; 
and intra-parenchymatous fibrous septa in the thyroid (Fernandez et al., 1998). Moreover, 
CD38’s presence has been also documented in the inner nuclear envelope, for instance, in the rat 
hepatocytes, in addition to its localization in the plasma membrane (Khoo and Chang, 2000). 
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CD38 as a cell surface receptor is expressed in cells of hematopoietic origin (Terhorst et al., 
1981). However, its expression has been most appropriately termed ‘discontinuous’ (Jackson and 
Bell, 1990) since CD38 expression is repeatedly changeable as bone marrow precursors develop 
into mature elements of the various lineages. For instance, in B cells, CD38 expression is tightly 
regulated during B cell ontogenesis and is highly present in bone marrow (BM) precursors. 
However, it is down-regulated in resting normal B cells and then is expressed in terminally 
differentiated plasma cells (Malavasi et al., 1994). CD38 expression is also changeable in T cells 
(Deaglio et al., 2001). Furthermore, studies suggest that CD38 is down-modulated during 
differentiation into immature human monocyte-derived dendritic cells and expressed again upon 
maturation induced by Lipopolysaccharide (LPS; Fedele et al., 2004). CD38 is also expressed by 
cells of the innate immune system, including circulating and residential natural killer (NK) cells 
(Mallone et al., 2001). Collectively, in the immune system, CD38 is expressed by immature 
hematopoietic cells, down-regulated by mature cells and re-expressed at high levels by activated 
lymphocytes; T cells, B cells, dendritic cells and NK cells (Funaro et al. 1990). CD38 is also 
expressed in the BM (Byk et al., 2005), granulocytes (Fujita et al., 2005), circulating monocytes 
(Zilber et al., 2000), on the surface membrane of erythrocytes and platelets (Zocchi et al., 1993; 
Ramaschi et al., 1996) and circulating osteoclast precursors (Shalhoub et al., 2000). CD38 has 
been also detected in lamina propria cells in the gut (Fernandez et al., 1998). Finally, it is worth 
mentioning that CD157 expression is also involved in most tissues, including the hematopoietic 
system, like CD38 expression, but the tissue distribution of CD157 is limited compared to CD38 
(Ortolan et al., 2002). 
10 
1.4 CD38 (the type-II & -III glycoprotein) and cyclase crystal structures 
The cyclase crystal structure reveals a homo-dimer; the enzyme is a bean-shaped molecule with 
most of the β sheets in the carboxyl domain, while the helixes are in the amino domain (Fig. 1.3 
A; Prasad et al., 1996). The two domains are separated by a central cleft, with the active site 
located in a pocket near the cleft, as shown by crystallography and site-directed mutagenesis 
(Munshi et al., 1999), with a catalytic residue identified as Glu179. It is interesting to note that 
for the ADP-ribosyl cyclase, 86 of its 256 amino acid are identical to those in CD38, and an 
additional 110 amino acids are conservative substitutions (States et al., 1992). However, the 
structure of human CD38 is more complicated than the cyclase structure (Jackson and Bell, 
1990). The structure of CD38 consists of an amino tail of 21 residues, a transmembrane segment 
of 23 residues and a large carboxyl domain of 256 residues that contains four glycosylation sites 
(Fig. 1.3 B; Jackson and Bell, 1990). The equivalent residue of Glu179 in CD38 is Glu226, 
which represents the catalytic residue of CD38 (Munshi et al., 2000).  
The crystal structure of CD38 has revealed a molecule with a high degree of structural 
conservation with the cyclase. Thus, it was suggested that the overall homology between the two 
proteins is 69% (States et al., 1992). However, Liu and others (2005) reported that these proteins 
have about 34% protein sequence identity. CD38 has a single binding pocket for multiple 
enzymatic activities, and it was observed that CD38’s critical residues are localized in the 
carboxyl terminal and spread out in the last 100 amino acid residues of the protein (Munshi et 
al., 2000). Other studies have shown that the CD38 active site is constructed by helices α5 and 
α6 from the N-terminal domain and helix α7 and strand β5 from the C-terminal domain (Fig. 1.3  
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Figure 1.3 Structures of ADP-ribosyl cyclase and CD38. (A) The Aplysia ADP-ribosyl cyclase is a 
homo-dimer and the surfaces of the two monomers are coloured differently. Transparent grey revealing 
the secondary structures underneath. The colour code is: helix-red, β-sheet-yellow, coil-grey. The NAD 
molecules bound at the active sites are rendered using sticks. Colour code is: nitrogen-blue, oxygen-red, 
phosphorus-yellow, carbon-green. The letter C indicates the carboxyl end (adapted from Lee, 2012). (B) 
CD38 structure shows its membrane interaction. (C) The overall structure of human CD38. The N-
terminal structures (in the red circle) and the C-terminal structure circled in blue (adapted from Liu et al., 
2005).  
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B). These two distinct domains are connected by a hinge region composed of three peptide 
chains including: residues 118-119, 143-144, and 200-201 (Liu et al., 2005). 
It is important to note that there are many types of membrane proteins with different 
arrangements, as shown in Fig. 1.4, and CD38 is one of these proteins that spans from the 
internal to the external surface of the biological membrane (integral protein). Moreover, CD38 
was initially classified as a type II transmembrane glycoprotein (Fig. 1.4b), with an extracellular 
carboxyl active domain (Jackson and Bell, 1990), expressed both the cADPR synthesizing and 
hydrolyzing activities. However, a recent thorough study by Zhao et al. (2012) showed that 
CD38 has the characteristics of a type III integral membrane protein, in which the C-terminus 
would be in opposite orientation to that in a type II membrane protein, so that the active site of 
CD38 would  face the cytoplasm, with an extracellular N-terminal tail (Fig. 1.4a). Furthermore, 
some considerable studies have reported that the full-length CD38 can form dimers on the cell 
surface (Moreno-Garcia et al., 2004) or even oligomers (Ferrero and Malavasi, 1999; Fig. 1.5). 
 
Figure 1.4 Schematic representation of different types of integral membrane proteins as follows (a) type-
1 transmembrane, (b) type-2 transmembrane, (c) multipass transmembrane, (d) lipid-chain anchored 
membrane, and (e) GPI-anchored membrane (modified from Cai and Chou, 2006). 
13 
 
Figure 1.5 Simplified diagram representing monomeric, dimeric and oligomeric forms of CD38. 
Cleavage of the surface membrane form gives rise to p39 (soluble), its dimeric form is p78 and p190 
represents a tetramer of the membrane form (modified from Ferrero and Malavasi, 1999). 
The similar glycoprotein to CD38, CD157, also exhibits both monomeric and dimeric forms 
(Malavasi et al., 2008). The C-terminal end of CD157 is anchored to the plasma membrane, by a 
glycophosphatidylinositol (GPI) molecule, while the N-terminal region, which includes the 
catalytic domain, is out of the membrane (Funaro et al., 2009). Therefore, and on the cell surface 
membrane, the two molecules (CD38, CD157) are oppositely oriented with respect to one 
another (Ferrero and Malavasi, 1999). 
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1.5 CD38 as a cell surface receptor 
CD38 has multiple functions through its roles as an enzyme and a receptor (Deaglio et al., 1996). 
As a receptor, CD38 is expressed in various cell lineages, where it mediates cell-cell interactions 
and delivers transmembrane signals. The role of CD38 as a receptor was first identified by means 
of agonistic monoclonal antibodies (mAbs), which suggested the existence of a non-substrate 
surface ligand, namely CD31/platelet endothelial cell adhesion molecule-1; PECAM-1 (Deaglio 
et al., 1998). CD38 receptor functions are regulated through interactions with its non-substrate 
ligand, CD31, which is expressed in a variety of cells including endothelial cells, platelets and 
nurse-like cells (for example, macrophages and epithelial cells; Deaglio et al., 2000; 2005). 
CD38/CD31 crosstalk has been extensively analyzed in a number of different environments, 
ranging from T lymphocytes to B, NK, and myeloid cells, from normal to pathological situations 
(reviewed in Deaglio et al., 2000). For instance, CD31 interaction with CD38 induces activation, 
proliferation, cell adhesion and cytokine release in lymphocyte subsets (Deaglio et al., 1998). 
CD38/CD31interactions also lead to increased B-cell proliferation and survival, through direct 
cooperation with CD100, a cell surface receptor member of the semaphorin family known as 
sema 4D (Kikutani and Kumanogoh, 2003). Other proposed ligands for CD38 include 
hyaluronate in humans (Nishina et al., 1994), and an unidentified 130-kDa glycoprotein in mice 
(Wykes et al., 2004). 
Several lines of evidence indicate that the receptor functions mediated by CD38 are regulated at 
multiple levels (Malavasi et al., 1984). The first level involves the dynamic structure of CD38, 
which allows a monomer to dimer transition, which modulates the functions of the molecule 
(enzyme and receptor functions). Additional control is provided by the dynamic localization of 
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CD38 in lipid microdomains of the plasma membrane (Pavon et al., 2006). A significant fraction 
of the membrane CD38 pool is localized in cholesterol-rich regions, while the remaining fraction 
of CD38 is localized in the raft pool (Deaglio et al., 2007a). That localization makes it possible 
for CD38 to expand its interaction horizontally and frontally with molecules other than its 
substrate (NAD), forming large supramolecular complexes; thus it attracts transducers in spite of 
its short tail (Rah et al., 2007). 
Extensive observations that were made on CD38 receptor functions suggest that CD38 controls 
specific signalling pathways in B cells, T cells, NK cells, and monocytes. However, CD38 
associations with surface molecules are lineage-dependent, and they also vary according to the 
maturation steps within each lineage (Deaglio et al., 2001). For instance, CD38 signalling in B 
cells and in human or murine systems (Funaro et al., 1993; Lund et al., 1996) depends on the 
presence of a functional B-cell–receptor (BCR) complex. CD38-associated molecules in human 
B cells include the CD19/CD81 complex, the chemokine receptor CXCR4, and adhesion 
molecules, such as CD49d (Deaglio et al., 2007a; 2010). The ability of CD38 to deliver its 
signals in B cells appears completely linked to the stage of maturation. Thereby, the presence of 
blocking mAbs in cultures of CD19
+
 B-cell precursors suppresses B-cell proliferation and 
induces apoptosis (Kumagai et al., 1995). However, in mature circulating B lymphocytes, CD38 
ligation is followed by activation, apoptosis inhibition, proliferation and cytokine secretion 
(Zupo et al., 1994; Funaro et al., 1997). 
Furthermore, in T cells, the CD38 molecule is also associated with the T-cell receptor 
(TCR)/CD3 complex (Zubiaur et al., 1999), and it has been shown that CD38 initiated functional 
signals in a subset of membrane rafts containing CD3 (Zubiaur et al., 2002; Munoz et al., 2003). 
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The observation in immature T cells indicated that CD38 enhances apoptosis when it is cross-
linked with a goat anti-mouse antiserum or interacts with CD31 (Tenca et al., 2003). However, it 
has been shown that following T-cell activation, the final outcome includes cytokine secretion 
and cell proliferation (Malavasi et al., 2008). 
In monocytes, CD38 signalling has been shown to be associated with HLA class II and CD9 
molecules. The CD38/HLA class II/CD9 complex shares a common pathway of tyrosine kinase 
activation, and cytokine secretion in human monocytes (Zilber et al., 2005). CD38 expression in 
human monocytes was found also to be regulated in response to proinflammatory cytokines 
(Musso et al., 2001). CD38 expression is also known as a marker of the transition of monocytes 
to dendritic cells (DC) induced by inflammatory processes (Fedele et al., 2004). Furthermore, 
CD38 mediates important signalling that is involved in dendritic cell migration; the 
CD38/cADPR signalling pathway is required for the migration of immature dendritic cells to 
CXC ligand 12 (CXCL12) and of mature dendritic cells to CC ligand 19 (CCL19) and CCL21 
(Partida-Sanchez et al., 2004a; 2004b). 
CD38 is also expressed by resting and activated natural killer (NK) cells; it forms part of a 
supramolecular complex that includes CD16. Indeed, CD38-CD16 association controls an 
activation pathway that includes Ca
2+
 fluxes, increased expression of HLA class II and CD25, 
tyrosine phosphorylation of cytoplasmic substrates (such as ZAP-70 and ERK), release of 
cytokines and cytotoxic responses (Mallone et al., 2001). Collectively, the general events that 
take place after CD38 activation in several cell lineages include calcium (Ca
2+
) mobilization 
from cytosolic stores, as well as the triggering of the phosphorylation of a cascade of 
intracellular substrates, including phosphatidylinositol 3-kinase, leading to the activation of 
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nuclear factors (such as the nuclear factor-κB complex), and the secretion of cytokines (Kitanaka 
et al., 1997; Deaglio et al., 2000). 
Additionally, in neutrophils, CD38 signalling plays an important role in the regulation of cell 
trafficking; it has been shown that trafficking of neutrophils to sites of infection and 
inflammation is dependent on CD38 expression (Partida-Sanchez et al., 2001; 2003). This 
process is controlled through cADPR production, which is triggering by the release of 
intracellular Ca
2+
 (Partida-Sanchez et al., 2004b). Finally, as with CD38 receptor functions, 
CD157 also transduces activation signals, but no non-substrate ligand equivalent to CD31 has 
been described for CD157 (Malavasi et al., 2006). 
1.6 CD38 as active enzyme 
CD38 is pleiotropic in function (Malavasi et al., 1994); it is considered as the major NAD-
consuming enzyme in humans (Malavasi et al., 2008). CD38 is capable of catalyzing four major 
enzymatic reactions: NAD glycohydrolase (NADase), cyclic adenosine diphosphate ribose 
(cADPR) hydrolase, base-exchange reactions and ADP-ribosyl cyclase activity (Fig. 1.6 A, B). 
The ADP-ribosyl cyclase activity generates cADPR, and the NADase activity generates 
adenosine diphosphate ribose (ADPR) directly from NAD (Lee, 2006), while the cADPR 
hydrolase activity generates ADPR from cADPR (Howard et al., 1993). However, it has been 
observed that the majority of the NAD (~95%) is converted to ADPR, and only a minor fraction 
of the total product appears to be cADPR (Howard et al., 1993). Finally, CD38 can also use 
NADP
+
 as a substrate and, in the presence of nicotinic acid (NA), to catalyze the exchange of the 
nicotinamide (Nam) group of NADP
+
 with nicotinic acid, producing NAADP and nicotinamide 
(Lee, 2006). This reaction predominates in acidic conditions, while at neutral and alkaline pH the 
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enzyme mainly catalyzes cyclization of NAD
+
 (Aarhus et al., 1995). Furthermore, Graeff et al. 
(2006) documented that CD38 may also catalyse the hydrolysis of NAADP to ADP-ribose 2’- 
phosphate (ADPRP) at acidic pH. CD38 is also known to metabolize analogs of NAD, such as 
nicotinamide guanine dinucleotide (NGD) and nicotinamide hypoxanthine dinucleotide (NHD), 
releasing cyclic compounds (Cyclic guanosine diphosphate ribose (cGDPR) and cyclic inosine 
diphosphate ribose (IDPR), respectively) with fluorescent properties, but without calcium-
releasing activity (Graeff et al., 1994a). cGDPR, unlike cADPR, is a poor substrate for the 
hydrolase activity of CD38, and thus its measurement provides the basis of a continuous assay of 
cyclization for distinguishing CD38-like enzymes (with cyclase activity) from classical NADases 
(Graeff et al., 1994a). 
It is noteworthy that there are a number of critical residues that are highly conserved across the 
ADP-ribosyl cyclase family, and that have an essential role in the major enzymatic activities. For 
example, there are twelve conserved cysteine residues in the cyclase family, with only four of 
them (Cys119, Cys160, Cys173 and Cys201) having an essential role in the cADPR synthetic 
and hydrolytic activities of CD38 (Tohgo et al., 1994). Moreover, the carboxylic domain of 
CD38 contains Cys275, which contributes to the NAD glycohydrolytic activity of CD38 
(Hoshino et al., 1997). Disulfide bonds between cysteine residues are important for the catalytic 
activity of CD38, as it has been shown that CD38 enzymatic activity can be inhibited by 
reducing agents such as dithiothreitol, 2-mercaptoethanol or reduced glutathione (Tohgo et al., 
1994; Zocchi et al., 1995). Furthermore, three of the critical residues, Trp125, Trp189 and 
Glu226, are also highly conserved across the ADP-ribosyl cyclase family, with two of them 
(Trp125 and Trp189) essential for positioning NAD in the CD38 binding pocket, via 
hydrophobic interactions (Munshi et al., 2000). However, a unique critical residue to CD38 is 
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Lys129; it is known to form a hydrogen bond with cADPR (Tohgo et al., 1997). Additionally, 
there are two critical acidic residues in the catalytic domain of CD38 that are necessary for the 
pH-dependent base-exchange reaction: Glu146 and Asp155 (Graeff et al., 2006). 
It has been reported that CD157 shares a similar enzymatic function with CD38 (Malavasi et al., 
2006), except that CD157 does not produce NAADP. Surprisingly, CD38 knockout mice studies 
suggest that CD157 might undergo modification to enhance its cyclase activity to produce 
cADPR in some cells and tissues (Partida-Sanchez et al., 2001; Lee, 2012). However, CD157 
catalytic activity is one hundred-fold lower than that of CD38 (Hussain et al., 1998). 
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Figure 1.6 Schematic representation of CD38 (A) cyclase and hydrolase reactions by using β-NAD as 
substrate (Modified from Zhang et al., 2011). (B) Base exchange reaction in the presence of β-NAD with 
the pH optimum of 4 (modified from Yamasaki et al., 2005). 
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1.7 The interdependence between CD38 enzymatic and receptor functions 
CD38 as a cell surface receptor and a multifunctional enzyme has drawn the attention of several 
studies, focusing on how it is that the single molecule (CD38) has a multifunctional role 
(receptor and enzymatic functions), and what the role of the enzymatic activity of CD38 is in the 
initiation of the signalling cascade. Indeed the answer to these questions is still not completely 
known, because the possibility of finding CD38 inhibitors is still limited, in addition to the 
complexity of CD38 being a multifunction enzyme with a variety of enzymatic products. 
However, the initial hypothesis is that they are completely unrelated, as enzymatic mutants and 
enzyme inhibition of CD38 have no effect on its receptor functions in human B, T, and myeloid 
cells (Lund, 2006; Congleton et al., 2011). 
The alternative hypothesis by Malavasi et al., (2011) and Vaisitti et al., (2011), is that CD38 
enzymatic functions are regulated through interactions taking place between CD38 and different 
proteins or molecules that are critical for cell homeostasis. This suggests that the human CD38 
enzymatic activity is not only limited in function by the availability of the substrate (NAD), but 
also by the opening or closing of the enzymatic site that is further controlled by the interactions 
with other non-substrate ligands (Malavasi et al., 2011; Vaisitti et al., 2011). Indirect evidence in 
support of this hypothesis comes from the crystal structure of CD38, which has shown CD38 as a 
dimer coupled to different ligands (Zhang et al., 2011). In addition, the study by Liu et al., 
(2005) suggested that CD31 binding regulates the access of NAD to its enzymatic site. A 
possible explanation is that CD31 acts as modulator of CD38’s three-dimensional structure and 
thus alters its propensity to bind the substrates or to initiate signalling (Liu et al., 2005). 
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The membrane localization of CD38 in close association with signalling receptors is suggested to 
initiate enzymatic and receptorial coupling machinery important for signal transduction (Munoz 
et al., 2008). Moreover, the products of the enzymatic activities of CD38 might be necessary for 
the receptor functions. For instance, it is believed that a direct contribution of cADPR to the 
signalling process is induced after CD38 binds with agonistic mAbs in humans (Hoshino et al., 
1997; Munshi et al., 2000). Thus, CD38 provides a connection between Ca
2+
-modulation via 
cADPR and the classical signalling cascades that are responsible for the activation of Ca
2+
-
dependent kinases and initiating antigen receptor signalling (Deaglio and Malavasi, 2006). 
Collectively, the functions attributed to CD38 are linked either to enzymatic or receptor 
functions. However, the final outcome is dependent on the interactions with other ectoenzymes 
and/or signalling molecules, which vary according to tissue and sub-cellular localization 
(Deaglio et al., 2008). 
1.8 Visualization of the cyclization reaction (enzyme-NAD interaction) 
Until recently, it was not possible to visualize the wild type cyclase complexes with its substrate 
NAD, or to visualize cADPR formation, without modification. The excellent study by Kotaka et 
al. (2012) solved the previous difficulties of visualizing CD38 with its substrate, without 
limitations, by crystallography. The previous restriction was that CD38 converted NAD to its 
products during crystallization, and hence the only option was to use an inactive mutant of 
CD38, e.g. E226Q or E179G, or even to use substrate analogs that are resistant to enzymatic 
conversion. However, even with the limitations in the previous results, they were still consistent 
with the results recently obtained by Kotaka et al. (2012). Generally, the cyclization can proceed 
with either NAD, to produce cADPR, or with its analog, ara-2’FNAD, which, like NAD, is a 
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substrate for the Aplysia cyclase and CD38, except with the substitution of a fluorine atom at the 
2’-position of the adenylyl ribose (Liu et al., 2008; Zhang et al., 2011; Kotaka et al., 2012). It 
has been found that ara-2’F-NAD, or NAD enters the active site pocket with its nicotinamide-
end first, which interacts with the catalytic residue Glu226 in CD38 and Glu179 in the cyclase. 
The interaction is not via the anomeric carbon (C1) of the terminal ribose, the cyclization site, 
but through the two -OH groups of the ribose, forming hydrogen bonding with the carboxyl 
group of the catalytic residue (Liu et al., 2006; Kotaka et al., 2012). This leads to straining of the 
ribose ring and a cleavage of the glycosidic bond to release the nicotinamide group. 
Moreover, Lee (2012), using cyclase crystallographic information, identified 22 folding 
conformations (folding states) during the interaction of NAD with the enzyme to produce a 
cyclic compound, of which only 3 are shown in Figure 1.7. The conformations started from an 
extended (initial) state (coloured yellow) in which the adenine ring stacks parallel and interacts 
hydrophobically with Tyr81. During the intermediate state (transparent) the N1 of the adenine 
brings closure to the anomeric carbon C1 of the terminal ribose. In the fully folded state 
(coloured cyan) the adenine interacts with Trp140 and the N1 of the adenine is only 5.2 Å from 
C1 in order to form the cyclization linkage (Lee, 2012). The same crystallography technique has 
also been applied to CD38 to visualize the folding process (Zhang et al., 2011). 
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Figure 1.7 Visualization of the ara-2’FNAD cyclization reaction catalyzed by the cyclase. Adapted from 
Lee (2012). 
 
1.9 The Second Messengers (cADPR and NAADP) 
There are several known calcium mobilizers. First, inositol trisphosphate (IP3), a second 
messenger that facilitates Ca
2+ 
mobilization from its endoplasmic reticulum (ER) stores, was first 
shown in pancreatic acinar cells after activation by carbachol (Streb et al., 1983, Churchil et al., 
2002). Several years later, a second active calcium inducer (cADPR) was purified by Lee et al. 
(1989). cADPR as a second messenger was found to induce calcium release from sea urchin egg 
homogenates through a variety of mammalian cells, including human cells (Dargie et al., 1990; 
Lee, 2002). Evidence suggests that cADPR is an endogenous modulator of the Ca
2+
-induced Ca
2+
 
release (CICR) mechanism in cells, which is known to be mediated via the ryanodine receptor, 
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RyR (cADPR main target) in the endoplasmic reticulum (Lee et al., 1995a). The activation of 
RyR by cADPR requires the presence of accessory proteins, such as calmodulin (Thomas et al., 
2002) and FK506-binding protein; FKBP (Zhang et al., 2009b). 
The third and the fourth calcium mobilizers are NAADP (Lee and Aarhus, 1995) and ADPR, 
which also play important roles in Ca
2+
 signalling (Lee, 2006). While ADPR acts on plasma 
membrane transient receptor potential cation channel member 2 (TRPM2), the NAADP channels 
have been identified as the two-pore channels (TPCs) in lysosomes, and the main role of 
NAADP in Ca
2+
 releasing correlates positively with the expression of TPC proteins (Perraud et 
al., 2001; Brailoiu et al., 2009; Calcraft et al., 2009). 
Indeed, CD38 activity to produce either NAADP or cADPR is dependent on its environment and 
is regulated by pH (Lee, 2006). For example, at physiological pH, CD38 cyclises NAD to 
produce cADPR, and also breaks it down to ADP-ribose, inactivating its signalling function. 
However, that it is able to synthesise and hydrolysise NAADP only at acidic pH, confirms that 
CD38 could be located in two separate environments in cells and perform different Ca
2+
 
signalling functions. Therefore, CD38 is known as a unique Ca
2+
-signalling enzyme that is 
responsible for cADPR and NAADP production in various cells (Lee, 2012). The first 
demonstration was in sea urchin spermatozoa, which contain micromolar concentrations of 
NAADP (Billington et al., 2002). It has been shown that the synthesis of NAADP can be 
stimulated by several stimuli, including those that elevated cADPR synthesis (extensively 
reviewed by Lee, 2012). Furthermore, it was proposed that NAADP may serve as an initial Ca
2+
 
inducer, whose signal may be amplified by cADPR- and IP3-dependent Ca
2+
 release (Guse and 
Lee, 2008). 
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Interestingly, studies revealed that these two novel Ca
2+
 messengers (NAADP and cADPR) can 
act either individually or in coordination, depending on stimulus type, suggesting a crosstalk 
between the two calcium-mobilizing pathways (Park et al., 2011; Kang et al., 2012; Lee, 2012). 
Also, it is worth mentioning that the entry of cADPR into cells is either mediated via CD38, or 
by members of the equilibrative (ENT2) and the concentrative nucleoside transporters; CNT2 
and CNT3 (De Flora et al., 2004) as suggested mechanisms to resolve the CD38 ‘topological 
paradox’. However, the NAADP transporter has not been identified, although it has been 
suggested that the proteins involved in NAADP transport are different from those characterized 
for cADPR transport (Billington et al., 2006). In conclusion, these messengers bind via different 
receptors and channels involved in the regulation of Ca
2+
, and activate important signalling 
pathways, for instance, muscle contraction (uterus and bronchi) and gland secretion (pancreas). 
These functions were initially identified in CD38 knockout mice studies or mice modified to 
over-express CD38 (Jin et al., 2007). They have also been confirmed in human disease models 
(Munesue et al., 2010). 
1.10 Role of CD38/second messengers in pathophysiological conditions 
1.10.1 CD38 and obesity 
Obesity is a major disease, defined as an increase in the body’s storage of fat, causing health 
problems leading to increased mortality (Sorensen et al., 2010). It increases the risk of a number 
of health conditions, including hypertension, adverse lipid concentrations, and type 2 diabetes 
(National Institutes of Health, 1998). However, the biochemical explanation for this disease is 
still unclear. Recently, Barbosa et al. (2007) described a novel and unique role for the enzyme 
CD38 as a necessary molecule in the biochemical pathway that leads to the development of 
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obesity, as confirmed by CD38 knockout mice studies. CD38 has been implicated in the 
regulation of a wide variety of signalling pathways in numerous cell types (Galione and 
Churchill, 2000). For instance, CD38 hydrolase activity (NADase) has a key role in the 
regulation of intracellular NAD levels and subsequently regulates NAD-dependent deacetylases 
such as sirtuins; also known as SIRT enzymes (Aksoy et al., 2006). Importantly, SIRT enzymes 
have been implicated as regulators of energy metabolism, cell life span (longevity) and activation 
of peroxisome proliferator-activated receptor γ co-activator-1 (PGC-1α; Rodgers et al., 2005). 
The latter is known as a co-activator with pleiotropic function (Knutti and Kralli, 2001). It plays 
a significant role in energy metabolism and reduces the problems of obesity (Baur et al., 2006), 
by controlling the function and biogenesis of the mitochondria (Lin et al., 2005). Recent studies 
have shown that activation of SIRT (by resveratrol) can protect laboratory animals from a high 
fat diet-induced obesity and its deleterious effects, by increasing levels of PGC1-1α, cellular 
mitochondrial numbers, and energy expenditure (Lagouge et al., 2006). 
However, in the case of CD38-deficient mice, one of the possible mechanisms for mice’s 
resistance to diet-induced obesity is mediated via activation of the NAD-dependent deacetylase 
(SIRT)/PGC1α pathway (Baur et al., 2006). It has been proposed that increasing intracellular 
levels of NAD following CD38 deficiency will promote activation of the SIRT enzymes. SIRT 
activation leads to the activation of PGC1α (Fig.1.8), which is involved in protection from 
obesity (Barbosa et al., 2007).  
Furthermore, several reports have highlighted a crucial role of CD38 as a novel pharmacological 
target to treat metabolic diseases via NAD
+
-dependent pathways. Thus, the manipulation of 
NAD
+
 metabolism has emerged as a reasonable strategy to improve metabolic syndromes, such 
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as protecting against obesity. More recently, a study by Escande et al. (2013), reported that in 
vitro and in vivo inhibition of CD38 activity (via quercetin and apigenin) results in elevated 
cellular NAD levels, decreased overall protein acetylation and improved lipid homeostasis. 
 
 
 
 
 
 
Figure 1.8 The crucial role of CD38 deficiency in preventing the development of obesity through 
activation of SIRT/PGC1α following NAD elevation. 
In summary, in addition to the knockout of CD38, the inhibition of CD38 activity, and elevation 
of sirtuin activity were successful mechanisms for preventing the development of obesity, which 
is part of the NAD manipulation strategy. Another suggested mechanism that might have a 
beneficial effect is through the activation of one of the NAD biosynthesis pathways to increase 
NAD levels, which again could activate the SIRT enzymes, consequently leading to an increase 
in PGG1α activity and reduce the problems of obesity. Successful completion of these proposed 
29 
studies will lead to a better understanding of obesity and may lead to new therapeutic approaches 
for this condition. 
1.10.2 CD38 and diabetes 
Diabetes is a metabolic disorder characterised by chronic hyperglycaemia with disturbances of 
carbohydrate, fat and protein metabolisms, resulting from the destruction of insulin production 
by beta cells in the islets of Langerhans (type 1 diabetes), or from an impairment in insulin 
secretion; type 2 diabetes (Harris, 1989; Atkinson and Maclaren, 1994). The role of CD38 
products in insulin signalling has been demonstrated in diabetes patients by several studies. The 
first pathway proposed for insulin secretion by glucose is mediated by the CD38-cADPR system 
in pancreatic β-cells (Okamoto et al., 1997). It is suggested that in the process of glucose 
metabolism, the generation of ATP induces cADPR accumulation by inhibiting the cADPR 
hydrolase activity of CD38, since the ATP produced competes with cADPR for the binding 
residue, Lys129, of CD38 (Kato et al., 1995). cADPR then stimulates insulin secretion by 
mobilizing intracellular Ca
2+
 from the endoplasmic reticulum (Noguchi et al., 1997). The 
CD38/cADPR system prevents β-cell apoptosis through activation of RyR2 in diabetes 
(Paraskevas et al., 2001). The evidence shows that the Arg140Trp mutation on CD38 might be 
responsible for the development of type II diabetes mellitus, via the impairment of glucose-
induced insulin secretion (Yagui et al., 1998). Furthermore, CD38-deficient mice studies have 
shown an alteration in Ca
2+
 levels, in addition to a reduction in the responsiveness to insulin, 
which is regarded as a survival factor; consequently CD38 deficiency increased islet apoptosis 
(Paraskevas et al., 2001; Johnson et al., 2006). The apoptosis leads to decreased β-cell mass, and 
a disruption of islet architecture (Bonner-Weir, 2000). Another pathway involves the 
CD38/NAADP system, which mediates Ca
2+
 mobilization by insulin in human pancreatic β-
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cells. It has been shown that NAADP-generating enzymes may be involved in insulin signalling. 
Thus, CD38 has important roles in controlling the anti-apoptotic signalling pathway in pancreatic 
β-cells (Johnson et al., 2006). 
The causal relationship between CD38 and insulin release in humans has been further 
investigated, showing that auto-antibodies (a marker of autoimmunity in human diabetic 
patients) to CD38 might be playing a key role in impaired glucose-induced insulin secretion 
(Ikehata et al., 1998). Auto-antibodies against CD38 have been found in sera from Caucasian 
type 1 (insulin-dependent, 13.1%) and type 2 (non-insulin dependent, 9.7%) diabetic subjects 
(Pupilli et al., 1999). They have also been found in 13.8% of Japanese non-insulin dependent 
diabetes (NIDDM) patients along with abnormalities of both the CD38-cADPR signal system 
and effects on insulin secretion (Ikehata et al., 1998; Mallone et al., 2001a). The different results 
of studies may result from the use of different types of islet samples.  
Altogether, these studies might indicate that the auto-antibodies altered the in vivo ADP-ribosyl 
cyclase activity of islet CD38 and impaired glucose-induced insulin secretion. Further studies 
have confirmed that the absence of CD38 accelerates development of autoimmune diabetes in 
non-obese diabetic (NOD) mice (Chen et al., 2006). In summary, CD38 has a regulatory role in 
insulin secretion by glucose in β-cells, via its metabolites, the calcium mobilizers (NAADP, 
cADPR), and that CD38 deficiency may contribute to the pathogenesis of diabetes (Fig. 1.9). 
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Figure 1.9 Simple diagram showing the role of CD38 activities and its products in protection against 
diabetes. 
 
1.10.3 CD38 and Chronic Lymphocyte Leukaemia (CLL) 
Chronic lymphocyte leukaemia (CLL), a B-cell malignancy, is the most frequent leukaemia in 
the western world, and is characterised by increased lymphocytosis (an increase in the number of 
lymphocytes) that results from the accumulation of a population of CD5
+
/CD19
+
/CD23
+
 mature 
B lymphocytes in the peripheral blood, bone marrow (BM) and lymphoid nodes; LN (Rozman 
and Montserrat, 1995; Van Bockstaele et al., 2009). It is also defined as a disease characterized 
by a dynamic balance between cells circulating in the blood and cells located in permissive 
niches in lymphoid organs (Zenz et al., 2010). 
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There are two subgroups of CLL patients, according to CD38 expression, which correlates with 
different clinical outcomes (Damle et al., 1999). CLL patients show either
 
an indolent or a 
progressive course (Caligaris-Cappio and Hamblin, 1999). The two patient subgroups, with 
CD38
+
 or CD38
-
 CLL, differ clinically in several ways, including overall survival (Ibrahim et al., 
2001), time to first treatment (Morabito et al., 2002), bias toward male gender (Damle et al., 
1999), number of leukaemic cells with atypical morphology (Morabito et al., 2002), extent and 
level of adenopathy, lactate dehydrogenase, β-microglobulin levels (Ibrahim et al., 2001; 
Domingo-Domenech et al., 2002) and absolute lymphocyte counts (Del Poeta et al., 2001). 
Hence, CD38
+
 CLL patients have an unfavourable clinical
 
course with a more advanced stage of 
the disease, poor responsiveness
 
to chemotherapy, and a shorter survival state compared to 
CD38
-
 CLL patients (Morabito et al., 2002). Initial studies indicated that CD38 might be useful 
as a surrogate marker for the absence of mutations in immunoglobulin variable (IgV) genes in 
CLL patients (Damle et al., 2007). Furthermore, the correlation between CD38 expression levels 
and cells’ susceptibility to apoptosis makes this molecule a valuable prognostic marker and a 
disease modifier in leukaemia; CLL (Malavasi et al., 2008). 
Researchers have confirmed that in combining CD38 with other negative prognostic markers, 
such as the cytoplasmic kinase zeta1-associated protein of 70 kDa (ZAP-70) and CD49d 
(Morabito et al., 2009), cytogenetic abnormalities, CD23, b2m, p53 function and cell size 
(Shanafelt et al., 2004), all together provide complementary prognostic information in CLL. It 
has been documented that CD38 ligation leads to phosphorylation of the activatory tyrosines 
within the proliferation marker ZAP-70 (Roos et al., 2008). It has been suggested that CD38 in 
association with ZAP-70 in CLL may contribute to the signals mediated by the B cell receptor 
complex (BCR; Chen et al., 2002). This relation may explain why the simultaneous expression 
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of the two molecules is considered an efficient identifier of the high-risk patient subset (Schroers 
et al., 2005). Therefore, patients with CD38
+
 ZAP-70
+
 clones are more responsive to activation 
of intracellular proteins than CD38
+
 ZAP-70
-
 patients (Deaglio et al., 2007a). Moreover, CD38
+
 
CLL clones express specific activation markers in addition to ZAP-70
+
, that are not found in 
CD38
-
 CLL clones (Damle et al., 2002), such as expressing high levels of CD69 and human 
leukocyte antigen (HLA)-DR (Damle et al., 2007). Another characteristic of the CD38
+
 and 
CD38
-
 CLL subgroups is variable telomerase levels (Damle et al., 2004). Lastly, they differ in 
high-risk genomic abnormalities (Krober et al., 2002) in the development of new DNA 
mutations (Ottaggio et al., 2003). 
The earliest investigations of the role of CD38 in CLL pathogenesis and progression, was in vitro 
activation of CD38, elicited by agonistic mAbs that induced a portion of the CLL clone (10%-
30%) to proliferate (Deaglio et al., 2003). The following studies substituted the mAb with the 
CD31 ligand, which proved the same proliferation effect (Deaglio et al., 2005). Noticeably, there 
are many indications of the significant association between CD38 expression and chemotaxis in 
CLL (Deaglio et al., 2007a; Vaisitti et al., 2010). The first indication came from a functional 
cooperation between CD38 and CXC receptor 4 (CXCR4), using a CD38 agonistic mAb which 
was able to enhance the chemotaxis of CLL cells in response to CXCL12 chemokine. However, 
this effect was inhibited by blocking mAbs. This functional cooperation was partial, owing to the 
co-localization of CD38 and CXCR4 in the same membrane region (Vaisitti et al., 2010). 
Furthermore, a recent study has confirmed that co-expression of CXCR4 and CD5 creates a 
percentage of newly born cells that is proximally 10 times higher in CD38
+
 than in CD38
-
 clones 
(Calissano et al., 2009). 
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A strong relationship between CD38 expression, CLL cell migration to solid tissues and clinical 
outcome exists, and that CD38 expression might reflect in vivo CLL cell activation (Fig. 1.10). 
Interestingly, the variable activation status may decline over time, leading to the conversion of 
CD38
+
 cells to CD38
-
 cells, but is reactivated again when the cells are recruited into lymphoid 
tissues (Calissano et al., 2009).  
The most favourable conditions for expansion of CLL clones exist in two separate proliferation 
centre (PCs) sites; in lymphoid nodes (LN) and BM (Jaksic et al., 2004), where a favourable 
microenvironment which provides growth and survival signals mediated by CD38 is available 
(Deaglio et al., 2005). In the proliferation centres, Leukaemic cells come into contact with 
accessory cells, such as T lymphocytes (Patten et al., 2008), follicular dendritic (FDC), stromal, 
endothelial, and mesenchymal cells (Malavasi et al., 2011) and some cytokines and chemokines, 
as shown in Figure 1.10. 
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Figure 1.10 Hypothetical model of the interactions between CLL cells and distinct environments, 
suggesting a role for CD38 in the pathogenesis of CLL.  CD38
+
 CLL cells (grey) are more sensitive to 
CXCL12 signals, with a higher propensity to home to lymphoid tissues than the CD38
-
 (orange). CLL 
lymphocytes in LN (PCs) come into contact with nurse-like (NLC) cells, follicular dendritic (FDC) cells, 
stromal cells, endothelial cells (EC), mesenchymal, and T cells. The presence of these environments, in 
addition to the cytokines and toll-like receptors (TLR) lead to CLL cell proliferation and disease 
progression; these events are more apparent in the CD38
+
 subsets (adapted from Malavasi et al., 2011). 
The initiating event for this activation is still unclear, though a study by  Chiorazzi and Ferrarini 
(2011) which has suggested BCR signalling as a factor promoting cellular stimulation, as CD38
+
 
CLL cells are generally more responsive to BCR signalling in vitro, which is not always the case 
in CD38
-
 clones (Morabito et al., 2010). However, evidence for involvement of CD38 in the 
BCR signalling pathway is indirect and linked to lateral associations with CD19 and CD81 and 
to the co-localization in the same lipid rafts as the BCR (Deaglio et al., 2007b). Hence, besides 
BCR signalling, CD38
+
 cells also respond to signals coming through chemokine and other 
receptors (Lopez-Giral et al., 2004). For instance, nurse-like cells (NLC) that are present in solid 
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lymphoid tissues in vivo express CD38 ligand (CD31), and the interaction between CD38 and 
CD31 in this system promotes proliferation and survival (Deaglio et al., 2005; Burger et al., 
2009). Several reports have shown that CD31/CD38 signals that regulate the adhesion and 
chemotactic response of CLL cells are part of a molecular circuit involving the CCL3 and CCL4 
chemokines, and the integrin CD49d (a4), the latter being a negative prognostic marker in CLL 
(Zucchetto et al., 2009). Collectively, trafficking of a CLL cell to the proliferation centre might 
affect the cell's capacity to express more activation markers such as ZAP-70 and CD49d. 
Moreover, the percentage of CD38
+
 CLL cells might also be extended, favouring 
survival/proliferation of CLL cells over apoptosis (Malvasia et al., 2011). Additionally, the 
ability of leukaemic cells to recirculate from blood to lymphoid organs (the homing process) is 
also regulated by specific subsets of adhesion (integrin) molecules and by matrix 
metalloproteinases (MMPs). The latter play a significant role in mediating cell proliferation and 
prevention of apoptosis in association with chemokine receptors (Vaisitti et al., 2011) by 
degrading the extracellular matrix to facilitate cell migration. One example of MMPs in CLL is 
MMP-9 (Kamiguti et al., 2004), which is found to be involved in CLL cell migration and 
survival (Vaisitti et al., 2011). However, targeting the CLL MMPs is suggested, to block cell 
trafficking to LN and BM (Deaglio et al., 2010). 
Recently, studies have indicated that nicotinamide phosphoribosyl transferase (NAMPT), the 
rate-limiting enzyme in the salvage NAD biosynthesis pathway in leukocytes, also exerts pro-
survival activity in CLL, as recently confirmed from in vitro and vivo studies, suggesting the 
existence of a CD38/extracellular NAMPT (eNAMPT) loop in CLL cells, where CD38 
consumes NAD and generates nicotinamide, triggering eNAMPT expression and activation to 
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resynthesize extracellular NAD levels. Finally, by this pathway pro-survival and activation 
signals will be generated in CLL (Audrito et al., 2012). 
In summary, the coexistence of a large supra-molecular complex, derived from the formation of 
extracellular and intracellular molecules in B-CLL cells, where CD38 looks to be a bridging 
element cooperating with all these molecules, might be one of the reasons for the higher 
migratory potential of CD38
+
 CLL (Willimott et al., 2007). This might provide an initial 
explanation for the clinical observation that patients with CD38
+
 CLL clones have more 
aggressive disease with poor patient outcome. However, whether CD38 expression can affect the 
CLL homing process, through modulation of extracellular NAD
+
 levels, or the generation of Ca
2+
 
active compounds, or through structural re-organization of the membrane, still needs to be 
completely investigated (Vaisitti et al., 2011). 
Altogether, CD38 has been implicated in multiple pathological conditions. Therefore, to further 
assess CD38’s physiological functions and to investigate the role of its products in other 
pathophysiological environments, several CD38 ablation and knockdown studies have been 
established. For instance, CD38-knockout mice studies have shown a highly depleted level of 
endogenous cADPR (Partida-Sanchez et al., 2001). The consequence of cADPR depletion and 
the impairment of its metabolism caused multiple abnormalities and defects (reviewed in Lee, 
2012), including in neutrophil chemotaxis and bacterial clearance (Partida-Sanchez et al., 2001); 
bone resorption (Sun et al., 2003); aortic muscle contraction (Mitsui-Saito et al., 2003); 
regulation of airway tone in response to agonists (Deshpande et al., 2005); oxytocin secretion 
and social behaviour (Jin et al., 2007); fibrosis after hepatic damage (Kim et al., 2010); and 
inflammation after cerebral ischemia (Choe et al., 2011). Recently, Xu et al. (2012) suggested a 
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beneficial role for the CD38/cADPR pathway in mouse coronary arterial myocytes (CAMs). In 
addition to the interesting role of cADPR, the functions regulated by NAADP/TPC are also 
significant (reviewed in Galione et al., 2011). All these functions might also be disrupted in 
CD38 knockout mice, referring to the importance of the NAADP role in addition to cADPR as 
the main CD38 products. In conclusion, most previous and recent studies have supported the role 
of CD38/cADPR signalling cascade in various pathophysiological conditions in human and 
animal models. 
1.10.3.1 CD38 as a possible therapeutic target in human leukaemia 
The distinct differences in CD38 expression between normal cells and their leukaemic 
counterparts has made it attractive for the design of therapeutic protocols driven either by cells or 
by monoclonal antibodies (mAbs; Fig.1.11). These mAbs have a high ability to select CD38
+
 
tumour cell lineages, in addition to the stability of the complex (mAb-target) on the cell surface 
(Maloney et al., 1999). However, in addition to the positive points, the limitation with in vivo use 
of anti-CD38 mAbs, is its widespread expression in multiple cell types and differentiation stages, 
in addition to a presence of CD38 expression in the brain, pancreas, and retina (reviewed in 
Malavasi et al., 2008). These substantial limits, however, have not prevented the design of 
models for in vivo applications. One of these designs includes antibody-dependent cellular 
cytotoxicity against CD38
+
 lymphoid cell lines (Stevenson et al., 1991). 
Additional studies have developed anti-CD38 immunotoxins capable of killing human myeloma 
and lymphoma cells (Bofill et al., 1994). Other models are based on either the use of antibodies 
alone (Tesar, 2007), or conjugated to toxins; mostly for purging applications (Bolognesi et al., 
2005), or conjugated to radiopharmaceuticals. In this design the mAbs are used as carriers of 
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radiopharmaceuticals delivering a lethal hit either by surface or cytoplasmic irradiation (Mehta et 
al., 2004). These models have been applied in myeloma and acute leukaemia cases (Stevenson, 
2006). The mechanisms of action for using antibodies alone as a therapy include the inhibition of 
the migration function that is considered critical for CLL progression. This inhibition might be 
the result of the action of a mAb binding a specific domain of CD38 and disturbing ligation of a 
chemokine (CXCL12) to its receptor. Alternatively, a divalent anti-CD38-anti-CXCR4 
therapeutic reagent might also provide simultaneous binding to CD38 and CXCR4, thereby 
increasing ligand specificity (Deaglio et al., 2008). 
CD38 can also be used as a target for gene therapy by using oncolytic viruses as anticancer 
drugs. These viruses propagate in tumour tissue and destroy it without causing excessive damage 
to normal or non-cancerous tissues, through selective targeting of CD38 (Nakamura et al., 2005). 
The tumour cell is killed by the oncolytic virus as it takes over the cellular translational and 
transcriptional machinery, ultimately leading to an induction of cell necrosis or apoptosis (Parato 
et al., 2005). 
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Figure 1.11 Potential applications of CD38 as a therapeutic target (adapted from Deaglio et al., 2008). 
Recently, two CD38 mAbs have been in clinical development: a humanized mAb; SAR650984 
and a human mAb; daratumumab (de Weers et al., 2011; van der Veer et al., 2011). 
Alternatively, a useful and distinct approach could rely on the use of inhibitors of the enzymatic 
activities of CD38 instead of the mAbs strategy (Kellenberger et al., 2011). This might be a 
useful strategy when CD38 inhibition is used as a therapeutic target in leukaemia and obesity 
patients. On the other hand, using activators of CD38 enzymatic activity might be important for 
other diseases, for instance diabetic patients. 
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In summary, several observations have suggested that CD38 is a potential therapeutic target for 
leukemia. Generally, targeting of CD38 may impair the proliferation of leukaemia cells, and 
might also render it more susceptible to conventional chemotherapy. However, more studies are 
still needed to investigate the role of CD38 as a therapeutic target in leukemia, and probably 
other diseases. 
Finally, it is worth noting that CD38 regulation induced by all trans retinoic acid (ATRA) was 
interestingly involved in the induction of human leukaemia cells’ (HL60) differentiation to 
neutrophil-like cells, as well as restricted cell proliferation. It has been documented that ATRA-
induced CD38 expression is mediated by direct transcriptional regulation via activation of a 
retinoic acid receptor (RAR) and retinoid x receptor (RXR) (Kishimoto et al., 1998). However, it 
has also been indicated that phosphoinositide 3-kinase (PI3-K) is involved in the modification of 
CD38 antigen expression in the ATRA-induced granulocytic differentiation of HL60 cells 
(Lewandowski et al., 2002). Another study by Shen and Yen (2008) documented a causal role 
for Cbl-CD38 interaction in promoting ATRA-induced differentiation of HL60; this interaction 
enhances mitogen-activated protein kinase (MAPK) signalling, leading to myeloid 
differentiation. 
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1.11 The HL60 cell line and induction of differentiation 
The HL60 cell model was derived from a patient with acute promyelocytic leukaemia (Collins et 
al., 1977). These myeloid-restricted precursor cells are a well-characterized model for studying 
the terminal differentiation processes. HL60 cells exhibit the typical properties of leukaemia: 
unlimited proliferation capacity, inability to respond to normal differentiation stimuli, and 
increased obstruction of apoptosis (Palis et al., 1988). However, many agents are known to 
induce differentiation in HL60 cells, with the hope of treating cancer cells by overcoming their 
blocked differentiation through several suggested mechanisms. These include: inhibiting histone 
deacetylase, inhibiting topoisomerase, interfering with DNA and RNA synthesis, and disturbing 
signal transduction (Tsiftsoglou et al., 2003). For instance, induction of promyelocytic HL60 
cells to mature into neutrophil-like cells has been shown after 5-7 days culture with DMSO 
(Collins et al., 1978) or 5 days culture with ATRA (Breitman et al., 1980). In contrast, exposure 
of HL60 cells to phorbol 12-myristate 13-acetate (PMA) or to sodium butyrate under a mild 
alkaline condition induces differentiation into monocyte- and eosinophil-like cells, respectively 
(Fischkoff, 1988; Ahmed et al., 1991). Interestingly, the differentiated HL60 cells have many of 
the functional characteristics of normal peripheral blood granulocytes, including phagocytosis, 
complement receptors (such as CR1, the C3b receptor, and CR3), chemotaxis, and the ability to 
reduce nitroblue tetrazolium; NBT (Collins et al., 1978; Newburger et al., 1979). 
One of the recognised myeloid differentiation agents is all-trans retinoic acid (ATRA), the acid 
form of vitamin A. ATRA treatment has been shown to modulate the secretion of certain 
cytokines as well as the expression of different adhesion molecules, for instance CD38 (Gao et 
al., 2007). CD38 upregulation was observed in several types of myeloid cells, for instance 
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human myeloid leukaemic cell lines HL60 and KG-1, as well as in freshly isolated cells from 
acute promyelocytic (APL) and myeloblastic (AML) leukaemia when exposed in vitro to ATRA 
and in vivo during oral treatment with ATRA (Breitman et al., 1981; Drach et al, 1993, 1994). It 
has been observed that this effect is mediated by the activation of nuclear receptors, RAR and 
RXR, which act as ligand-inducible transcription factors. It has been suggested that ATRA-
induced CD38 expression is mediated via a RAR-RXR heterodimer, rather than an RXR-RXR 
homodimer (Mehta et al., 1997). Indeed, the nuclear receptors, RAR and RXR are encoded by 
distinct genes and bind to specific ligands and response elements. Each RAR and RXR family of 
receptors consists of three subtypes, each subtype being encoded by a distinct gene (Pfahl et al., 
1994; Sporn et al., 1994). RAR subtypes can bind both ATRA and its isomer, 9-cis retinoic acid 
(9-cis RA), whereas RXR subtypes bind only 9-cis RA (Heyman et al., 1992). Thus, each may 
specifically regulate the expression of subsets of retinoid target genes, such as CD38, during 
ATRA-induced granulocytic differentiation of HL60 cells (Drach et al., 1994). These 
observations were confirmed by a study by Kishimoto et al. (1998) in which the presence of a 
retinoic acid-response element (RARE), known as a DR5 repeat, was described, in intron 1 of the 
CD38 gene. 
ATRA has been used in clinical therapy for promyelocytic leukaemia (PML) patients with 
satisfactory results (Warrell et al., 1991). ATRA was either used alone in APL therapy or in a 
combination regimen of ATRA with cytotoxic chemotherapy (Tallman et al., 2002). Another 
example includes ATRA/ATO (arsenic trioxide) and anthracycline-based chemotherapy (Sanz et 
al., 2009). However, the differentiation of APL cells by ATRA shows a side effect known as 
retinoic acid syndrome (RAS), the most dangerous side-effect of ATRA treatment (Mehta, 
2000). RAS is marked by acute respiratory distress and pulmonary oedema (Gruson et al, 1998). 
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Interestingly, an interaction between CD38 and CD31 might be involved in the pathophysiology 
of this syndrome (Lewandowski et al., 2002). The differentiation of APL cells by ATO has also 
shown a side effect similar to that found with ATRA (Sanz et al., 2009). 
1.12 CD38 and HL60 differentiation 
Studies on CD38 expression during ATRA-induced HL60 differentiation are quite varied, as 
some of them suggest that for ATRA-induced CD38 expression during myeloid leukaemia cells 
differentiation, this effect is independent of differentiation and is mediated by RAR activation in 
HL60 cells (Drach et al., 1994). Meanwhile, a further study has demonstrated that the degree of 
the cellular response to retinoic acid (cell differentiation or loss of viability) depends on the 
CD38 expression level (Lamkin et al., 2006). Recently, Congleton et al. (2011) have confirmed 
that induction of CD38 expression promotes myeloid maturation, whereas knocking it down has 
an inhibitory effect on ATRA-induced differentiation, and that effect is mediated through CD38 
receptor functions rather than its enzymatic functions. Hence, CD38 either enhanced or blocked 
cellular differentiation. 
It has been shown that granulocyte differentiation inducers in HL60, including dimethylsulfoxide 
(DMSO), failed to induce CD38 expression, unlike the case with ATRA (Guida et al., 2004). 
However, not only is CD38 expressed in ATRA-induced HL60 differentiation, but the 
differentiation of HL60 is also accompanied with expression of CD11b, CD45RO, CD11c, CD54 
and CD36, and suppression of CD117 and CD44, as investigated in immunophenotyped studies 
using a CD antibody microarray (Barber et al., 2008). Finally, in most previous studies on the 
link between CD38 expression and the differentiation process, one theme remains clear: CD38 
expression affects the differentiation status and might cause this abnormal differentiation. 
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Therefore, by studying this process, an understanding of extracellular/intracellular CD38 levels 
is gained, and even how its role in regulating other intracellular factors might affect the 
differentiation process against a proliferation. 
1.13 The strengths of the HL60 model 
The HL60 cell line is a well-characterized model that is possible to differentiate into cells 
morphologically similar to normal neutrophils, monocytes, macrophages, and eosinophils 
(Breitman et al., 1980; Fischkoff et al., 1984). However, the promyelocytes would normally 
differentiate terminally into only granulocytes. Importantly, the HL60 cell line provides a 
continuous source of human cells expressing CD38 (neutrophil-like cells), after being stimulated 
with ATRA. These cells are grown in culture, and therefore a large number of cells are available 
for experimentation. This would be of high importance for assays that require large numbers of 
cells. 
Additionally, it is well known that peripheral blood neutrophils are short-lived cells and once 
removed from the blood their viability is limited to several hours (Mauer et al., 1960). Therefore, 
a long-lived cell line such as HL60 cells has been found to overcome such a shortcoming. These 
cells are stimulated to neutrophil-like cells in a manner similar to blood neutrophils, and stay 
alive for several days, which is especially important for researchers who are only interested in 
neutrophil studies. Finally, the HL60 cell line is a model of acute myelocytic leukaemia (APL), 
so use of these cells to study terminal differentiation allows one to discover new factors that 
might affect this maturation. Additionally, they might be used as a potential therapy for 
differentiation diseases like APL. 
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1.14 Objectives of the study 
As a receptor and a multifunction enzyme, CD38 plays important roles in the pathophysiology of 
several human diseases. Several human studies suggest a potential key role for CD38 receptor 
functions in the development of leukemia (for instance CLL). However, the effect of the 
enzymatic function of CD38 on leukemia development needs to be established to find a relevant 
therapy for CD38
+
 leukemia patients. In the current study it was hypothesized that inducing 
CD38 expression or its enzymatic activity might significantly degrade intracellular NAD levels 
and hence have effects on several NAD dependent processes in cells. To test this hypothesis, 
HL60 cells were used as a model for human leukaemia that is able to express CD38 when treated 
with ATRA. The hypothesis that CD38 might control NAD levels and its related metabolic 
reactions might be one of a number of possible mechanisms that are responsible for poor 
prognosis and other consequences in CD38
+
 leukemia patients. The specific objectives were: 
a) to develop methods for determination of NAD levels and CD38 activity; 
b) to determine whether CD38 levels are differentially elevated, both intracellularly and 
extracellularly, during the time course of HL60 differentiation induced by ATRA, by 
measuring cyclase activity of CD38 (cyclase assay), CD38 protein expression by 
flowcytometry and Western blotting, in addition to measuring CD38 gene expression by 
qPCR; 
c) to determine the intracellular NAD(H) levels during a time course of HL60 
differentiation, using a cycling assay; 
d) to develop a novel inhibitor of CD38 activity, in order to test our hypothesis; 
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e) to determine the physiological consequences of the effect of low NAD levels in the cells 
by measuring the NAD/NADH ratio, lactate levels, total glutathione, the lipid 
peroxidation state, DNA damage and cell apoptosis.; and 
f) to investigate the possibility of regulating CD38 gene expression under multiple 
conditions, such as using a CD38 inhibitor (kuromanin), NAD biosynthesis inhibitor 
(FK866), increasing NAD levels, and using several hypoxia conditions. 
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CHAPTER 2 
GENERAL MATERIALS & METHODS 
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2. Materials and Methods 
2.1 Materials 
The HL60 cell line was a kind gift from Anwar Al-mzaiel (University of Plymouth, UK), and the 
human B-lymphocyte-derived cell line (RAJI Cells) was obtained from ECCAC (European 
collection of cell culture). RPMI-1640, Fetal Calf Serum (FCS), L-glutamine, penicillin, 
streptomycin, and trypan blue were all from Lonza, Slough, UK. NGD; kuromanin and all-trans-
retinoic acid (ATRA) were from Sigma-Aldrich Ltd. (Poole, UK); and PBS and NAD were from 
Melford Laboratories (Ipswich, UK). Antibodies for Western blotting, anti-human CD38 mouse 
monoclonal antibody was from BD Bioscience (Oxford, UK) and mouse monoclonal (10H) to 
PADPR was from Abcam (Cambridge, UK). M-MLV reverse transcriptase, dNTPs, random 
nonamers, SYBR Green, and other PCR reagents were purchased from Sigma-Aldrich Ltd. 
(Poole, UK). 
2.2 Culture of HL60 and RAJI cells 
The cells were maintained in suspension in Roswell Park Memorial Institute (RPMI-1640) 
medium supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin and 100 
µg/ml streptomycin, 2 mM L-glutamine, and kept at 37 °C in a 5% CO2 humidified incubator. 
Cultures were passaged twice weekly by dilution in fresh medium to a density of 0.3 × 10
6
 
cells/ml in both 25 and 75 cm
2
 flasks. 
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2.3 HL60 and all-trans retinoic acid (cell differentiation) 
To induce HL60 differentiation with ATRA (Breitman et al.,1980), the cells (2.5 × 10
5
 cells ml
-
1
) were incubated with 1 µM ATRA at 37 °C in a humidified atmosphere of 5% CO2 for up to 5 
days (Fig. 2.1). The cells were then washed twice in RPMI-1640, centrifuged at 200 × g for 5 
min, and subsequently counted and assayed for further analysis. ATRA stock solution was 
dissolved in pure ethanol (99% v/v) at a concentration of 10 mM and diluted into the growth 
media to a final concentration of 1 µM ATRA; the final ethanol concentration in cultures was 
0.01%. HL60 cells were also treated with ethanol (0.01%) as a control. 
 
Figure 2.1 Diagram illustrating HL60 differentiation by ATRA over 5 days.  
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2.4 NBT differentiation assay  
Differentiation of HL60 cells was assessed using the nitroblue tetrazolium (NBT) reduction test. 
Briefly, 100 μl of 1 × 106 cells ml-1 in RPMI media were incubated in 96 well plates with 100 μl 
of 2 mg/ml (0.2% w/v) NBT and 100 μl (200 ng/ml) of freshly prepared phorbol myristate 
acetate (PMA) in RPMI. After 30-60 min incubation at 37 °C in 5% CO2 a humidified incubator, 
cells then were dissolved in 100 μl DMSO to solubilise the reduced NBT (formazan product). 
The absorbance of the solution was measured at 590 nm on a plate reader (VersaMax, Molecular 
Devices, Sunny Vale, CA).  
2.5 Assessment of viability 
A viability test was used to determine the number of viable cells present in cell suspensions; it 
was carried out on all cell samples before they were assayed in each experiment. This assay is 
based on the principle that live cells possess intact cell membranes that exclude the dye, trypan 
blue, whereas dead cells take up the dye. 
In this test, cell suspension (10 µl) was mixed with 90 µl of 0.1% trypan blue, and then (after 5 
min incubation) 10 µl from the mix (cells with trypan blue) were visually examined to determine 
whether cells had taken up or excluded the dye. In this assay, viable cells have clear cytoplasm 
whereas nonviable cells have a blue cytoplasm. 
2.6 Cell proliferation assay (MTT)  
To carry out the MTT assay, 10 µl of 5 mg ml
-1
 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) was added to 100 µl of cell suspension at a density of 1 × 10
6 
cells 
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ml
-1
 in PBS (137 mM NaCl, 2.7 mM KCl and 10 mM phosphate, pH 7.4) in 96 well plates. The 
plate was incubated in a humidified incubator for 2-3 h at 37 °C to allow reduction of MTT. The 
reduced MTT was solubilized by the addition of 100 µl DMSO to each well and each sample 
was pipetted several times to aid dissolution. Plates were read in a plate reader (VersaMax, 
Molecular Devices, Sunny Vale, CA) set to 540 nm. 
2.7 mRNA isolation and Quantitative Real-Time PCR 
Levels of mRNA for CD38, GAPDH, CD157, IDO, NMNAT and NAMPT were determined in 
ATRA-treated and untreated HL60 cells during the time course of differentiation using 
quantitative real-time PCR. After cell incubation, total RNA was isolated using a commercially 
available GenEluteTM mammalian total RNA miniprep kit (Sigma, Poole, UK), which utilizes a 
column based technique to isolate and purify RNA. An On-column DNase-I treatment step was 
used to remove genomic DNA. RNA quantity (A260) and purity (A260:A280) was measured using a 
Nandrop spectrophotometer (ND-1000; Labtech, UK). RNA (1 μg) from control and ATRA-
treated HL60 cells was reversed transcribed to cDNA using M-MLV reverse transcriptase in 
thin-walled PCR tubes (Sigma, Poole, UK) using a GeneAmp PCR System 9700 instrument. 
RNA was denatured at 70 °C for 10 min in the presence of dNTPs (dATP, dCTP, dGTP, TTP; 
0.5 mM) and random nonamers (1 μM); following the Sigma reverse transcription protocol. 
Reaction mixes were cooled on ice for 5 min and then 1 unit of MMLV-reverse transcriptase was 
added to each. Reaction mixes were then incubated at room temperature for 10 min, 37 °C for 50 
min and 94 °C for 5 min. cDNA samples were stored at 4 °C until use. Primer sequences were 
designed using the NCBI website and according to the mRNA sequence of each gene published 
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in the same website using primer Blast software. Primers (Table 1) were purchased from 
Eurofins MWG Operon (Germany), and all primers produced 100-105 bp products. 
Quantitative RT-PCR was performed using a 96 well plate using the StepOne plus sequence 
detection system (Applied Biosystems, UK) and using the DNA-binding dye SYBR green for 
detection of PCR products. GAPDH was used as a housekeeping gene to normalise mRNA 
levels. cDNA was amplified by adding 2 μl to a final reaction volume of 25 μl containing SYBR 
green, 0.05 U/μl Taq polymerase, 300 nM reference dye and 0.2 μM of the specific primers. 
Reactions were performed under the following conditions: 94 °C for 2 min followed by 40 cycles 
of 94 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s. The fluorescence obtained in the reaction 
was normalized using the reference dye included in the master mix. Results of the levels of 
CD38, GAPDH, CD157, IDO, NMNAT and NAMPT expression were indicated by the number 
of cycles required to achieve the threshold level of amplification. The Ct (cycle at threshold) 
value from control HL60 was compared with that of ATRA-treated cells using the ΔΔCt 
methodology to determine the relative target quantity in samples (Livak and Schmittgen, 2001). 
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Table 2.1 Primers used for qPCR experiments, the size and product was shown for each primer. 
 
 
 
 
Genes Primers Size Product 
(bp) 
GAPDH For:CCCACTCCTCCACCTTTGAC   20 100 
 Rev:CTGTTGCTGTAGCCAAATTCGT 22  
CD38 For: GCACCACCAAGCGCTTTC 18 100 
 Rev:TCCCATACACTTTGGCAGTCTACA 24  
CD157 For: GGGAAGGCAGCATGAAAGTC 20 105 
 Rev: GGTCCACGCACTGTAAGAGCTT 22  
IDO For: GCCTGCGGGAAGCTTATG 18 100 
 Rev: TGGCTTGCAGGAATCAGGAT 20  
NMNAT For: TCATTCAATCCCATCACCAACA 22 105 
 Rev: AGGAGAGATGATGCCTTTGACAA 23  
NAMPT For: TCCGGCCCGAGATGAAT 17 105 
 Rev: TGCTTGTGTTGGGTGGATATTG 22  
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2.8 Assessment of CD38 expression during HL60 differentiation by western blotting 
2.8.1 Plasma membrane and whole cell lysate preparation 
75-100 μl pre-cooled lysis buffer (consisting of; 1% Nonidet (NP-40), 150 mM sodium chloride 
and 50 mM Tris HCl (pH 8.0) with freshly added a protease inhibitor (AEBSF 104 mM, 
Aprotinin 80 μM, Bestatin 4 mM, E-64 1.4 mM, Leupeptin 2 mM, Pepstatin A 1.5 mM)), were 
added to the cell pellet (2.5 × 10
6 
cells ml
-1
) with constant agitation for 20 min at 4º C. Cell 
lysate was centrifuged for 30 min at 6000 × g, 4º C. The supernatant was harvested in a fresh 
tube and stored at -20º C for further assays, and the pellet was discarded. 
2.8.2 Preparation of Nuclear Extract 
Cells nuclear extracts were prepared as described by Whiteside et al., (1992). Cells were 
harvested in ice-cold PBS by centrifugation (6000 × g for 30 s) and washed once with ice-cold 
PBS. Cell pellets were then lysed in 150 µl hypotonic lysis buffer (HLB; consists of 10 mM 
HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.125% NP-40 with freshly added protease inhibitor and 1 
mM DTT, pH 7.9). After incubation on ice for 5 min, lysates were centrifuged at 6000 × g for 1 
minute, 4 °C. Cleared lysates (supernatant) were then moved to fresh tubes, frozen and stored at -
20 °C for further estimation of cytosolic protein concentration. 
The nuclei pellets were washed in HLB to remove contaminating cytosolic proteins. After 
washing the pellets, they were resuspended in 100 µl of hypertonic extraction buffer (HEB; 
consisting of 5 mM HEPES, 1 mM MgCl2, 0.5 M NaCl, 0.2 mM EDTA and 25% glycerol with 
freshly added protease inhibitor cocktail (100 µl per 1 ml of lysis buffer; P8340, Sigma, Poole, 
UK) and 1 mM DTT, pH 7.0) for 1 h at 4 °C under agitation. After centrifugation (6000 × g for 
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10 min at 4 °C), supernatants containing the nuclear protein were moved to fresh tubes and 
stored at -70 °C.  
2.8.3 Determination of protein concentration 
Protein concentrations were assessed according to a simple protocol described by Bradford 
(1976). In this assay, 200 μl Bradford reagent was added to 50 μl of each sample and standard 
solutions of bovine serum albumin in 96 well plates. After 5 min incubation the absorbance was 
read at 595 nm using a plate reader. As blank, water was mixed with the Bradford reagent 
The reference standard for the protein under test was bovine serum albumin (BSA), and 
concentrations between 0-20 μg protein ml-1 were used to generate a standard curve for each run 
of the assay. The concentration of protein in each sample was then interpolated from the standard 
curve. 
2.8.4 Western blot assessment of protein expression 
Total protein samples (20 μl containing 50 μg or 100 μg) were mixed with 5 μl of 5× loading 
buffer (60 mM Tris-chloride, pH 6.8, containing 2% (v/v) SDS, 10% (v/v) glycerol and 0.1% 
(v/v) bromophenol blue), and subsequently denatured by incubation for 5 min at 100 °C under 
reducing conditions with freshly added 5% (v/v) mercaptoethanol. 
Equal amounts of protein were electrophoresed on 12% sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) gels using standard conditions. The gel was run in 1 × SDS 
running buffer (192 mM glycine, 25 mM Tris base and 0.1% w/v SDS, pH 8.3) for 45-50 min. 
The voltage was set to 200. After electrophoresis, the protein-containing gel was sandwiched 
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between buffer-soaked filter papers. Polyvinylidene fluoride (PVDF) membranes were used and 
were placed immediately next to the gel. The sandwich was placed in the blotting tank full of 1× 
pre-cooled blotting buffer (192 mM glycine, 25 mM Tris base and 20% methanol) with the gel 
towards the anode, and the blot was run at 100 V for 36 min. Two sets of molecular weight 
markers were used to calibrate the gels as well as to assess transfer efficiency; prestained 
markers (10 kDa to 190 kDa; from Bioline Reagents Ltd., London, UK) and biotinylated 
(unstained) protein ladder (9 kDa to 200 kDa; from New England Biolabs, Hitchin, UK). 
When blotting was complete, the membrane was blocked at room temperature by shaking in 
Tris-buffered saline-0.05% Tween 20 (TBS-T) solution containing 5% skimmed milk (w/v) for 1 
h. The proteins were then (after blocking) probed overnight at 4 °C with the primary antibody 
(CD38 or PAR antibody) at a dilution 1:500 in 2.5% blocking buffer. After the incubation with 
the primary antibody, the membranes were washed 3 times for 5 min in TBS-T before the 1 h 
incubation with the HRP-conjugated secondary antibody (goat polyclonal anti-mouse IgG; 
Abcam Cambridge, UK), which was used with dilution (1:1000) and prepared in 2.5% blocking 
buffer. 
The same washing steps were performed with TTBS before the membrane was soaked briefly for 
5 min in the detection reagents. Before images were captured (exposed for a maximum of 10 
min) the excess detection reagent was drained off by holding the membrane with forceps and 
touching the edge against a tissue. The plot, protein side down, was placed onto a fresh piece of 
Saran Wrap, wrapped up and any air bubbles gently smoothed out with the protein side up. 
Bands were visualized by electro generated chemiluminescence staining (Amersham 
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Biosciences, UK). Digital imaging with a charge-coupled device (CCD) camera-based imagery 
system was used (UVP EC3 Imaging system, Cambridge, UK). 
2.9 NAD
+
 assays 
Multiple enzymatic cycling assays have been used for the determination of NAD
+
 levels as 
follows. 
2.9.1 Glucose 6-phosphate dehydrogenase (G6PDH)/diaphorase cycling assay 
This assay was used to determine NAD
+
 levels fluorimetrically; it consists of two enzymatic 
reactions. In the first reaction, NAD
+
 is reduced to NADH catalysed by glucose 6-phosphate 
dehydrogenase (G6PDH). This reaction was conducted in the presence of an excess of glucose 6-
phosphate. In the second part of reaction NADH is reoxidized to NAD
+
, catalyzed by diaphorase. 
Diaphorase catalyzes the conversion of resazurin into the highly fluorescent resorufin (indicator 
reaction). Fluorescence was measured with excitation wavelength 530 ± 25 nm and emission 
wavelength 590 ± 35 nm. 
2.9.2 Alcohol dehydrogenase cycling assays 
This cycling assay involves a single enzyme catalysed reaction (Fig. 2.2). This assay was 
previously described by Bernofsky and Swan (1973), Self (1988) and Leonardo et al. (1996). In 
this system NAD
+ 
is first reduced to NADH catalysed by yeast alcohol dehydrogenase utilizing 
ethanol as cosubstrate, after which NADH reduces phenazine ethosulfate (PES), regenerating 
NAD
+
 for the next cycle. The PES is then oxidized by passing electrons to a tetrazolium dye ; 
MTT (Self, 1988). The signal from the NAD is then amplified using an enzyme-cycling system. 
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The product of the reaction, a formazan dye, is measured spectrophotometrically at 565 nm. 
However, the method used for NAD determination in this thesis was a slight modification of 
alcohol dehydrogenase cycling assay described by Leonardo et al. (1996). 
Figure 2.2  The principle of enzymatic cycling reaction for the colorimetric determination of NAD
+
. 
 
2.9.2.1 Modified NAD(H) cycling assay 
NAD
+
 and NADH were extracted (Fig. 2.3) by a modification of the protocol described by 
Leonardo et al. (1996). Cells with and without treatment were placed in microcentrifuge tubes 
and centrifuged at 7000 × g for 1 min. After removal of the supernatant, the pellets were 
immediately frozen in a dry ice-ethanol bath. For NAD
+
 extraction, 250 µl of 0.2 M HCl were 
added to the frozen pellets or 250 µl of 0.2 M NaOH for NADH extraction. To extract NAD(H), 
samples were placed in a 100 °C water bath for 10 min and then centrifuged at 4000 × g for 5 
min to remove cellular debris. NAD
+
 or NADH-containing supernatants were transferred to fresh 
tubes and stored in -20 °C until needed. Extracted NAD
+
 or NADH were assayed as described 
below. 
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Figure 2.3 A simple diagram for nucleotides extraction and assay illustrating NAD
+
  extraction by HCl 
and NADH extraction by NaOH. 
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For NAD(H) determination, the NAD
+
, NADH recycling assays were performed in triplicate as 
follows: 49 µl of extracted NAD
+
 (or NADH) was added to the following reaction mixture 
containing 151 µl of 98 mM of sodium bicine, pH 8.0, 24 mM of either NaOH (neutralizing base 
for NAD
+
) or HCl (neutralizing acid for NADH), 1.63 mM of PES, 0.412 mM MTT, 19.6 µl of 
absolute ethanol, 3.92 mM of EDTA and 5 µl of yeast ADH (400 U/mg in 0.1 M bicine buffer, 
pH 8.0). The absorbance at 565 nm was recorded in a plate reader (VersaMax, Molecular 
Devices, Sunny Vale, CA), after 30 min incubation in the dark. NAD
+
 and NADH standards 
from 5 to 60 µM were repeated with each separate experiment, to calibrate the assay (Fig. 2.4 A, 
B).  
The reaction specifically detects NADH and NAD
+
, but not NADPH nor NADP
+
. The enzyme 
cycling reaction significantly increases the detection sensitivity and specificity. NAD
+
 or NADH 
can be easily quantified by comparing with standards of NAD
+
 and NADH. The NAD
+
/NADH 
ratio was calculated by dividing intracellular NAD
+
 levels by NADH levels in the same sample 
after they had been normalized to the cell number. 
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Figure 2. 4 (A) The NAD cycling assay. NAD (5-60 µM) extracted with HCl, the mixture was 
equilibrated in the dark at 25ºC for up to 30 min (r=0.99). (B) The NAD(H) cycling assay. NADH (5-30 
µM) extracted with NaOH, the mixture was equilibrated in the dark at 25ºC for up to 30 min (r=0.99). 
Change in absorbance is recorded at 565 nm. Data are means ± SEM, n=3. 
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2.9.2.2 Effect of cell number on the sensitivity of the NAD assay 
Intracellular NAD was determined in the HL60 cell line to examine the possibility of an effect of 
differences in cell number on NAD levels, which might potentially interfere with the results of 
treatment effects on NAD levels. Thus, different cell numbers were used to assess variations in 
NAD levels in HL60 cells. As shown in Figure 2.5, there were no apparent differences in NAD 
levels in HL60 cells observed using different cell numbers. Therefore, in subsequent studies, 
final cell numbers between 0.24 × 10
6
 ml
-1 
and 0.98 × 10
6
 ml
-1 
were routinely used in the 
experiments. 
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Figure 2. 5 Intracellular NAD levels determined in HL60 cells with cell density (0.24-0.98 × 10
6 
cells ml
-1
) 
and incubation time 30 min. Data are means ± SEM, n = 3 (7 measurements). 
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CHAPTER 3 
THE EFFECT OF CD38 EXPRESSION ON 
NAD LEVELS IN HUMAN LEUKEMIA CELLS 
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3.1 Introduction 
CD38 has a dual behaviour, with enzymatic and receptorial functions. As a receptor, CD38 
controls signalling pathways involved in the activation, growth and survival of lymphoid and 
myeloid cells (Mallone et al., 2001). The role of CD38 as a negative prognostic marker in CLL 
has also been widely confirmed (Matrai, 2005). The CLL published data, in which the levels of 
CD38 expression correlated inversely with patient outcome have generated much attention. In 
CLL, CD38 measurements have become more straightforward than those of  IgVH mutation and 
other negative prognostic markers (Damle et al., 1999). While much accumulated data has 
shown a distinct role of the CD38 receptor functions in the poor prognosis in CLL patients, to 
this author’s knowledge nothing is known about the role of CD38 enzymatic functions in 
leukemia. To address this issue, HL60 cells, which express CD38 when treated with ATRA, were 
used as an available model for human leukaemia. Another leukemia cell line was also used in 
this study; RAJI cells (Burkitt lymphoma) also express the CD38 molecule (Trubiani et al., 
2008). Our hypothesis was based on the previous findings of Barbosa et al. (2007), who reported 
that in CD38 knockout (KO) mice, intracellular NAD levels are increased. Furthermore, another 
study in macrophages has shown that when CD38 is genetically deleted, an increase in 
intracellular NAD levels occurs (Iqbal and Zaidi, 2006). This might reflect the major role that 
CD38 has as an endogenous and extracellular regulator of NAD levels. Therefore, the hypothesis 
of this study was that NAD levels might be depleted in the case of CD38 upregulation. It was 
also expected that low levels of NAD, an important coenzyme for the network of enzymes 
involved in vital metabolic pathways in the cell, might have physiological consequences, such as 
in the case of leukemia patients where the CD38
+
 subset of patients show poor prognosis and 
short survival. 
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It is worth mentioning that CD38 receptor functions in CLL have been well documented over 
many years by different groups (Deaglio et al., 2008; Malavasi et al., 2008). However, the 
purpose of the current study was to draw attention to the cellular enzymatic function of CD38 in 
the poor prognosis in leukemia. To do this, a number of approaches were used: HL60 cells were 
differentiated to neutrophil-like cells using ATRA, and CD38 protein levels, cyclase activity and 
CD38 mRNA levels were all investigated by different methods; the intracellular NAD levels 
were evaluated during the differentiation process by using a modified NAD cycling method; the 
levels of other enzymes that catalyse NAD-consuming reactions such as CD157, PARP, and 
sirtuins, in addition to the expression of NAD biosynthesis enzymes were all determined during 
the differentiation. The current study shows for the first time that when CD38 expression is 
induced by ATRA, intracellular NAD decreases significantly and that this high degree of NAD 
degradation correlates with CD38 expression. 
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3.2 Material and methods 
3.2.1 Materials 
RPMI-1640 medium, fetal calf serum (FCS), L-glutamine, penicillin, streptomycin, trypsin and 
trypan blue were all purchased from Lonza Ltd. (Slough, UK). NAD was from Melford (Ipswich, 
UK). NGD, kuromanin, ATRA, M-MLV reverse transcriptase, dNTPs, random nonamers, 
SYBR® Green and other PCR and western blotting reagents were all purchased from Sigma-
Aldrich Ltd. (Poole, UK). FACS antibodies; phycoerythrin (PE)-conjugated anti-CD38 antibody 
and mouse IgG1 K isotype control (PE) were all from eBioscience Ltd. (Hatfield, UK). The 
MCF-7 cell line was a kind gift from Niketa Ferguson (University of Plymouth, UK). 
3.2.2 Culture of the MCF-7 cell line 
The adherent breast cancer cell line, MCF-7, was cultured in RPMI-1640 medium supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-
glutamine. The confluent cells were passaged by treating them with 0.05% trypsin-EDTA (Life 
Technology, UK). The cells were maintained in culture at 37 °C and under a 5% CO2 atmosphere 
with cell viability greater than 95% as assessed by trypan blue exclusion. 
3.2.3 Measurement of the cyclase activity of CD38 
CD38 cyclase activity was assayed by monitoring the conversion of nicotinamide guanine 
dinucleotide (NGD) to cyclic GDP-ribose (cGDPR), essentially as described previously (Graeff 
et al., 1994; Genazzani et al., in: Putney, 2005). This method was applied to measure the cyclase 
activity for 1.3 - 2.0 × 10
6
 cells ml
-1
 from both whole and lysed cells, and in nuclear extracts (see 
Sections 2.8.1and 2.8.2). The enzyme assay was started by adding 1.3 - 2.0 × 10
6 
cells to a 
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reaction mixture containing 100 µM NGD and phosphate buffered saline (PBS), pH 7.4, to final 
volume of 0.75 ml in a UV-cuvette. The production of fluorescent cGDPR was monitored for 5-
10 min fluorimetrically with an excitation wavelength of 300 nm and an emission wavelength of 
410 nm, using an LS50B luminescence spectrophotometer (Perkin Elmer, UK). The initial rate 
was expressed as the change in fluorescence intensity per second (ΔF/s). 
3.2.4 Detection of surface and intracellular CD38 during HL60 differentiation by 
fluorescence-activated cell sorter (FACS) 
3.2.4.1 Flow cytometry for extracellular staining 
Following treatment of HL60 cells (Section 2.3) with ATRA (1 µM), 1.5 × 10
6
 cell ml
-1
 were 
washed twice with PBS. After this, pellets were resuspended in 100 µl of FACS staining buffer 
(PBS containing 1% w/v bovine serum albumin) and then incubated for 30 min at 4 °C followed 
by washing three times by centrifugation at 200 × g for 5 min. The pellets (1.5 × 10
6 
cells) were 
resuspended in 100 µl FACS staining buffer, and 15 µl aliquots of cell suspension were 
incubated with either conjugated monoclonal anti-CD38 antibody (HIT2-PE, 0.25 µg/100 µl; 
1:20 dilution), or isotype control-PE (0.25 µg/100 µl; 1:20) for 30 min at 4 °C in the dark. After 
incubation, cells were washed twice with 500 µl of FACS buffer and resuspended in 500 µl PBS. 
Samples were incubated on ice after mixing and kept in the dark to avoid photo bleaching until 
they were analysed. The samples were sorted on a BD FACSAria
TM
II flow cytometer (Becton-
Dickinson, USA), and data from 10,000 events were collected and analyzed by the BD 
FACSDiva version 6.1.3 software.  
In each experiment, CD38 antibody conjugated to a fluorochrome (PE) was used to distinguish 
CD38 positive cells (cells that bind antibody) from CD38 negative cells (cells that did not bind 
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antibody) or from the isotype control (negative control). CD38 positive cells give much greater 
fluorescence intensity than CD38 negative or unstained and control cells. 
Before analysis, cells were gated and the cell debris was discounted using the forward scatter 
(FSC) and side scatter (SSC) profiles (Fig. 3.1). Data were analyzed using WinMDI 2.8 software 
(Joe Trotter, Pharmingen, CA). Mean fluorescence index (mfi) was calculated as: mfi = 
fluorescence (test) – fluorescence (isotype control)/ fluorescence (isotype control). 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 cells were gated and cell debris was gated out based on forward scatter (FSC) and side scatter 
(SSC) profiles as shown in the SSC-FSC dot plot, to analyse data by using WinMDI 2.8 software and 
to calculate mean fluorescence index. 
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3.2.4.2 Flow cytometry for intracellular staining 
Intracellular staining was performed according to the protocol described by Jacob et al. (1991). 
Cells were harvested, washed twice with PBS at 200 × g for 5 min, and resuspended at 
approximately 1.5 × 10
6
 cells ml
-1
 of PBS. Cell viability was assessed using trypan blue, and was 
not less than 99%. Cells were fixed with a 1× fixation buffer containing 4% paraformaldehyde 
(eBiosciences, UK) for 20 minutes on ice. For permeabilization, cells were washed twice with 
SAP buffer (PBS containing 2% v/v fetal calf serum and 0.3% w/v saponin). The cells were then 
stained for 30 min at 4 °C with the anti-human CD38 PE (0.25 µg/100 µl, clone-HIT2) in SAP 
buffer or with 0.5 µg/100 µl of mouse IgG1 K isotype control PE. After two washes in PBS 
containing 1% BSA and 0.1% saponin, cells were resuspended in 500 µl PBS and analyzed on a 
BD FACSAria
TM
II flow cytormetry (Becton-Dickinson, USA). For each case studied, 10,000 
events were processed, and data were analyzed using BD FACSDiva version 6.1.3 software. For 
negative controls, the primary antibody was omitted. 
3.2.5 Co-culture of differentiating cells with MCF-7 cells and measurement of cell 
proliferation by MTT assay 
The cell lines (HL60, RAJI, MCF-7 and differentiating cells) were maintained in culture at 37 °C 
under a 5% CO2 atmosphere at cell viability greater than 95%. For the co-culture experiments, 
the adherent MCF-7 cells (2 ×10
5
 cells/ well) were grown in six-well plates and incubated for 24 
h. On the day of the experiment, 1 ml of 3 × 10
6
 HL60 cells (3 days differentiated) were added to 
plates containing the adherent cells, and cultured for a further 24 h in the same medium and 
incubated at 37 °C. The supernatant containing the suspended, differentiated cells was collected 
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and washed with PBS. Cell proliferation was measured using the MTT cell proliferation assay as 
previously described (Section 2.6). 
3.2.6 Determination of intracellular NAD levels in cells treated with CD38, PARP and Sirtuin 
inhibitors 
HL60 cells (2.5 × 10
5
 ml
-1
) were seeded in a 25 cm
2
 culture flasks and incubated with 1 µM 
ATRA for 3 days in the presence or absence of a PARP inhibitor (4-amino-1,8-naphthalimide, 1-
30 µM) or a sirtuin inhibitor (sirtinol). The cells were then harvested and collected by 
centrifugation, washed and counted. The intracellular NAD was extracted and the level 
determined by the enzymatic cycling assay as previously described (Section 2.9.2.1). 
The intracellular NAD levels was determined in HL60, RAJI or differentiating HL60 cells (2.5 × 
10
5
 cells ml
-1
) treated with 1-30 µM kuromanin, an inhibitor of CD38 cyclase activity, at times 
up to 6 h. In addition to measuring NAD levels, both cell proliferation (MTT assay) and 
nitroblue tetrazolium reduction (NBT assay) were also determined in all cell lines after being 
treated with kuromanin at various concentrations and for different incubation times. 
 3.2.7 Statistical analysis 
Statistical analysis of the data was assessed using Fisher’s one way analysis of variance 
(Statview 5.0.1; Abacus concepts, USA) or Student’s t-test as appropriate. Data are expressed as 
means ± SEM for three separate experiments in triplicate, unless otherwise stated. A difference 
of P < 0.05 was considered statistically significant.  
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3.3 Results 
3.3.1 ATRA-induced HL60 mature granulocyte cell differentiation and inhibited cell 
proliferation  
HL60 cells can terminally differentiate to granulocytic (neutrophil-like) cells after incubation 
with 1 µM ATRA for 5 days. To confirm this characteristic, the NBT assay was used to evaluate 
cell differentiation. NBT, a water-soluble dye, is widely used to detect the production of 
superoxide anions within phagocytic cells, and in the process it is reduced to an insoluble 
intracellular blue-black formazan. The measurement of superoxide anions is considered to be an 
accurate method for estimating the ability to generate a respiratory burst (Baehner et al., 1976).  
The results showed a significant increase (1-way ANOVA, p < 0.01) in the NBT reduction 
capacity (Fig. 3.2) in HL60 cells treated with ATRA for 5 days (0.51 ± 0.15), compared with 
treated cells at time zero (0.23 ± 0.068) and undifferentiated HL60 cells (0.14 ± 0.04), indicating 
mature granulocyte differentiation. These results are consistent with the previous reports that 
indicated that approximately 70-80% of HL60 cells matured towards granulocyte like cells after 
day 4 of differentiation (Imaizumi et al., 1987).  
Further evidence for cell differentiation induced by ATRA is provided by the morphological 
change of HL60 cell to neutrophil-like cells as determined by Wright-Giemsa-stained cytospin 
slide preparations. HL60 cells were successfully differentiated to neutrophil-like cells (Fig. 3.3). 
HL60 cells cultured without ATRA are predominantly promyelocytes with characteristic 
cytoplasmic granules, large nuclei. However, after 5 days of incubation with 1 µM ATRA, a high 
percentage of HL60 cells resembled mature granulocytes (mainly segmented neutrophils). Thus, 
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the results (Fig. 3.3) confirm that ATRA induces relatively extensive morphological 
differentiation of HL60 cells. 
The proliferation capacity of HL60 cells after incubation with 1 μM ATRA was determined 
using the MTT assay. As illustrated in Figure 3.4, ATRA inhibited HL60 cell proliferation; 
reduction of cell vitality, compared with the untreated control (100 ± 0.2%), was evident after 24 
h (87.8 ± 11.1%) and was significant on the 3
rd
 (75.2 ± 2.0%) and 5
th
 (74.9 ± 2.0%) days of 
differentiation. These results indicate that ATRA induces HL60 differentiation, but inhibits the 
proliferation process. 
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Figure 3.2 The NBT reduction ability of ATRA treated HL60 cells for 5 days comparing to untreated 
HL60 cells (as control). Data are means ± SEM, n = 3 (3-5 measurements per replicate). * denotes 
significant difference from the control, P < 0.05. 
Figure 3.3 Morphology of undifferentiated (control) and differentiated HL60 cells. Differentiation was 
induced using ATRA for 5 days. Cytospin slide preparations of cell culture suspensions were stained with 
Wright-Giemsa stain and examined using light microscopy (×1000 magnification). Scale bar: 30 µm.  
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Figure 3.4 Effect of ATRA-induced HL60 differentiation over 5 days on cell vitality (MTT assay) as 
compared to the untreated control (HL60). Data are means ± SEM, n = 3 (3 measurements per replicate). 
* denotes significant difference from the control (HL60), P < 0.05. 
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3.3.2 ATRA-induced HL60 differentiation is accompanied by CD38 induction 
Treatment of HL60 cells with ATRA was accompanied with upregulation of CD38 expression 
(Munshi et al., 2002). However, the full mechanisms of CD38 regulation, and the initial 
induction time for its mRNA expression, cyclase activity and protein levels were not fully 
investigated during ATRA-induced HL60 differentiation. Therefore, in this Chapter, a time 
course of CD38 expression during HL60 differentiation was obtained. Also, a comparison of 
surface and intracellular CD38 protein levels and cyclase activity has been determined, which is 
first reported in this Chapter. 
3.3.2.1 Measuement of CD38 mRNA expression by qPCR 
The level of CD38 mRNA expression during cell differentiation was measured using real time 
PCR coupled with reverse transcription. qPCR analysis demonstrated that CD38 mRNA is 
expressed early, from 3 h of differentiation, and reached a maximum at 24 h in a time-dependent 
manner (Figure 3.5); thereafter it remained at a constant level. This finding suggests that ATRA 
induced transcriptional regulation of the CD38 mRNA, and also supports a previous finding of 
Uruno and colleagues (2011) that showed an early-phase increase of CD38 mRNA expression at 
1.5-6 h after incubation of HL60 cells with ATRA. Furthermore, it was of particular interest to 
test whether the second member of the NADase/ADP–ribosyl cyclase gene family (Ferrero and 
Malavasi, 1997), CD157, would also show changes in gene expression during the differentiation. 
Therefore, CD157 mRNA expression in HL60 after treatment with ATRA was analyzed for up 
to 120 h. It was found that CD157 showed only a slight but significant increase after 3 and 5 
days of differentiation (Fig. 3.5). Hence, CD157 does not appear to be upregulated during HL60 
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differentiation. These results suggest the possibility of CD38 being the major NAD-consuming 
enzyme that is expressed during HL60 differentiation, rather than its homologue, CD157. 
 
 
 
Figure 3.5 Time-course analysis of CD38 mRNA induction in HL60 cells treated with ATRA over 5 days 
differentiation showing the increase in CD38 expression, but not in CD157 expression comparing to 
untreated control (HL60). Data are means ± SEM, n = 3 (4-7 measurements per replicate). * denotes a 
significant difference from the control (HL60), P < 0.05. 
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3.3.2.2 Surface and whole cell lysate CD38 cyclase activity during HL60 differentiation 
In light of previous evidence which showed that CD38 mRNA was upregulated during 
differentiation of HL60 cells, the relationship between gene expression and the active form of the 
protein was investigated. Therefore, in this study, the intracellular and extracellular cyclase 
activities of CD38 were explored. CD38 cyclase activity was measured for whole cell lysate 
(representing intracellular and extracellular cyclase activity), and viable differentiated cells 
(representing extracellular cyclase activity) as shown in Figure 3.6. There was a significant 
increase in the CD38 cyclase activity during the first 24 h of differentiation. CD38 activity 
reached its maximum level in both cases at 6 h during the differentiation, with lower activity 
seen at 8 - 12 h. However, at 24 h, a twofold increase activity was seen in both the cell lysate 
(200.0 ± 8.2%) and live cells (260.0 ± 29.7%) compared to the untreated control. It is noteworthy 
that CD38 cyclase activity in cell lysate was found to be (unexpectedly) lower than that of viable 
cells. One explanation is that using a lysis buffer might result in lowered enzymatic activity in 
comparison to that for viable cells. In addition, if it is possible that extracellular nucleotides (in 
this case NGD) are able to enter cells as previously reported by Billington et al. (2008a), then the 
NGD cyclization activity in viable cells might represent whole CD38 cyclase activity.  
As confirmed above, CD38 is active during the early stages of differentiation. Therefore, the 
extracellular CD38 cyclase activity was further measured on the 1
st
, 3
rd
 and 5
th
 days both in 
HL60 cells and in differentiated HL60 cells. A significant increase in cyclase activity was shown 
(Fig. 3.7) on the third day of differentiation. Thereafter, the activity increased gradually up to 
day 5, as compared to the appropriate control. Altogether, the data presented in this section 
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confirm a continuing increase in CD38 activity during the in vitro differentiation process. This 
increase is initiated within 4 hours and progresses over the 5 days of differentiation. 
 
 
 
Figure 3.6 Time courses of measuring of CD38 cyclase activity in whole cell lysate (solid line) and in 
live cells (dashed line) in HL60 cells during differentiation using ATRA over 24 hours comparing to 
untreated control (100%). Data are means ± SEM, n = 3 (1 measurement per replicate). * denotes 
significant difference from the untreated control (HL60), P < 0.05. 
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Figure 3.7 Time course of CD38 cyclase activity in HL60 cells treated with ATRA over 5 days 
comparing to each untreated control (HL60). Data are means ± SEM, n = 3 (3 measurements per 
replicate). * denotes significant difference from the appropriate control (P < 0.05). 
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3.3.2.3 Analysis of intracellular and extracellular CD38 by FACS 
As stated above, a comparatively rapid increase in CD38 expression occurs in response to ATRA 
in HL60 cells. This can be conveniently measured by using flowcytometry, in addition to the 
previously measured ADP-ribosyl cyclase activity of CD38, using the NGD technique, or its 
mRNA expression using qPCR. Thus, CD38 expression was analyzed before and after 
permeabilization using saponin, to distinguish between surface and internal CD38 expression. 
Saponin is a detergent which complexes with membrane cholesterol and thereby disrupts the 
lipid structure (Schroeder et al., 1998).  
In the current work, extracellular staining with a CD38-antibody in HL60 cells was determined 
after treatment with 1 µM ATRA for 10 h, 18 h, 1 day, 3 days and 5 days as shown in Figure 3.8 
A; 3.10 with significant differences in the CD38 positive cells being observed compared to the 
control. These results confirm that CD38 was significantly expressed at 10 h of differentiation, 
and up to 5 days. Parallel cultures of HL60 cells without the ATRA treatment and RAJI cells 
served as negative and positive controls, respectively (Figure 3.9).  
Cell permeabilization with saponin, was also applied before staining with CD38 antibody in 
order to allow internal access which facilitates intracellular CD38 investigation in addition to 
measuring its surface localization. Unexpectedly, our findings (Fig. 3.8B) did not show an 
increase in the MFI from CD38 positive cells staining with a CD38-antibody compared to the 
extracellular staining. However, the results (Figure, 3.10) show more internal (total) CD38 
expression at 10, 18, and 24 h differentiation compared to the undifferentiated HL60 cells.  
83 
The results suggest that, both in CD38 positive cells (RAJI) and during the differentiation, it 
seems likely that CD38 antibody was probably able to detect surface CD38 epitope better than 
the internal CD38 even under permeabilization circumstances. It might also suggest that CD38 is 
mostly expressed on the cell surface with less expressed intracellularly. 
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Figure 3.8 Expression of CD38 in HL60 cells treated with ATRA, analyzed by FACS after staining with 
CD38 antibody (HIT2-PE) and expressed as mean fluorescence index comparing to untreated HL60 cells 
(as control). (A) Extracellular CD38 expression from 10-120 hours of differentiation and (B) Total CD38 
expression at 10, 18, and 24 h of differentiation. Data are means ± SEM, n = 3 (1 measurement per 
replicate). * denotes significant difference from the control (P < 0.05). 
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Figure 3.9 Expression of extracellular CD38 (red histograms) versus intracellular CD38 (blue 
histograms) in RAJI cells (positive control), and undifferentiated HL60 cells (negative control), in 
comparison with the Isotype control (IgG)-stained cells shown in the black histograms. Cells were stained 
with PE-labeled anti-CD38 mAb and analyzed by FACS. Data are representative of three independent 
experiments. 
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Figure 3.10  Expression of extracellular CD38 (red Histogram) versus intracellular CD38 (blue 
Histogram) in the time course of ATRA-induced HL60 differentiation, in comparison with the Isotype 
control (IgG) stained cells shown in the black histograms. Cells were stained with PE-labelled anti-CD38 
mAb and analyzed by FACS. Data are representative of three independent experiments. 
 
A  HL60 cells 
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3.3.2.4 CD38 Western blots for whole cell lysate and nuclear extract 
In this part of the work CD38 expression was investigated both in cell lysates from 
undifferentiated (control) and differentiating HL60 cells by Western blotting, in order to 
determine the time course of CD38 accumulation after ATRA treatment. An additional aim was 
to investigate the molecular forms of CD38 that are present in differentiating cells or the control 
on the plasma membrane and the subcellular location. Thus, Western blotting was used for all 
cell lysates under reducing and denaturing conditions by using a mouse monoclonal CD38 
antibody. The results (Figure 3.11 A, B) showed that both HL60 cell lysate and differentiating 
HL60 cell lysate at 0-120 h (after ATRA treatment) possess a single 45 kDa monomer of CD38, 
but with different intensity. In all experiments, the positive control used, RAJI cell lysate always 
contained a single 45 kDa band form of CD38. A strong 45 kDa band corresponding to CD38 
appeared after 10 h of incubation of HL60 cells with ATRA (Figure 3.11 A), with the maximum 
band intensity clearly shown on day 3 of differentiation. A weak 45 kDa band was observed in 
control cells as well as at 0, 3 and 6 h of differentiation. In addition, the results (Figure 3.11 A) 
confirmed that lysate from both differentiating and undifferentiated HL60 cells contain high 
molecular weight (HMW) forms of CD38 together with 60 kDa and 190 kDa molecular forms. A 
HMW form, 190 kDa has been observed clearly after 6 h of ATRA incubation with HL60 
leukemic cells. 
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Figure 3.11 Time-course of ATRA treatment of HL60 cells over 5 days showing (A) Western blot of 
differentiating cells for CD38 showing the 45 kDa band corresponding to membrane CD38 under 
reducing, denaturing conditions and 12% SDS-PAGE. 100 µg of protein/ well were used each experiment 
with 1:500 primary antibody dilution (data represent 1 of the 3 separated experiments) (B) The 
luminescence intensity of CD38 single band 45 kDa. Data are means ± SEM, n = 3 (1 measurements per 
replicate). * denotes significant difference from the untreated control (HL60), P < 0.05. 
A 
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In summary, the Western blotting results support FACS data, since the extracellular CD38 
clearly appeared within 10 h of differentiation compared to undifferentiated HL60 cells. 
Therefore, as CD38 was expressed on the plasma membrane from early in the differentiation 
process, it seemed important to determine whether CD38 was also expressed intracellularly in 
the nuclei. Thus, to address this issue, the nuclei of ATRA-treated HL60 cells were extracted and 
the molecular forms of CD38 were investigated in both HL60 cells and HL60 cell lysate after 0, 
10, 24 and 72 h of incubation with ATRA (Figure 3.12A).  A weak 45 kDa band appeared at 24 
h of differentiation and increased after 3 days of differentiation (Figure 3.12A). The same 45 
kDa band, the monomeric form of CD38, was also seen in the RAJI cell nuclear fraction but was 
absent both in the undifferentiated HL60 cell lysate and in the cell lysate at 0 h and 10 h of 
differentiation. A high molecular weight (80 kDa) form of CD38 also appeared in nuclear 
fractions and was clearly visible in both RAJI cell lysate and after one day of HL60 
differentiation.  
It is important to mention that reducing conditions with mercaptoethanol were used in both the 
plasma membrane and nuclear fractions. Furthermore, ATRA-induced expression of CD38 on 
nuclei from HL60 cells was also investigated using the NGD assay (Figure 3.12B) at 10, 24 and 
72 h after treatment with ATRA, and also using undifferentiated HL60 cells as a control. The 
results revealed NGD cyclization by CD38 activity which is clearly observed on the surface of 
nuclei after treatment with ATRA at 1 and 3 days. These and previous observations indicate that 
the majority of the CD38 cyclase activity occurred in the plasma membrane fraction and, to a 
lesser extent, in the nuclei, indicating that CD38 enzymatic activity might have an important role 
in the nucleus in addition to its extracellular activity.  
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Figure 3.12 Time course of ATRA treatment of HL60 cells over 3 days showing (A) western blotting of 
nuclear CD38 under reducing and denaturing conditions. A 12% SDS-PAGE gel with 60 µg of 
protein/well was used in each experiment (gel shown representative of 3 experiments) (B) CD38 
expression in the nuclear fraction was measured as the rate of cGDPR production from NGD. Data are 
means ± SEM, n = 3 (1 measurements per replicate). No significant differences in activity during 
differentiation and comparing to untreated control (HL60) were found (P ˃ 0.05). 
A 
91 
It is important to note that the nuclei used in this investigation were isolated by a conventional 
method (Whiteside et al., 1992). The purity of a nuclear preparation can be characterized by 
either measuring the activity of an endoplasmic reticulum marker; glucose-6-phosphatase or a 
plasma membrane marker; 5-nucleotidase. (Colowick and Kaplan, in: Fleischer and Packer, 
1974). However, this approach was not carried out because contamination of the nuclear extract 
could be excluded on the basis of the absence of CD38 protein in the extract; in HL60 cells, 
CD38 is localised in the plasma membrane and not in the nuclear membrane. Importantly, the 
respective findings of this investigation provide further evidence for ATRA-promoted nuclear 
and plasma membrane CD38 activation. CD38 was previously detected in nuclear membrane of 
differentiating cells (Yalcintepe et al., 2005). Further reports have also revealed that CD38 
enzymatic activity is present not only in the plasma membrane, but also in intracellular 
membranes of organelles such as mitochondria and nuclei (Yamada et al., 1997; Liang et al., 
1999; Khoo et al., 2000; Iqbal and Zaidi, 2006). Interestingly, in all of the work described in this 
Chapter, HL60 differentiation was accompanied by a large increase in CD38 expression and 
cyclase activity (both extracellular and intracellular) from early in the differentiation process. 
Thus, CD38 expression might not only serve as a marker of HL60 maturation to neutrophil-like 
cells, but the enzyme might also catalyse the degradation of NAD during ATRA-induced HL60 
differentiation. This expression might have important consequences on cell metabolism. 
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3.3.3 Effect of CD38 expression on NAD levels during HL60 differentiation  
High levels of CD38 expression and cyclase activity were observed during ATRA-induced HL60 
differentiation. Therefore, it was of importance to investigate the effect of this increased 
expression on the levels of the substrate of CD38, NAD, during ATRA-induced HL60 
differentiation. However, in order to evaluate NAD levels during differentiation, it was important 
to first examine the effect of ATRA on the NAD assay. Therefore, to address this issue, two 
concentrations of ATRA (10 nM and 1 µM) were analyzed along with a range of NAD 
concentrations (0.975 µM, 1.95 µM, 19.5 µM and 195 µM).  
The results (Fig. 3.13) show that both 10 nM and 1 µM ATRA had no apparent effects on the 
NAD assay, even though 10 nM ATRA, at an NAD concentration of 19.5 µM, was the only 
concentration that exerted a significant effect on the NAD assay when compared to other NAD 
concentrations and the control (not treated with ATRA). Importantly, with 1 µM ATRA, the 
concentration which was used to induce HL60 differentiation, the results confirmed that there 
was no interference with the NAD assay. 
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Figure 3.13 The effect of different ATRA concentrations (0, 10 nM and 1 µM) on the NAD assay, at a 
range of NAD concentrations (0.97, 1.95, 19.5 and 195 µM). Data are means ± SEM, n = 3 (3 
measurements per replicate). * denotes significant difference from the appropriate untreated control (P < 
0.05). 
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Thus, NAD levels were determined at 4 - 120 h of differentiation compared to the control (cells 
not treated with ATRA). Surprisingly, a substantial time-dependent decline in intracellular NAD 
levels was clearly detected in response to ATRA treatment in HL60 cells (Figure 3.14). There 
was a significant drop in NAD levels as differentiation occurred to 64.6 ± 8.9% on day 1, 47.3 ± 
7.0% on day 3 and 40.5 ± 8.7% on day 5 compared to the control. 
 A significant decrease in the intracellular NAD levels was seen from early in the differentiation 
(4 h), and levels continued to drop up to 5 days. This rapid decline in NAD levels was 
concomitant with the rise of CD38 mRNA expression as seen in Figure 3.15. Interestingly, the 
latter was seen after 3 h, while NAD degradation started at 4 h differentiation time. These novel 
data might support a major role for CD38 as a regulator of intracellular NAD. 
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Figure 3.14 The decline in intracellular NAD levels during HL60 differentiation estimated over 5 days of 
differentiation and compared to untreated control (HL60). Data are means ± SEM, n = 3 (3 - 7 
measurements per replicate). * denotes significant difference from the control (100% HL60), P < 0.05. 
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Figure 3.15 The decline in intracellular NAD levels (solid line), concomitant with CD38 mRNA 
induction (dashed line) during HL60 differentiation estimated over 5 days of differentiation and compared 
to untreated control (HL60). Data are means ± SEM, n = 3 (3 - 7 measurements per replicate). 
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3.3.4 Kuromanin inhibited NAD-cyclization activity of CD38 and elevated NAD levels, but 
PARP and sirtuin inhibitors had no effect on NAD levels during the differentiation 
To establish whether the novel finding of low NAD levels during HL60 differentiation was due 
to upregulation of CD38 and its enzymatic activity as evaluated in the current study, it was 
hypothesized that inhibition of CD38 activity might lead to elevation of intracellular NAD. 
Therefore, a novel inhibitor of the NAD cyclization activity of CD38, kuromanin, was tested. It 
has recently reported that flavonoids such as kuromanin and luteolin act as inhibitors of human 
CD38 at low micromolar concentrations (Kellenberger et al., 2011). Thus, the effect of the 
inhibition of the enzymatic activity of CD38 by kuromanin was investigated in both RAJI cells 
and the differentiating HL60 cells on intracellular NAD levels (Fig. 3.17). It is worth noting that 
RAJI cells show high CD38 activity compared to HL60 cells, but they have low intracellular NAD 
compared to HL60 cells (Fig. 3.16). 
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Figure 3.16 (A) CD38 cyclase activity in HL60 and RAJI cells as expressed as initial rate. (B) 
Intracellular NAD levels in HL60 and RAJI cells as expressed as pmol/10
6
 cells. Data are means ± SEM, 
n = 2-3 (3-5 measurements per replicate). * denotes significant difference between group (Student’s t test, 
P < 0.05). 
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In the current study, the effect of inhibition using 8 µM kuromanin on NAD levels was first 
investigated in RAJI and HL60 cells up to 2 h of incubation. The results (Fig. 3.17) show that 
RAJI cells have lower NAD levels than HL60 before kuromanin treatment, but they have higher 
NAD levels after kuromanin treatment, which might suggest that CD38 activity was inhibited by 
kuromanin.  
Interestingly, Figure 3.18 A shows that inhibition of CD38 cyclase activity in RAJI cells with up 
to 30 µM kuromanin resulted in significantly elevated intracellular NAD levels after 6 h of 
treatment. As kuromanin leads to elevated intracellular NAD levels, the MTT assay was used to 
monitor cell vitality during kuromanin treatment. Cell vitality was not changed after 6 h 
incubation with kuromanin (Fig. 3.18 B), which might suggest that kuromanin has no effect on 
growth of RAJI cells after 6 h incubation, but nevertheless it significantly affects cell 
proliferation after 48 h incubation (Fig. 3.18 B). 
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Figure 3.17 Intracellular NAD levels in RAJI and HL60 cells treated with kuromanin (8 µM) for up to 2 
h comparing to appropriate untreated control (RAJI or HL60 cells). Data are means ± SEM, n = 3 (4-5 
measurements per replicate), P ˃ 0.05. 
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Figure 3.18 Effect of treatment with kuromanin up to 30 µM on (A) intracellular NAD levels in RAJI 
cells over 6 h comparing to untreated control (100% RAJI cells), and (B) the vitality (MTT assay) of 
RAJI cells when incubated for up to 48 h with kuromanin comparing to untreated control (100% RAJI 
cells). Data are means ± SEM, n = 3 (3-6 measurements per replicate).* denotes significant difference 
from the untreated RAJI cells (P < 0.05). 
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The effect of kuromanin on differentiating HL60 cells was also evaluated. Firstly, the results of 
kuromanin exposure on NBT reduction showed that it might inhibit the differentiation of HL60 
in a concentration-dependent manner (Fig. 3.19). NBT reduction levels also decreased as the 
incubation with kuromanin was prolonged to 4 days, compared to 4 days differentiation without 
kuromanin. However, the mechanism of this effect was not really clear, and it might be due to an 
additional, unknown factor.  
Secondly, treatment of the differentiating cells with kuromanin also affected NAD levels. The 
results showed significantly increased NAD levels in differentiating cells treated with 10 µM 
kuromanin after 6 h (Fig. 3.20). This increase in NAD levels was time-dependent, apparently 
concomitant with inhibition of CD38 activity. 
Upregulation of CD38 expression during ATRA treatment was associated with a significant 
decrease in NAD levels to 60.41 ± 0.92% by 6 h of differentiation. However, inhibition of CD38 
activity by kuromanin (Fig 3.20) was seen to stop the decrease in intracellular NAD and led to an 
increase in NAD levels to 120.71 ± 14.81% after 6 h differentiation with ATRA. The strong 
relationship between CD38 and NAD levels shown in several experiments may confirm a major 
role of CD38 as the main enzyme involved in the regulation of NAD levels. The findings with 
kuromanin are supported by CD38 knockout studies (Aksoy et al., 2006 b; Barbosa et al., 2007), 
and findings in macrophages where CD38 has been genetically deleted (Iqbal and Zaidi, 2006). 
Overall, whether CD38 removed or inhibited, intracellular NAD levels are significantly elevated. 
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Figure 3.19 The effect of treatment with kuromanin up to 30 µM on NBT reduction by ATRA treated 
HL60 cells for 4 days comparing to untreated HL60 cells (control). Data are means ± SEM, n = 3 (4-6 
measurements per replicate). * denotes significant difference from the control (P < 0.05). 
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Figure 3.20 Effect of treatment with 10 µM kuromanin on intracellular NAD levels of differentiated cell 
up to 6 h comparing to differentiated cells without kuromanin treatment (as control). Data are means ± 
SEM, n = 3 (4 measurements per replicate). * denotes significant difference from the control 
(differentiated cells), P < 0.05. 
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To avoid the possibility of other known NAD-consuming enzymes (for example; PARP1, 
SIRT1) participating in the decline in NAD, in addition to the degradative role of CD38, during 
the differentiation process, other experiments were carried out, including treatment with SIRT1 
and PARP1 inhibitors during ATRA-induced HL60 differentiation. The PARP1 inhibitor; 4-
amino-1, 8-naphthalimide, has previously been shown to have a potent inhibitory effect on 
PARP activity in tumour cells (Schlicker et al., 1999). PARP is also known as a major cellular 
NAD
+
 consumer, in addition to CD38 (Sims et al., 1981). Thus, inhibition of PARP activity is 
reported to increase NAD levels in brown adipose tissue and muscle (Bai et al., 2011). PARP 
inhibitors are currently in clinical development as antitumour drugs (Fong et al., 2009).  
On the other hand, NAD works as a substrate and regulator of NAD-dependent deacetylases such 
as SIRT1 which are located in the nuclei, and modulate ageing and energy metabolism in 
mammalian cells (Grubisha et al., 2005; Guarente and Picard, 2005; Pillai et al., 2005). Indeed, 
seven sirtuins (SIRT1-7) have been identified, which target histone and various nonhistone 
proteins in distinct subcellular locations. Both SIRT1 and SIRT2 may have a role in the 
development of cancer (Peck et al., 2010). In addition, it has also been confirmed that Sirtinol, a 
SIRT1 inhibitor, can effectively induce significant growth inhibition or apoptosis in vitro studies 
(Peck et al., 2010), or in in vivo studies such as with adult T-cell leukemia-lymphoma (ATL) 
patients (Kozako et al., 2012). Thus, SIRT1 inhibitors have been suggested to be therapeutic 
agents for leukemia (Kozako et al., 2012). 
The results (Fig. 3.21 A, B) show that neither 4-amino-1,8-naphthalimide (PARP inhibitor),  nor 
sirtinol (SIRT1 inhibitor) changed the intracellular levels of NAD during the differentiation 
compared to the control (the differentiating cells without the inhibitors). The results suggest that 
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there was not sufficient activity of either enzyme to impact on the intracellular levels of NAD. 
Interestingly, PARP activity has previously been reported to be decreased during neutrophilic 
differentiation of HL60 cells (Kanai et al., 1982). This decline is suggested to be achieved 
through changes in the specific activity of PARP and increases in the NAD glycohydrolase 
activity (Kirsten et al., 1991) and these findings strongly support the results obtained (Fig. 3.21 
A). Moreover, the data (Fig. 3.21 B) on NAD levels during the differentiation and in 
combination with sirtinol, might suggest that sirtuin activity is not significant during the 
differentiation or that NAD levels might be mostly controlled by other NAD consuming 
enzymes, mainly CD38. 
In conclusion, the decrease in NAD levels appears to be controlled by the main degrading 
enzyme CD38, and it is clearly independent of the actions of other NAD consuming enzymes 
(PARP and SIRT1) during HL60 differentiation. Moreover, the results of this part of the work 
have further confirmed that the endogenous activities of SIRT1 and PARP might be regulated via 
CD38 enzymatic activities by controlling the availability of their substrate, NAD. 
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Figure 3.21 Intracellular NAD levels were investigated in differentiated cells for 3 days with ATRA after 
treatment with (A) PARP inhibitor (4-amino-1,8-naphthalimide) up to 30 µM or (B)  sirtuin inhibitor 
(sirtinol) up to 30 µM. Data are means ± SEM, n = 3 (3 measurements per replicate). No significant 
differences in NAD levels were found between differentiated cells with or without inhibitor, P ˃ 0.05. 
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3.3.5 Evaluation of the NAD biosynthesis enzymes during ATRA-induced HL60 
differentiation 
A considerable decline in NAD levels was clearly indicated in the time course of HL60 
differentiation, which might be mediated mainly by the activity of CD38 and not by CD157, 
PARP or sirtuin. As it has been shown here that CD157 has negligible gene expression, it 
appears that it cannot account for the decline in NAD levels. Also inhibition of both PARP and 
sirtuin activities did not have any significant effect on intracellular NAD levels. Overall, the 
above data suggests that these enzymes might not participate in the consumption of NAD. 
Hence, having investigated the NAD consuming pathways, it was important to look for other 
mechanisms that might be involved in the decline of intracellular NAD. Thus, NAD biosynthesis 
enzymes were investigated in this study. The hypothesis was that changes in the level of 
expression of NAD biosynthesis enzymes might affect NAD levels.  
It is well known that cellular NAD is synthesized either via the de novo pathway from tryptophan 
or via one of two possible recycling pathways: from nicotinic acid or nicotinamide; vitamin PP, 
or niacin (Magni et al., 2004), and via the nicotinamide riboside pathway (Bieganowski and 
Brenner, 2004). Thus, mRNA levels of some NAD-biosynthesis enzymes were investigated from 
both the de novo (Fig. 3.22) and salvage pathways (Fig. 3.23 A, B). 
Expression of IDO (a de novo pathway enzyme) was found to be upregulated early, at 12 h of 
differentiation (p ˃ 0.05), with a clear decline later on. An increase in IDO mRNA levels then 
was observed at 72 h of differentiation with a continuous increase (P < 0.05) up to 120 h (Fig. 
3.22). It has been demonstrated that the expression of the tryptophan-catabolizing enzyme (IDO) 
in neutrophils (as occurs during influenza infection), in addition to impairing host defense 
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against secondary bacterial infections, also enhances neutrophil apoptosis in vivo (Van der Sluijs 
et al., 2011). This might suggest further functions for IDO in addition to its role in NAD 
biosynthesis. 
The expression of the salvage pathway enzymes NMNAT and NAMPT was also investigated 
during the differentiation. Significantly increased NMNAT mRNA was observed (Fig. 3.23 A) at 
120 h of differentiation, in addition to increases at 18 h and 72 h. NAMPT expression was also 
investigated during the time course; there was no significant change over time (Figure 3.23 B).  
The results indicate an increase in NAD-biosynthesis enzymes, especially IDO, during 
differentiation. Taken together, the data suggest that differentiating HL60 strongly depend on the 
NAD de novo pathway to resynthesize intracellular NAD and to maintain the NAD pool. 
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Figure 3.22 Time course of ATRA-induced differentiation of HL60 cells over 5 days showing the 
increase in IDO expression comparing to untreated HL60 cells (as control). Data are means ± SEM, n = 3 
(3-6 measurements per replicate). * denotes significant difference from the control (P < 0.05). 
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Figure 3.23 Time courses of ATRA-induced differentiation of HL60 cells over 5 days showing (A) 
NMNAT expression (B) NAMPT expression and were compared to untreated HL60 cells (as control). 
Data are means ± SEM, n = 3 (3-4 measurements per replicate). * denotes significant difference from the 
control (P < 0.05). 
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3.3.6 CD38 and cell proliferation 
It is well known that induction of granulocytic differentiation in HL60 cells by ATRA is 
followed by cell death via apoptosis (Mehta et al., 1996). Hence, a reduction in cell proliferation 
was evident after 24 h of culture with ATRA and was most pronounced after 3 and 5 days of 
differentiation (Fig. 3.4). However, the finding of less cell proliferation was not expected in cells 
expressing CD38, since, as previously mentioned (Chapter 1), CD38
+
 CLL cells proliferate more 
in comparison to CD38
-
 CLL cells. However, one possible explanation was the presence of 
CD31, as an effective proliferation factor, known as a CD38 non- substrate ligand. The CD38/ 
CD31 interaction has a role in CLL progression via the induction of a proliferation effect 
(Deaglio et al., 1998; 2000; 2005). Therefore, the hypothesis was to test whether creating 
environments similar to those of leukemia (CLL), by culturing  CD38
+
 cells (differentiated cells) 
with human solid tumour cell lines expressing CD31 such as MCF-7 (breast carcinoma; Tang et 
al., 1993), would induce a proliferation in differentiating cells that are expressing CD38, but not 
CD31.  
There was a significant decrease in cell vitality in the 3 day- differentiated cells as assayed using 
MTT (Fig. 3.24). However, a reversed effect on cell proliferation was interestingly shown after 
co-culturing the differentiated cells (CD38
+
) with MCF-7 cells (CD31
+
) for 1 day. This suggests 
that an interaction between CD38 and CD31 signalling might have occurred. CD38/ CD31 
interactions and their effects have been previously reported; Gao and colleagues (2007) stated 
that CD38 expression induced by ATRA increases adhesion of differentiated HL60 cells to 
vascular endothelial cells (CD31
+
), that results from a protein-protein interaction between CD31 
and CD38 molecules. 
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Figure 3.24 The effects of 1 day culture of differentiated cells (3 days) with MCF-7 cells on cell 
proliferation (MTT assay) as compared to the differentiating cells for 3 days (as control). Data are means 
± SEM, n = 3 (8 measurements per replicate). * denotes significant difference from the control (P < 0.05).  
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It is worth mentioning that important evidence for the effect of CD38/CD31 interaction on cell 
proliferation can also be confirmed in HL60 cells. The undifferentiated HL60 cells have a high 
proliferation capacity and low CD38 levels, but express significant levels of CD31 (Gallay et al., 
2007). Moreover, no observed regulation of CD31 antigen was reported when HL60 cells were 
stimulated to granulocytes by ATRA (Trayner et al., 1998). That explains the low proliferation 
capacity of the CD38
+
 cells (the differentiated cells) compared to the leukemia cell line (HL60). 
Thus, cell proliferation increased especially when CD38
+
 cells interacted with CD31. This also 
suggests the effective role of CD38/CD31 interaction on cell proliferation in CD38
+ 
leukemia 
patients. 
3.4 Discussion 
The role of CD38 as a modulator of NAD levels has not been completely elucidated. Therefore, 
in the present work, the effect of CD38 expression on NAD levels was investigated in the human 
leukaemia cell line (HL60) as a relevant model which can differentiate to neutrophil-like cells. A 
novel key finding of the present study is that HL60 cells are CD38
-
 and have high levels of 
NAD, whereas the differentiating cells were CD38
+
 and have a low content of NAD, which 
correlates with CD38 expression. These results suggest that CD38 may be a main NAD 
degrading enzyme that is expressed during HL60 differentiation. The expression of CD38 in the 
cells was demonstrated using real time PCR coupled with reverse transcription, western blotting 
and flow cytometer. These findings might help with the understanding of the mechanisms that 
regulates NAD levels, and the consequences of this degradation on different cell functions in 
health and disease. This is because NAD has important roles in energy homeostasis, signal 
transduction and ageing by serving as a substrate for a network of enzymes. Based on the current 
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results, it was further hypothesized that in CD38
+
 leukemia cells NAD levels might also be 
decreased compared to CD38
-
 leukemia cells. In reviewing the literature, no data was found on 
the association between CD38 and NAD levels in leukemia. Thus, CD38 enzymatic function 
speculated to have an important role, in addition to its receptor function, in leukemia. It was 
hypothesized that CD38 behaviour as a receptor is independent of its enzymatic function (Lund, 
2006; Congleton et al., 2011). However, there might be a connection between CD38 as a 
receptor and as an enzyme to achieve its functions in processes such as cell proliferation, 
apoptosis, differentiation and activation in disease as in leukemia patients, where CD38 is known 
to be a distinct prognostic marker (Malavasi et al., 2008). The upregulation of CD38 expression 
might affect intracellular NAD levels and several consequences on cell physiology might occur. 
Hence, poor prognosis might be a result of a complex mechanism derived from the effect of 
CD38 enzymatic function, in addition to its receptor functions. 
The present studies, employing a range of techniques, show that differentiating HL60 cells 
possess CD38 which is located extracellularly in the plasma membrane as well as intracellularly 
in the nucleus. Interestingly, CD38 expression can significantly degrade intracellular NAD 
during HL60 differentiation, since the results confirmed that CD38 was not just expressed on the 
plasma membrane. The findings of this study, as well as those of previous reports, have further 
confirmed the presence of intracellular CD38 expression where intracellular NAD, its main 
substrate, is present (Trubiani et al., 2008; Zhao et al., 2012). The presence of intracellular CD38 
was demonstrated by western blotting (a weak 45 kDa band for CD38 at 24 h; Fig. 3.12 A) and 
cyclase activity associated with the nuclear extract (activity shown on day 1; Fig. 3.12 B). Also, 
FACS data for intracellular CD38 shows unexpected, high protein formation levels starting at 
least by 10 h of differentiation. Indeed, CD38 antibody showed high reactivity with extracellular 
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CD38 positive cells before permeabilization with less reactivity to detect the intracellular CD38 
after permeabilization. This might be due to the presence of CD38 as type II and type III 
(opposite orientations) in the cell membrane. These two types were confirmed to be present in 
differentiating HL60 cells (Zhao et al., 2012), which might explain the high levels of 
extracellular CD38 detected, since this antibody might also detect the intracellular CD38 at the 
time of its expression from the cytosol to the cell surface. 
Furthermore, the other NAD-consuming enzymes (CD157, PARP, and SIRT) showed a negative 
contribution to NAD degradation during the differentiation. Since there was a virtually 
undetectable level of CD157 mRNA expression, this suggests that this enzyme cannot account 
for the large decline in NAD levels. Moreover CD157 cyclase activity has been reported to be 
one hundred-fold lower than that of CD38 when murine BST-1 has been expressed in yeast 
(Hussain et al., 1998). Additionally, low activities of PARP (Kanai et al., 1982) and SIRT have 
also been suggested during HL60 differentiation. This was confirmed by the lack of change in 
intracellular NAD levels following the addition of inhibitors of PARP and SIRT. Interestingly, 
sirtuin activity is strongly controlled by NAD availability that is, in turn, regulated by the main 
consuming enzyme; CD38 (Aksoy et al., 2006b). Importantly, for enzyme inhibition, 
concentrations of 1-30 µM of the sirtuin inhibitor (sirtinol) and PARP inhibitor (4-amino-, 1, 8-
naphthalimide) were applied during HL60 differentiation. It is worth noting, that this range of 
concentrations has previously been shown to inhibit both enzymes (Hegan et al., 2010; 
Fernandes et al., 2012). The current results during HL60 differentiation, also suggest that CD38 
might be limiting the availability of NAD to other NAD-consuming enzymes. Furthermore, they 
reflect the restricted role of other NAD-consuming enzymes in the degradation of NAD during 
the differentiation. 
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The strongest evidence that clearly confirms the essential role of CD38 in degrading NAD levels 
during the differentiation comes from the observed effects of kuromanin. The effect of inhibition 
by kuromanin on CD38 cyclase activity occurred at micromolar concentrations. Kuromanin 
efficiently elevated intracellular NAD levels compared to those in untreated cells. The 
mechanism of this inhibition is suggested to be through interaction of the inhibitor with the 
active site of CD38, which affects the binding of CD38 with NAD
+
 (Kellenberger et al., 2011). 
In addition to increasing NAD levels, treatment with kuromanin also suppressed the 
differentiation of HL60 to neutrophil-like cells as assessed by the NBT assay. This might be 
through the inhibition of CD38 activity, which is involved in the mechanism of HL60 
differentiation. The recent data strongly confirm the major CD38 role in degrading NAD, 
because CD38, and no other NAD-consuming enzymes (PARP, sirtuin and CD157), is mainly 
expressed over time during the differentiation. Inhibition of CD38 activity might serve as a 
pharmacological target for multiple disease conditions, especially in CLL. Indeed, in CLL, 
studies have developed from CD38 as a marker to CD38 as a disease modifier and a therapeutic 
target (Deaglio et al., 2008). The effects of kuromanin might also need to be investigated in other 
leukaemia cells expressing CD38 in vivo and in vitro. Following these investigations, kuromanin 
may represent a possible therapeutic agent to target CD38 in leukaemia. 
As it was confirmed that NAD appeared to be consumed via the activity of CD38 during the 
differentiation, resynthesis of NAD would be necessary to maintain the functions of a wide 
variety of NAD-dependent enzymes in cells. It was found that during HL60 differentiation 
NMNAT expression showed a significant increase, but the rate-limiting enzyme (NAMPT) 
showed no significant change in expression. Hence, this pathway is unlikely to be able to 
compensate for the decrease in NAD levels through CD38 activity. An apparent elevation in IDO 
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expression was also recorded. However, IDO activity might also not be able to compensate for 
the decline in NAD levels, since it has been previously estimated that only 1/60 of NAD 
synthesis comes from tryptophan degradation via IDO (Bender, 1992). Thus, IDO expression 
might be linked to other functions; for instance, IDO serves more than one role in the immune 
system (Mellor and Munn, 2004). Furthermore, it has been documented that overexpression of 
the NAD biosynthesis enzymes might not necessarily affect NAD levels as the pyridine 
nucleotides can be turned over at a considerable rate (Mack et al., 2001; Anderson et al., 2002). 
Thus, the change in the expression of NAD biosynthesis enzymes might have other functions 
rather than maintaining NAD levels. For instance, It has been mentioned that NAMPT and 
NMNAT have important roles in regulating the functions of NAD-dependent enzymes such as 
the protein deacetylase, SIRT1, and PARP1 (Zhang et al. 2009). It has also been found that 
NMNAT activity correlates with DNA synthesis during the cell cycle (Solao and Shall 1971). 
Moreover, it has been suggested that IDO expression has a role in controlling autoimmune 
diseases (Opitz et al., 2007) and chronic infection (Zelante et al., 2009). Importantly, it is 
chronically activated in many cancer patients (Schroecksnadel et al., 2007). Thus, IDO 
expression or enzymatic activity correlates with a poor prognosis in patients with various cancers 
(Ino et al., 2008; Pan et al., 2008). The role of IDO in the poor prognosis in cancer is therefore 
an interesting area and is yet to be determined. This could be achieved by exploring whether a 
link exists between CD38 expression, IDO expression, low intracellular NAD levels and poor 
prognosis. Hence, IDO might also serve as a target in patients with various cancers, such as 
CD38
+
 leukemia subset patients. Moreover, further investigation is needed to confirm whether 
NAMPT or NMNAT expression are associated with CD38 expression and low levels of NAD 
which are also expected to be as potential targets for therapeutic applications in leukemia.  
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Furthermore, in view of the results obtained in this study, it would be interesting to investigate 
the effect of low intracellular NAD levels on cADPR production. cADPR is a key messenger in 
the mobilization of intracellular Ca
2+
 stores, and is involved in a variety of cellular processes, 
including fertilization, cell proliferation, and differentiation (Lee, 2004; Guse, 2005). Thus, the 
observed decline in intracellular NAD levels might either suggest a high turnover of intracellular 
NAD levels to produce high levels of this secondary messenger, or alternatively that low levels 
of the messenger might be formed because of a low availability of its precursor, NAD. However, 
it has been found that CD38, in addition to inducing cell proliferation, also increases intracellular 
Ca
2+
 levels (Zocchi et al., 1998), so, when CD38 is expressed, a consequential accumulation of 
cADPR might occur. Importantly, the ability of cADPR to increase cell proliferation has been 
observed in several human cell lines (Bruzzone et al., 2003; Kim et al., 2008; Yue et al., 2009). 
Moreover, CD38-mediated cADPR production has been implicated in several diseases (Chapter 
1), and the current finding may have attractive functional implications in CD38
+
 leukemia 
patients. One of the possible implications is that the decrease in NAD levels concomitant with 
CD38 expression might be accompanied by a peak in cADPR production that might play a 
causal role in mediating leukemia proliferation and poor prognosis. However, the effect of CD38 
expression in degrading NAD levels suggests that there is still much work to be done to 
understand this interesting relationship. 
It is worth noting that the extracellular location of CD38 and the intracellular location of the 
substrate NAD and its product cADPR have raised an unresolved issue known as the ‘topological 
paradox’, since it was hard to understand how the product, cADPR, could exert its calcium-
mobilizing activity intracellularly if it were produced extracellularly (De Flora et al., 2000). 
However, there are two mechanisms that have been suggested to resolve the CD38 topological 
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paradox, depending on the membrane orientation of CD38. The first mechanism for NAD and 
CD38 product trafficking has been suggested by De Flora’s group (De Flora et al., 2004). It is 
based on the observation that CD38 is expressed as a type II protein on the cell surface. These 
findings suggest that a connexin-43 (CX43) channel is present in the plasma membrane to 
transport the cytosolic substrates, NAD and NADP (Bilington et al., 2008a), and to make them 
available to the extracellular CD38 (Zocchi et al., 1999). Ultimately, both the products, cADPR 
and NAADP, are transported back into the cytosol via a nucleoside transporter (NuT) to act on 
their targets by affecting Ca
2+
 release from the intracellular stores (Bruzzone et al., 2001; Lee, 
2012). It has also been suggested that cADPR is transported through CD38 itself by a channel 
mechanism (Franco et al., 1998). Importantly, type III CD38 serves as a simple solution to the 
topological paradox (De Flora et al., 2000), and represents the second proposed mechanism. 
Indeed, CD38 with type III orientation should be more suitable than the type II isoform for 
performing intracellular signalling functions, since its substrate NAD location and the sites of 
CD38 action mediated by cADPR and NAADP, are all cytosolic. Altogether, these two 
signalling mechanisms are consistent with the wide range of functions that are regulated by this 
enzyme activity (Zhao et al., 2012). Interestingly, it has been suggested that both type II and type 
III orientations may possibly be in the same cell (Lee, 2012). For instance, both types of CD38 
are found on the cell surface of HL60 on the first day of ATRA-induced differentiation as well as 
in other cells, such as human primary monocytes and the U937 monocytic cell line after 
activation by IFN-γ (Zhao et al., 2012). In view of the results of this study, type III CD38, which 
has been shown in differentiating HL60 cells, supports the main role of CD38 in degrading 
intracellular NAD. Moreover, the presence of two signalling mechanisms in the differentiating 
cells might require a rapid NAD degradation by CD38 both extracellularly and intracellularly. In 
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summary, these findings further support the current investigations which confirmed a high drop 
in intracellular NAD levels in cells expressing high levels of CD38. In addition, in the context of 
leukaemia conditions, the presence of CD38 in two orientations might suggest a complex 
mechanism associated with CD38 signalling that is involved in cell proliferation and poor 
prognosis. 
In conclusion, the main aim in this particular study was to provide new evidence for the main 
role of CD38 as the major NAD regulatory enzyme in the cells. An elevated level of this efficient 
enzyme on the surface or in the cytosol of some cells might have an impact on different NAD-
dependent pathways. However, the three main processes which might be affected are (a) the 
NAD-dependent glycolysis pathway, which directly affects cellular energy since the 
NAD
+
:NADH ratio is a direct measure of the energy status of a cell, and (b) the formation of 
cyclic ADP-ribose, a Ca
2+
-mobilizing messenger, which is known to play a role in the control of 
gene expression and apoptotic cell death (Zupo et al., 1994; Hardingham et al., 1997). In this 
context, Yalcintepe et al., (2005) postulated that NAD may function as a signal that regulates 
nuclear calcium homeostasis and gene expression. Finally, (c) increasing CD38 cyclase activity 
not only decreases the intracellular NAD levels, but it also limits the substrate availability for 
other ectoenzymes such as ADP-ribosyl transferases and the intracellular enzymes such as PARP 
and sirtuin. These enzymes mediate important roles in modified cellular functions such as 
genomic stability, apoptosis, cell signalling and stress tolerance (Malavasi et al., 2010). Finally, 
further studies are needed to explore whether CD38-mediated NAD degradation might provide 
solutions that increase understanding of the reasons as to why patients with CLL and high CD38 
expression have a progressive stage of this disease and a lower survival rate (Deaglio et al., 
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2008). CD38 enzymatic function might also serve as a possible target in leukemia therapy, in 
addition to its receptor function. 
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CHAPTER 4 
EFFECT OF LOWERED NAD LEVELS ON 
CELL PHYSIOLOGY 
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4.1 Introduction 
NAD(H) and its phosphorylated form, NADP(H), play key roles in major aspects of energy 
metabolism (Berger et al., 2004; Ying, 2006). NAD mediates glycolysis by acting as a coenzyme 
for some key glycolytic enzymes (such as GAPDH). It also modulates other important energy 
metabolism-related reactions in cytosol, such as the lactate dehydrogenase catalyzed lactate-
pyruvate conversions. Furthermore, NAD(P)(H) is an essential co-enzyme in some of the most 
fundamental reaction pathways, such as the TCA cycle and the pentose phosphate pathway 
(Ziegler, 2000). In addition to NAD having major roles in energy metabolism, it can also affect 
cellular antioxidant capacity through its phosphorylated form, NADP, the precursor for 
synthesizing the major reducing molecule NADPH (Stryer, 1995). The latter carries out several 
cell protective functions (Pollak et al., 2007). Importantly, the role of NAD has been extended 
from simply being an oxidoreductase coenzyme to acting as a precursor for a wide range of 
products produced by other enzymes. These include ADP-ribosyl cyclase/NAD glycohydrolase 
(CD38), NAD-dependent protein deacetylases (sirtuins), poly (ADP-ribose) polymerases 
(PARP), and ADP-ribosyl transferases (ARTs). Altogether, NAD provides a direct link between 
the cellular redox status and the control of DNA repair (via PARP; Kim et al., 2005), post-
translational protein modification (via ARTs; Koch-Nolte et al., 2008), gene expression (via 
sirtuins; Michan and Sinclair, 2007) and Ca
2+
-signalling (via CD38/CD157; Malavasi et al., 
2008). Several studies have also confirmed that NAD works as a modulator of protein activities 
due to nucleotide availability (Ying, 2006; 2008). The NAD
+
:NADH ratio is an important 
regulator of mitochondrial permeability transition (MPT; Zoratti and Szabo, 1995), and may 
indirectly affect mitochondrial function by modulating calcium homeostasis, which is known to 
profoundly affect mitochondrial activities (Nicholls et al., 1999). NAD regulates calcium 
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homeostasis through the formation of Ca
2+
-mobilizing messengers, for example cADPR, which 
is known to play a role in the control of gene expression and also apoptosis (Zupo et al., 1994; 
Hardingham et al., 1997). 
As such, changes in NAD levels or the NAD
+
:NADH ratio, which lead to changes in 
metabolism, have been implicated directly and indirectly in the mechanisms of several age-
associated diseases such as diabetes, cancers and neurodegenerative diseases e.g. Parkinson’s 
disease (Soriano et al., 2001; Zhang et al., 2002; Greenamyre et al., 2001; Lin and Guarente 
2003). Thus, NAD has major roles in multiple physiological processes via a number of 
pathways, and there has been much interest in the NAD homeostasis pathways as potential 
pharmacological targets for a wide variety of diseases. However, studies have not fully examined 
the effect of low NAD levels on cell physiology, particularly in HL60 cells, during treatment 
with ATRA and under conditions of upregulation of CD38 expression. Therefore, the aim of this 
study was to extend the studies of Chapter 3, and to examine the effect of low NAD levels on the 
NAD
+
:NADH ratio and the levels of major antioxidants such as glutathione. In addition to 
examine the effect of low intracellular NAD in differentiated cells on lipid peroxidation status 
and glycolysis. From this study it might be possible to understand the reason for metabolic 
dysfunction and a resistence to apoptosis cell death or find a mechanism that explains the reason 
for the poor prognosis in CD38
+
 leukemia subset patients. 
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4.2 Materials and methods 
4.2.1 Materials 
Reduced glutathione (GSH), glutathione reductase, dithionitrobenzoate (DTNB), thiobarbituric 
acid (TBA), 1,1,3,3-tetraethoxypropane, lactate dehydrogenase (LDH), glycine, glucose, and 
PBS were all purchased from Sigma (Poole, UK). NAD,NADH, and NADPH were all from 
Melford Laboratories (Ipswich, UK). Hydrazine hydrate liquid and lactate were a kind gift from 
Mr. Nick Crocker (University of Plymoth, UK) and came from Sigma (Poole, UK). 
4.2.2 Measurement of the NAD
+
: NADH ratio 
The NAD
+
: NADH ratio was estimated by measuring both the NAD
+
 and the NADH 
concentration for each sample by using the NAD cycling assay as described in Chapter 2, 
Section 2.9.2.1. Briefly, the control cells and HL60 treated with ATRA for 1, 3 and 5 days were 
harvested and both NAD
+
 and NADH were extracted from each sample as detailed in Chapter 2. 
After the extraction, NAD
+
 and NADH levels were estimated by comparison with NAD
+
 and 
NADH standards. Also nucleotide levels were normalized to the cell concentration for each 
sample. The NAD
+
:NADH ratio was calculated by dividing intracellular NAD
+
 levels by the 
NADH levels in the same sample. 
4.2.3 Determination of total glutathione by the enzymatic recycling assay 
This assay was used to measure total intracellular glutathione levels (GSH and GSSG). In this 
assay, GSH reacts with the DTNB to produce 5-thio-2-nitrobenzoate (TNB) and a mixed 
disulphide (GSSTNB). The latter produce GSH again in the presence of glutathione reductase 
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(GR) and NADPH. A similar reaction may form two molecules of GSH by reducing GSSG in 
the presence of both GR and NADPH (Jones, 2002), as shown in Figure 4.1. 
 
Figure 4.1 Principle of the total glutathione assay. GSH produce GSSTNB in the presence of DTNB. 
GSSG or the mix (GSSTNB) converted again to GSH in the presence of glutathione reductase (GR) and 
NADPH. 
The total glutathione (GSH and GSSG) assay was performed as described by Adams et al. 
(1983). The control or ATRA-treated HL60 cells (1 × 10
6 
cells ml
-1
) were collected and washed 
twice with PBS. After collection, cells were lysed in the assay buffer (100 mM potassium 
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phosphate, pH 7.5, containing 5 mM potassium EDTA) by three cycles of freeze-thawing 
followed by centrifugation at 7000 × g for 5 min. Sample lysate (40 μl) or GSH standard  (after 
being mixed with an equal volume from fresh buffered DTNB (10 mM in assay buffer)) were 
added to 210 µl of assay buffer containing 0.15 U glutathione reductase. The reaction was started 
by adding 60 µl of freshly prepared 1 mM NADPH, and the absorbance at 412 nm was read at 
room temperature for 10 min. Total glutathione results are expressed as nmol per 10
6 
cells. 
4.2.4 Thiobarbituric Acid Reactive Substance assay 
Lipid peroxidation is used as an indicator of oxidative stress in cells and tissues. Lipid peroxides 
are unstable and decompose to form a complex series of compounds including reactive carbonyl 
compounds. Polyunsaturated fatty acid peroxides generate malondialdehyde (MDA) and 4-
hydroxyalkenals (HAE) (Esterbaue et al., 1991). The thiobarbituric acid reactive substances 
(TBARS) assay measures lipid hydroperoxides and aldehydes, such as MDA, in the cell culture 
medium and cell lysate. MDA combines with thiobarbituric acid (TBA) in a 1:2 ratio to form a 
coloured complex that is measured at 532 nm. TBARS are expressed as MDA equivalents 
(Dubuisson et al., 2000). 
The measurement of MDA was performed according to the protocol reported by Ohkawa et al. 
(1979). Briefly, untreated HL60 cells (the control) and cells treated with ATRA (5-10 × 10
6
 cells 
ml
-1
) were collected in 15 ml tubes, followed by low-speed centrifugation (200 × g) for 5 min. 
The cell pellets were re-suspended in 0.2 ml ice-cold PBS and sonicated for 15 s at low power 
sonication (4 W output, Microson TM Ultrasonic Cell Disruptor, USA) on ice. Aliquots (100 μl) 
of the cell lysate were assayed for MDA according to the following protocol: Ice-cold 10% TCA 
(200 µl) was added to 100 µl of each sonicated sample to precipitate proteins and the sample 
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centrifuged at 7000 × g for 5 minutes at 4 °C, followed by addition of 200 µl of 4.6 mM (0.67%) 
thiobarbituric acid (TBA) to an equal volume of each supernatant. The color was developed by 
incubating at 100 °C for 30 min and the reaction was stopped by cooling on ice for 5 min. Three 
hundred microlitres from each sample was transferred to a 96-well plate and the absorbance at 
532 nm was measured with reference to a reagent blank. The lipid peroxide levels were 
expressed in terms of pmol of malondialdehyde per 10
6
 cells of each sample and calculated from 
a standard curve (Fig. 4.2) made with various concentrations of 1,1,3,3-tetraethoxypropane (0-
100 µM). 
 
Figure 4.2 Standard curve of (0-100µM) 1,1,3,3-tetraethoxypropane, was used to estimate of TBARS 
levels for each sample. Change in absorbance is recorded at 532 nm. 
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4.2.5 Lactate assay 
Lactate accumulation in the medium was used to assess the rate of glycolysis during HL60 cell 
differentiation with ATRA for 1-5 days (Fig. 4.3). Two hundred and fifty microlitres of the assay 
mixture (containing 500 mM glycine, 400 mM hydrazine, 20 mM NAD
+
 and 16.6 U/ml of 
lactate dehydrogenase) was mixed with 50 μl from the sample (medium) or lactate standard 
solution (0.1-1 mM) and incubated at 37 °C for 30 min to complete the reaction. The absorbance 
at 340 nm was measured in a plate reader (VersaMax, Molecular Devices, Sunny Vale, CA). 
 
Figure 4.3 Simple diagram showing lactate production from glycolysis as product of lactic fermentation. 
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4.2.6 Glucose challenge 
Cells treated with either 1 µM ATRA, 100 µM NAD for 1 day, or untreated cells (control) were 
harvested by centrifugation (200 × g) for 5 min, resuspended in fresh medium and treated with 
25 mM glucose for 1 h at 37 
°
C. Incubated cell cultures catabolized glucose through glycolysis 
converting it into products including lactate. Following incubation, cells were separated as 
pellets, and the supernatant (containing the generated lactate) was removed for the analysis of 
lactate content using a previously described lactate assay (Section 4.2.5). 
4.2.7 Statistical analysis 
Statistical analysis of the data was assessed using Fisher’s one way analysis of variance 
(Statview 5.0.1; Abacus concepts, USA) or Student’s t-test as appropriate. Data are expressed as 
means ± SEM for three separate experiments in triplicate. A difference of P < 0.05 was 
considered statistically significant.  
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4.3 Results 
4.3.1 NAD
+
:NADH ratio during HL60 differentiation 
As has been previously shown (Chapter 3), CD38 expression during HL60 differentiation leads 
to a decrease in intracellular NAD
+
 levels in a time dependent manner. So, in this Chapter, it was 
questioned whether this NAD degradation could cause a further effect on cell metabolism, as 
NAD(H) is  a major coenzyme in glycolysis. 
Firstly, both oxidized and reduced nucleotides, NAD
+
 (Fig. 4.4 A) and NADH (Fig. 4.4 B) were 
investigated during the time course of HL60 differentiation. NAD
+
 levels significantly decreased 
throughout differentiation and a similar decline in NADH levels could be seen on the 3
rd
 and 5
th
 
days of differentiation compared to each appropriate control. 
As the results showed an apparent drop both in the oxidized and reduced forms, the 
NAD
+
:NADH ratio, as one of the important metabolic indicators, was therefore assessed during 
ATRA-induced HL60 differentiation (Fig. 4.4 C), to further investigate the consequences of 
CD38 expression on the nucleotide levels and on their dependent processes. Notably, there was 
no marked change in the NAD
+
:NADH ratio after 1 and 3 days of differentiation, i.e. the ratio 
remained relatively stable during early differentiation. 
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Figure 4.4 Time course of ATRA induced differentiation of HL60 cells over 5 days comparing to HL60 
(as control), showing (A) intracellular NAD levels (B) intracellular NADH levels (C) the NAD
+
: NADH 
ratio. Data are means ± SEM, n = 2 (3-6 measurements per replicate).  
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4.3.2 Effect of low intracellular NAD levels on lactate levels before and after glucose 
application and during cell differentiation 
To assess the effect of lowered NAD levels on cell physiology lactate production (the product of 
lactic fermentation) levels in the medium was measured, as it was expected that lactate levels 
might be reduced when NAD levels dropped due to the effect of lower levels of NAD on 
glycolysis. The data revealed that HL60 cells treated with ATRA showed a negligible, but 
significant decrease in lactate accumulation on days 1-3 after induction of HL60 differentiation 
compared to the control. However, the lactate levels after the 4
th
 day of differentiation were not 
different from the control (HL60), whereas they increased at day 5 of differentiation in 
comparison to the control as shown in Figure 4.5. These results suggest that lowered NAD levels 
might have an effect on glycolysis activity. 
The lactate production during cell differentiation was further investigated after supplying the 
glucose (25 mM) to the cells. In this test and after 1 day of HL60 differentiation, cells were 
treated for 1 h with 25 mM glucose. Glucose was used to assess the glycolytic activity and to 
investigate whether glycolysis can potentially use the glucose to produce lactate even at the 
lowered NAD levels. 
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Figure 4.5 Lactate production expressed as nmol/10
6 
cells during the time course of ATRA-induced 
differentiation of HL60 cells over 5 days compared to untreated HL60 cells (control). Data are means ± 
SEM, n = 4 (3 measurements per replicate). * denotes a significant difference from the appropriate 
control, P < 0.05. 
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The results (Fig. 4.6) show that the production of lactate was not increased in spite of the 
presence of 25 mM glucose when compared to the control incubated without glucose 
(differentiated cells). Treatment with glucose was also performed in HL60 cells with no 
significant change being recorded. However, this is not the case when the differentiating cells 
were treated with 100 M NAD+ for 1 day (to replenish the intracellular NAD, during the 
differentiation with ATRA; see Chapter 5), before they were treated with or without 25 mM 
glucose. The results (Fig. 4.6) show that lactate levels in the medium were relatively high after 
NAD
+
 application compared to the untreated differentiated HL60 cells and were similar to lactate 
levels in undifferentiated HL60 cells. A similar elevation in lactate levels was also seen in 
differentiated cells that treated with glucose following the incubation with NAD
+
 for 1 day (Fig. 
4.6). However, after treatment with glucose and/or NAD
+
 no changes in lactate levels were seen 
in HL60 cells, possibly because these cells already had high NAD levels compared to the 
differentiated cells. These data reveal the effect of low NAD levels on cell metabolism 
particularly glycolysis, as reflected by lactate levels.  
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Figure 4.6 Lactate production expressed as nmol/10
6 
cells after incubation of HL60 cells or 1 day-
differentiated cells (either treated or not treated with 100 µM NAD) for 1 h with 25 mM glucose and 
compared to appropriate untreated control. Data are means ± SEM, n = 3 (5 measurements per replicate), 
p˃ 0.05. 
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4.3.3 TBARS production during ATRA-induced HL60 differentiation 
To further determine the consequences of the decline in intracellular NAD levels on cell 
physiology, intracellular reactive oxygen species (ROS) were assessed during ATRA-induced 
HL60 differentiation. Lipid peroxidation was evaluated by measuring TBARS production (Fig. 
4.2). Lipid peroxidation in ATRA-treated HL60 cells, as well as untreated cells, was evaluated 
after 1, 3 and 5 days incubation. TBARS levels increased significantly in differentiating cells in a 
time-dependent manner (Fig. 4.7) compared to the appropriate control, reaching highest levels on 
day 5. 
Taken together, these data suggest that an imbalance in the oxidant/antioxidant status might have 
occurred, as high lipid peroxidation levels might reflect low antioxidant levels which might be a 
consequence of NAD depletion. 
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Figure 4.7 Lipid peroxidation as evaluated by TBARS levels during the time course of HL60 
differentiation over 5 days comparing to untreated HL60 cells (control). Data are means ± SEM, n = 3 (3 
measurements per replicate). * denotes a significant difference from each appropriate control, P < 0.05. 
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4.3.4 Total glutathione levels 
ATRA-induced HL60 differentiation seems to be accompanied by an increase in oxidative stress 
(as measured by TBARS levels) that may be due to the effect of CD38 expression and the 
significant drop in NAD levels. To further investigate this, a key cellular antioxidant system was 
also investigated by measuring total glutathione (GSH) levels during cell differentiation (Fig. 
4.8). 
A significant elevation in glutathione levels (oxidized GSSG and reduced GSH) after one day of 
differentiation (Figure 4.8) was observed, with less increase after three days of differentiation 
compared to the control. However, glutathione levels returned to control levels by the 5
th
 day of 
differentiation. 
The significant increase in glutathione levels after one day of differentiation suggests the 
involvement of glutathione during the differentiation as an antioxidant. However, glutathione 
levels were not further increased during the 3
rd
 and 5
th
 days of differentiation. These observations 
suggest a link between NAD depletion and glutathione levels; they also suggest that NAD 
depletion-mediated by CD38 might disturb the balance in the oxidant/antioxidant state during the 
differentiation. 
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Figure 4.8 Time course of ATRA-induced HL60 differentiation over 5 days showing the increase in total 
glutathione levels after day 1 of differentiation but not after 3 and 5 days comparing to untreated HL60 
cells (control). Data are means ± SEM, n = 4 (4 measurements per replicate). * denotes a significant 
difference from the control (HL60), P < 0.05. 
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4.4 Discussion 
As mentioned in Chapter 1, one of the interesting events during HL60 differentiation is the 
regulation of CD38 activity which could affect NAD levels over time. Although the pyridine 
nucleotides, NAD
+
 and NADH, have been shown to be important for glycolysis and its 
regulation (Tilton et al., 1991) and as vital cofactors for numerous enzymes, no previous studies 
or explanations are available for the effects of the apparent depletion of NAD levels on the cell 
metabolism, including lactate accumulation, NAD
+
: NADH ratio, antioxidant status represented 
by glutathione levels and TBARS levels (as a lipid peroxidation marker) during HL60 
differentiation. Low NAD levels might affect cell physiology particulary in cells expressing 
CD38 (for instance in leukemia). 
In this Chapter, cell metabolism was first investigated by measuring the NAD
+
:NADH ratio 
during HL60 differentiation using ATRA. In this study, levels of both nucleotides (NAD
+
, 
NADH) were significantly decreased. Surprisingly, despite the significant decreases in NAD
+
 
and NADH levels during the differentiation process, there were limited changes in the 
NAD
+
:NADH ratio during early differentiation. The NAD
+
:NADH ratio has been suggested to 
be relatively constant in order for normal physiological processes to proceed (Barron et al., 
2000); NAD is a coenzyme for over 700 oxidoreductases, such as glyceraldehyde-3-phosphate 
dehydrogenase and the pyruvate dehydrogenase complex that catalyze numerous biochemical 
reactions in cells (Matthew et al., 2000). For instance, in cancer cells the NAD
+
:NADH ratio is 
suggested to be constant, because the high glycolytic rate generates excessive pyruvate and 
NADH, which are converted to lactate and NAD
+
 by the action of lactate dehydrogenase (LDH), 
thereby  maintaining the stability of the NAD
+
:NADH ratio (Sun et al., 2012). Ultimately, the 
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NAD
+
:NADH ratio plays an important role in regulating the intracellular redox state (Droge, 
2002). The NAD
+
/NADH redox state also influences the production of ROS, since ROS 
production by the respiratory chain increases as the NAD
+
/NADH redox pair becomes more 
reduced (Starkov and Fiskum, 2003). Thus, in the current study, the negligible change in the 
ratio might also be linked with ROS generation during cell differentiation. Interestingly, in the 
current study, the data for NAD
+
:NADH ratio,  is within the range of previously reported ratios: 
3-10 in mammals (Swierczynski et al., 2001) and 0.03-4 in several cell lines derived from mice 
(Gaikwad et al., 2001; Sanni et al., 2001). 
The second factor related to the effects of lowered NAD levels during HL60 differentiation on 
glycolysis is lactate accumulation. Studies on HL60 differentiation using ATRA, in this Chapter, 
indicated that there was a relative decrease in lactate production during the early days of 
differentiation compared to undifferentiated HL60 cells and that this was correlated with the 
drop in NAD levels which might suggest a small effect on glycolysis at this stage. This decrease 
in lactate accumulation was also previously shown during HL60 differentiation with DMSO (Wu 
et al., 1991). Interestingly the presence of additional glucose failed to increase the glycolysis rate 
as shown by low lactate production. However, the same results were not obtained with NAD
+
 
application. These results suggest that the change in lactate accumulation might be linked to the 
change in NAD levels during the differentiation, but that it might be independent of changes in 
glucose levels. The lowered lactate production during early differentiation might be caused (a) 
by glycolysis dysfunction as a result of the lowered NAD levels, and (b) by ongoing metabolism 
of pyruvate via the Krebs’ cycle and oxidative phosphorylation. However, the increase in lactate 
production during the last days of differentiation might be because when HL60 cells differentiate 
to neutrophil-like cells they lose mitochondrial function and hence rely on increased glycolysis 
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(lactic fermentation), like neutrophils, which rely mainly on glycolysis for the generation of ATP 
(van Raam et al., 2008). 
However, it is also worth mentioning that HL60 cells show relatively high lactate production 
compared to the differentiatied cells. This might suggest that lactic fermentation is a dominant 
pathway for energy production in HL60 cells (Boyunaga et al., 2011). It is well known that a 
variety of cancer cells show high rates of lactate production from glucose, and an enhanced rate 
of lactic fermentation, despite the presence of oxygen and functional mitochondria; this is known 
as the Warbug effect (Warburg, 1956; Baggetto, 1992). This shift in cell metabolism ensures the 
propagation and survival of cancer cells, and allows them to obtain ATP at a faster rate through a 
simpler process (Tennant et al., 2009), without requiring oxidative metabolism (Boyunaga et al., 
2011). The enhancement of glycolytic activity is also thought to provide sufficient pyruvate, 
which might work as an antioxidant in cancer cells (Brand and Hermfisse, 1997). Lactic 
fermentation might also be preferred in leukemia cells. If so, one might expect that in CD38
+
 
leukemia, in addition to a high demand for NAD as the substrate for CD38, there will be a 
requirement for high levels of NAD to maintain the high rate of lactic fermentation. Low NAD 
levels might cause poor physiological consequences (such as a resistance to apoptotic cell death) 
and that might explain the reason for poor consequences in CD38
+
 leukemia patients. 
The remaining metabolic indicators used to evaluate the consequences of low NAD levels on 
redox state and cell physiology in cells expressing CD38, were TBARS (an indicator of lipid 
peroxidation) and total glutathione (as a key antioxidant). The results confirmed that when CD38 
expression was increased following ATRA treatment, lipid peroxidation was also enhanced, 
suggesting a link between CD38 expression mediating a lowering in NAD levels and the increase 
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in lipid peroxidation. One possible explanation for this is that CD38 might mediate intracellular 
O2
•-
 production via cADPR/Ca
2+
-mediated activation of NAD(P)H oxidase (NOX4). The latter 
has been reported to be a major source of ROS in the vasculature (Mohazzab et al., 1994; Xu et 
al., 2012). Interestingly, the production of ROS was markedly reduced in embryonic fibroblasts 
from CD38
−/−
 mice (Ge et al., 2010). This strongly suggests a connection between CD38 and 
ROS production; undifferentiated HL60 cells, which are CD38
-
, have lower TBARS levels than 
the differentiated (CD38
+
) cells. Hence, in common with differentiated HL60 cells, high ROS 
levels might be also expected in CD38
+
 leukemia compared to CD38
- 
leukemia. Interestingly, a 
relative increase in the oxidative stress state has been observed in CD38 positive CLL patients 
compared to CD38 negative patients (Ortin et al., 2012). These data suggest a possible reason for 
the observed resistance to apoptotic cell death and the induction of cell proliferation in cells 
expressing CD38, since high ROS might contribute to a resistance to apoptotic cell death and 
consequently poor prognosis in leukemia. 
In addition to evaluating the oxidative state, the antioxidant level was also evaluated by 
measuring glutathione, which is the major non-enzymatic component of intracellular antioxidant 
defenses, and is present both in a reduced, biologically active form (GSH), and in an oxidized 
form, namely glutathione disulphide; GSSG (Circu and Aw, 2010). During HL60 differentiation, 
the results showed a negligible increase in total glutathione levels in the first 24 h with decreased 
levels in the periods afterwards. Decreased glutathione levels might reflect depletion of the non-
enzymatic antioxidant reserve, due to overproduction of ROS (consistent with the TBARS 
results). GSH works as a vital intracellular scavenger of ROS, protecting the cells against toxic 
free radicals (Wu et al., 2004). Another possible explanation is that a decline in NAD levels 
might affect glutathione levels, i.e. that glutathione might be NAD-dependent. However, the 
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early increase in glutathione levels might suggest low ROS production. Interestingly, it has been 
demonstrated that GSH levels are dynamic during HL60 differentiation when stimulated by 
several inducing agents (Krance et al., 2010). Finally, a measurable change in the redox status 
during ATRA-induced HL60 differentiation was seen. These changes might be linked to the 
elevation in CD38 activity and a reduction in NAD levels. 
The indicated declines in NAD
+
 levels that are mediated by CD38 activities might have a further 
consequence on NADP
+
 levels, since the biosynthesis of NADP
+ 
requires the phosphorylation of 
NAD
+
 in a reaction catalysed by NADK (ATP:NAD 2-phosphotransferase) as shown in Figure 
4.9 (Pollak et al., 2007). Hence, a decline in NADP
+
 might be occurring due to the drop in NAD
+ 
levels. If so, one might expect further consequences on NADP-dependent processes, for instance 
NADPH synthesis. The latter is synthesised through NADP
+
-specific dehydrogenases, including 
glucose-6-phosphate dehydrogenase (G-6-P), isocitrate dehydrogenase (IDP), malic enzyme 
(ME) and aldehyde dehydrogenase (ALDH), (Fig. 4.9). Alternatively, NADPH can also be 
generated through phosphorylation of NADH via NAD kinase (Pollak et al., 2007). It is worth 
noting that the phosphorylated nucleotide, NADPH, has been shown to be crucial in maintaining 
an effective defense against oxidant-mediated damage. It has been shown to be essential in the 
function of catalase and the maintenance of reduced glutathione, both of which have important 
roles in the antioxidant defense as previously confirmed in the erythrocytes (Gaetani et al., 
1989). NADP
+
 is also involved in signal transduction as a precursor of the messenger molecule, 
NAADP. Hence, a decline in NAD might have an effect on NADP
+
 levels and cause a 
disturbance in the antioxidant defense system, or it might also affect other NADP-dependent 
processes. 
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Figure 4.9 Simple diagram representing generation of NADP
+
 from NAD and NADPH from NADP
+
. 
Adapted from Pollak et al. (2007). 
Studies on glutathione levels in leukemia are generally partial and contradictory. An elevation of 
glutathione levels in CLL patients was reported to cause cell survival and also to protect the cells 
from drug-induced cytotoxicity (Zhang et al., 2012). However, a decrease in cellular glutathione 
was also indicated in CLL patients along with an increase in TBARS levels (Trachootham et al., 
2008; Ortin
 
et al., 2012). Interestingly, disabling this protective mechanism significantly 
sensitizes CLL cells to drug treatment (Zhang et al., 2012). This seems to be because under mild 
oxidative stress, protein glutathionylation was shown to regulate the functions of multiple 
proteins (Ghezzi, 2005). For instance, it has been found that glutathionylation of the 
antiapoptotic protein MCL1, a novel substrate of glutathionylation, regulates its stability and 
protects it from being cleaved by caspase-3, and thus promotes cell survival (Trachootham et al., 
2008). However, removal of glutathionylation by a glutathione-depleting agent, such as PEITC, 
rendered MCL1 susceptible to rapid proteolytic cleavage, leading to leukemia cell death 
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(Trachootham et al., 2008). It is worth noting that recent studies are targeting the molecular 
mechanisms that control the redox environment in leukemia cells, made up from the production 
of ROS and the expression and activity of antioxidant enzymes. It has been demonstrated that 
leukemia cells gain proliferative and survival advantages by manipulating this system. Therefore, 
ROS production by the mitochondrial electron transport chain, NADPH oxidase, xanthine 
oxidoreductase, and cytochrome P450, have all been targeted to promote leukemia cell death 
(Irwin et al., 2013). In this Chapter, the results suggest that CD38 might also serve as a possible 
target to regulate the redox system specifically in CD38
+
 leukemia cells through controlling its 
role in ROS production. 
The data presented in this Chapter reveal novel findings concerning the effects of NAD depletion 
on cell physiology. As discussed above, NAD depletion during HL60 differentiation caused an 
enhancement of lipid peroxidation, and relative depletion of released lactate and total glutathione 
levels, while the NAD
+
:NADH ratio remained relatively constant. These data raise the possibility 
that lowered NAD levels might have effects on NAD-dependent processes such as glycolysis, 
depending on the availability of NAD
+
 (Kristian et al., 2011). An insufficient supply of NAD
+
 
limits cellular energy production (Wilhelm and Hirrlinger, 2012), and it might also affect cell 
survival and cause cell death (as in differentiated HL60 cells). However, the consequences of 
lowered NAD levels via CD38 expression in leukemia cells might promote anti-apoptotic effects, 
as shown in Figure 4.10. 
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Figure 4.10 The consequences of lowered intracellular NAD levels on cell metabolism. This diagram 
describes the role of CD38 expression as a determinant of NAD- mediated cell survival, leading to either 
apoptosis in differentiated HL60 cells or anti-apoptotic effects in CD38
+
 leukemia cells.  
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CHAPTER 5 
REGULATION OF CD38 EXPRESSION 
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5.1 Introduction 
The involvement of CD38 expression in various types of cells and in several diseases makes it a 
possible therapeutic target, especially in leukaemia. Thus, transcriptional regulation of CD38 has 
been extensively studied. Cytokines and hormones are two major groups of signalling molecules 
implicated in the regulation of CD38 expression. In CLL, studies have shown that interferons 
(IFN-, - and -), IL-2 and IL-4 increase CD38 mRNA expression (Bauvois et al., 1999; 
Deaglio et al, 2003; Levesque et al., 2006). Furthermore, the effects of tumour necrosis factor- 
(TNF-), IFN-, IL-1 and the Th2 cytokine, IL-13, on the increase of CD38 mRNA have also 
been studied in human airway smooth muscle (HASM) cells (Deshpande et al., 2004). Further 
studies suggest a transcriptional upregulation of CD38 by TNF- in myometrial cells (Barata et 
al., 2004) and macrophages (Iqbal, and Zaidi, 2007). Moreover, in human monocytes and the 
derived lines U937 and THP-1, the study of Musso et al. (2001) found that IFN- and IL-2 
increased CD38 expression but that lipopolysaccharide (LPS), TNF- and GM-CSF had no 
detectable effects. However, further studies showed that LPS increased CD38 mRNA expression 
in J774 macrophage cells (Lee et al., 2012a).  
The effects of hormones on CD38 expression have been studied in myometrial tissue (Dogan et 
al., 2002; 2006). In ovariectomized rats, administration of estradiol-17β caused a significant 
induction of CD38 expression in the myometrium (Dogan et al., 2004). However, 
glucocorticoids (a class of steroid hormones) have been found to inhibit CD38 expression as 
shown in HASM cells (Kang et al., 2006; 2008). 
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Transcriptional regulation of CD38 has been also investigated in the HL60 cell line during 
differentiation with various agents. It was observed that differentiation of HL60 to granulocytes 
induced by isonicotinic acid, led to CD38 expression (Iwata et al., 2003). Moreover, 1,25-
dihydroxy vitamin D3, which is an inducer of differentiation of HL60 towards monocyte-like 
cells, has also been shown to induce CD38 expression (Stoeckler et al., 1996). Importantly, the 
differentiation of HL60 into granulocytic cells using ATRA is accompanied by the induction of 
CD38 expression (Drach et al., 1993), while DMSO has no effect on CD38 expression (Iwata et 
al., 2003; Guida et al., 2004). It was suggested that ATRA-induced CD38 expression is mediated 
by direct transcriptional regulation via activation of a RAR/RXR heterodimer interacting with a 
retinoic acid response element located in the first intron of the CD38 gene (Mehta et al., 1997). 
In undifferentiated-HL60 cells, a mitochondrial NADH dehydrogenase inhibitor, rotenone, was 
also shown to induce CD38 expression (Matsunaga et al., 1996). Importantly, the finding of 
appropriate regulators that inhibit CD38 mRNA expression might be a useful approach, 
especially in CD38
+
 subset patients. Compared to CD38
-
 leukemia subset patients, inhibition of 
CD38 mRNA production in CD38
+
 leukemia might successfully inhibit cell proliferation and 
reduce resistance to apoptosis, and hence improve the prognosis. 
Collectively, several regulators of CD38 expression have been suggested that mostly regulate 
CD38 mRNA, such as ATRA, cytokines and hormones. However, regulation of CD38 
expression by its substrate, NAD, has not been studied. The novel work in this chapter suggested 
firstly that CD38 expression might be regulated by manipulating NAD levels, either by inhibiting 
a key enzyme in NAD biosynthesis, NAMPT, by using FK866 in order to decrease NAD levels 
or by supplementing cells with NAD to elevate the intracellular levels. Manipulation of NAD 
levels might be involved in CD38 regulation indirectly through the effect of NAD availability on 
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sirtuin and PARP, as NAD-consuming enzymes. Alternatively, NAD might be involved in CD38 
transcriptional regulation via a protein such as C-terminal binding protein (CtBP). This study has 
provided the first evidence indicating that controlling NAD levels can attenuate CD38 mRNA 
expression. 
5.2 Materials and methods 
5.2.1 Materials 
Kuromanin was purchased from Sigma (Poole, UK), NAD was from Melford (Ipswich, UK) and 
FK866 (APO866, (E)-N-[4-(1-benzoylpiperidin-4-yl) butyl]-3-(pyridin-3yl) acrylamide was 
from Axon Medchem (Groningen, The Netherlands). Plastic boxes for oxygen exposures and 
cylinders containing custom mixtures of O2, CO2 and N2 were all obtained from the Diving 
Diseases Research Centre (DDRC, Plymouth, UK). 
5.2.2 Evaluation of CD38 expression in differentiating cells after treatment with kuromanin 
Differentiated cells treated with 30 µM kuromanin for 6, 18 and 24 hours were subjected to 
qPCR analysis for CD38 expression as previously described in Chapter 2, Section 2.7. 
5.2.3 Determination of the effects of addition of FK866 or NAD on intracellular NAD levels, 
cell proliferation and CD38 expression in cell lines 
HL60 and RAJI cells (5 × 10
5
 cells ml
-1
) were incubated in 24-well plates at 37 
°
C in RPMI-1640 
culture media in the presence or absence of 1-100 µM NAD
+
 or 1-1000 nM FK866. After 24 
hours cells were removed from each well and used for analysis of intracellular NAD levels and 
MTT assay (Sections 2.9.2.1 and 2.6 respectively). 
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CD38 expression in RAJI, HL60 and differentiating HL60 cells were determined in the presence 
or absence of 100 µM NAD
+
 or 100 nM FK866 for 6, 12 and 24 hours incubation at 37 
°
C, by 
quantitative real-time qPCR (see Chapter 2, section 2.7). The ΔΔCT method was used to 
determine the relative quantity of CD38 mRNA in samples. 
5.2.4 Oxygen exposure protocol 
HL60 or RAJI cells (1-2 × 10
6
 ml
-1
) were placed in 6-well plates in air tight plastic boxes (21.5 
cm × 21.5 cm × 11 cm; total volume five litres) prepared at the DDRC (Fig. 5.1). Boxes were 
flushed for 5 min with gas mixtures either giving a hypoxic environment (2% O2, 5% CO2, 93% 
N2 or 5% O2, 5% CO2 and 90% N2) or a hyperoxic environment (95% O2, 5% CO2) at a rate of 4 l 
min
-1
. The boxes were then sealed and placed at 37 
º
C in a conventional cell incubator for 30, 60 
and 90 min. In each experiment the normoxic controls were incubated under conditions of 
atmospheric oxygen concentration (21% O2, 5% CO2 and 74% N2). All the cells were grown in 
RPMI-1640 medium supplemented with 10% FCS. 
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Figure 5.1 (A) boxes and (B) Oxygen cylinders used in normoxia, hypoxia and hyperoxia experiments. 
 
5.2.5 Statistical analysis 
Statistical analysis of the data was assessed using Fisher’s one way analysis of variance 
(Statview 5.0.1; Abacus concepts, USA) or Student’s t-test as appropriate. Data are expressed as 
means ± SEM for three separate experiments in triplicate, unless otherwise stated. A difference 
of P < 0.05 was considered statistically significant.  
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5.3 Results 
5.3.1 Effect of elevated NAD
+
 levels on CD38 expression after kuromanin treatment 
It was found previously (Chapter 3) that kuromanin, the novel human CD38 inhibitor, caused an 
elevation in intracellular NAD
+
 levels. In this Chapter the aim was to establish whether this 
elevation in intracellular NAD
+
 might regulate CD38 mRNA expression. Interestingly, qPCR 
results revealed that treatment with kuromanin leads to attenuation of CD38 expression.   
The results showed significant inhibition of CD38 mRNA expression in differentiating cells with 
30 µM kuromanin and started from as early as 6 h differentiation in the presence of kuromanin 
(Fig. 5.2). A significant drop in mRNA levels was also shown at 18 h and 24 h incubation 
compared to each control (differentiating cells without kuromanin). In this respect, low CD38 
mRNA expression during kuromanin treatment suggested that it might be regulated by 
intracellular NAD
+
. 
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Figure 5.2 Effect of kuromanin (30 µM) on CD38 expression during the time course of differentiation of 
HL60 cells with 1 µM ATRA up to 24 h comparing to differentiated cells without treatment (as control). 
Data are means ± SEM, n = 3 (3 measurements per replicate), * denotes a significant difference from each 
control, P < 0.05. 
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5.3.2 Manipulation of intracellular NAD
+
 levels by NAD application or using FK866 
To further investigate the kuromanin results, the NAD levels in the cells were manipulated by 
either elevating NAD
+
 levels by NAD
+
 application or decreasing the intracellular NAD
+
 levels 
after treatment with FK866, based on previously published reports by Billington et al. (2008a; 
2008b). In this part of the work, firstly it was tested whether NAD
+
 application could be used as 
a tool to elevate intracellular NAD
+
 levels. Hence, HL60 cells and RAJI cells were incubated 
separately for 24 hours with 0-100 µM extracellular NAD
+
 at 37 
°
C. The results showed an 
elevation in intracellular NAD
+
 levels that was significant in RAJI cells after 24 h incubation 
with 30 µM and 100 µM NAD
+
, and in HL60 cells with only 100 µM NAD
+ 
(Fig. 5.3A).  
As intracellular NAD
+
 levels were elevated, the MTT assay was performed to monitor cell 
vitality during treatment. The results show that treatment with NAD
+
 had an apparent effect on 
vitality of RAJI cells that was significant with 10 and 100 µM NAD
+ 
(Fig. 5.3B). In HL60 cells, 
a similar effect was seen, but it was not statistically significant (Fig. 5.3B). Collectively, an 
increase in intracellular NAD
+
 levels was confirmed both in HL60 and RAJI cells with the 
extracellular NAD
+
 application. 
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Figure 5.3 Effect of treatment with NAD
+
 (0-100 µM) for 1 day on RAJI and HL60 cells comparing to 
untreated control (100%). (A) Intracellular NAD
+
 levels and (B) cell vitality (as determined by MTT 
assay). Data are means ± SEM, n = 3 (3-4 measurements per replicate). * denotes a significant difference 
from the control (HL60 or RAJI cells without treatments), P < 0.05.  
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Several FK866 concentrations (0-1000 nM) were also incubated for up to 24 h with HL60 and 
RAJI cells, and intracellular NAD
+
 levels were determined. A significant reduction in 
intracellular NAD
+
 levels in RAJI and HL60 cells was evident after 24 h incubation with all 
FK866 concentrations (Fig. 5.4 A). Thus, FK866 caused a concentration-dependent decrease in 
intracellular NAD
+
 levels. 
Interestingly, intracellular NAD
+
 levels in RAJI cells after treatment with FK866 were lower 
than in HL60 cells; this may be because RAJI cells already showed lower NAD
+
 levels 
compared to HL60 cells accompanied by significantly higher CD38 activity. Furthermore, the 
MTT results have shown that cell vitality was rapidly depleted after 24 h treatment with FK866 
(Fig. 5.4 B). A significant drop in cell vitality was evident both in HL60 and RAJI cells and with 
1-1000 nM FK866. Moreover, cell vitality in RAJI cells was lower than that in HL60 cells when 
assayed using MTT reduction. Altogether, the cell vitality and NAD
+
 data in the present study 
and the effect of treatment with FK866 suggests a high turnover of intracellular NAD
+
, and after 
treatment with extracellular NAD
+
 suggests the cell's ability to uptake the extracellular NAD
+
. 
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Figure 5.4 Effect of treatment with FK866 for 1 day on RAJI and HL60 cells comparing to untreated 
control (100%).. (A) Intracellular NAD levels and (B) cell vitality (as determined by MTT assay). Data 
are means ± SEM, n = 3 (3-4 measurements per replicate). * denotes a significant difference from the 
control (HL60 or RAJI cells without treatments), P < 0.05. 
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5.3.3 Effect of intracellular NAD
+
 levels on CD38 expression 
In the above section it was confirmed that intracellular NAD
+
 levels in HL60 and RAJI cells 
were significantly depleted after treatment with FK866 and elevated after extracellular NAD
+
 
application. It was of interest to test whether decreasing or elevating intracellular NAD
+
 levels 
after treatment with FK866 and NAD
+
, respectively, would also participate in the regulation of 
CD38 expression, in the same way as the effect of intracellular NAD
+
 elevation by kuromanin. 
Therefore, analysis of CD38 gene expression profiles was performed using qPCR in HL60 and 
RAJI cells (Fig 5.5A and B, respectively), and during the time course of HL60 differentiation 
(Fig 5.6). 
qPCR analysis of HL60 cells (Fig. 5.5 A) demonstrated that the effect of NAD
+
 (100 µM) or 
FK866 (100 nM) was not the same at each time point, since an apparent decrease in CD38 
expression at 24 h (P ˃ 0.05) was found with all treatments, compared to the control (untreated 
HL60 cells). Also, there was a moderate, but not significant, increase in CD38 expression at 6 h 
and 12 h incubation with FK866 and NAD
+
. However, FK866 or NAD
+
 application had a similar 
effect on CD38 expression in HL60 cells.  
This experiment was also performed with RAJI cells with comparable results to those with HL60 
cells (Fig. 5.5 B). A visible attenuation in CD38 expression was shown at 12 h (P ˃ 0.05) and at 
24 h (P ˂ 0.05) after treatment with FK866 and NAD+. However, at 6 h, a notable rise in CD38 
expression after treatment with NAD
+
 was observed (but not with FK866) compared to the 
control. Overall, an apparent decline in CD38 mRNA expression was shown in both HL60 and 
RAJI cells, particularly after 24 h incubation with FK866 or NAD
+
 application. 
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Figure 5.5 Effect of treatment with 100 nM FK866 and 100 µM NAD
+
 on CD38 expression after 1 day 
incubation comparing to the control (untreated HL60 and RAJI cells) in (A) HL60 cells, and (B) RAJI 
cells. Data are means ± SEM, n = 3 (3 measurements per replicate). * denotes a significant difference 
from the control (RAJI cells without treatments), P < 0.05. 
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To further investigate the effect of manipulating NAD
+
 levels on the transcriptional regulation of 
CD38 expression, a similar experiment was also performed in differentiating HL60 cells by 
incubating the cells with FK866 or NAD
+
 up to 24 h. The data demonstrated a significant 
attenuation in CD38 expression at 6, 12 and 24 h of treatment with FK866 or NAD
+
 compared to 
untreated controls (differentiating cells, Fig. 5.6). A similar effect was observed with both 
treatments. Overall, attenuation in CD38 expression was clearly shown in cells treated with 
FK866. However, unexpectedly, the results showed that CD38 expression dropped rapidly even 
with increasing intracellular NAD
+
. The results of NAD
+
 application are consistent with the 
kuromanin results, showing an inhibition of CD38 expression when intracellular NAD
+
 levels 
were elevated. 
Hence, whether NAD
+
 is elevated or increased, attenuation in CD38 expression may have been 
occurring. This strongly confirmed a possible role of NAD
+
 levels in the regulation of CD38 
expression. These observations suggested that NAD
+
 metabolism might be considered as a novel 
target for regulating CD38 expression. 
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Figure 5.6 Effect of treatment with 100 nM FK866 and 100 µM NAD
+
 on CD38 expression after 1 day 
incubation in differentiating cells (ATRA treated cells) up to 24 h comparing to HL60 and ATRA treated 
cells without FK866 or NAD.  Data are means ± SEM, n = 3 (3 measurements per replicate). * denotes a 
significant difference from the appropriate control (differentiated cells without treatments), P < 0.05. 
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5.3.4 Effects of hypoxia and hyperoxia conditions on CD38 expression in leukaemia cell lines 
Hypoxia, a decrease in oxygen levels, is a hallmark of human cancer cells in vivo (Harris, 2002). 
For instance, leukaemia cells in bone marrow are considered physiologically hypoxic (Harrison 
et al., 2002). In the current study, the malignant cells, HL60 and RAJI cells, which are derived 
from human leukaemia cells and lymphoma cells respectively, might also be adapted to 
proliferate in a low-O2 environment. However, these cells were cultured in vitro under 21% O2 
(normoxia). This study aimed to culture these cells under conditions that mimic the in vivo 
environment in order to determine the effect of this environment on CD38 expression. As shown 
in Figure 5.7, RAJI cells were cultured under hypoxia (2% O2) and incubated for 30 and 90 min 
and CD38 expression was determined compared to normoxia conditions (21% O2). CD38 
expression, as measured by qPCR analysis, was slightly increased under hypoxia 2% O2 at 30 
min and 90 min incubation times compared with normoxia, but this was not significant (P ˃ 
0.05). It is important to note that the level of O2 (2% hypoxia) used was based on previous 
reports indicating that most cells can be maintained when cultured under these conditions (Han et 
al., 2006). These data might suggest a link between hypoxia and CD38 expression in the 
leukaemia cell line. However, the vitality results (Fig. 5.9B) showed no changes in cell vitality as 
assessed by MTT assay at 30 min under 2% O2 hypoxia in RAJI cells compared to normoxia. 
CD38 expression was also determined in HL60 cells under 2% O2 and 5% O2 (simulating 
hypoxia), and for 30 min, 90 min and 6 h incubation times. Interestingly, a significant effect at 
2% O2 compared to 5% O2 was observed on CD38 expression (Fig. 5.8). Furthermore, the data 
showed a strong and significant effect of 2% O2 hypoxia at 30 min on regulation of CD38 
expression in HL60 cells compared to 90 min and 6 h with both 2% O2 or 5% O2 (P < 0.05). An 
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apparent decrease in cell vitality was detected under hypoxia (2% O2) at 30 min incubation time 
(P < 0.05; Fig. 5.9 B).  
 
Figure 5.7 CD38 expression in RAJI cells exposed to hypoxia (2% O2) and incubated for 30 min and 90 
min compared to the untreated control (normoxia). Data are means ± SEM, n = 3 (3 measurements per 
replicate), no significant differences between groups were found (P >0.05). 
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Figure 5.8 CD38 expression in HL60 cells exposed to hypoxia (2% O2) and incubated for 30 min, 90 min 
and 6 h compared to the control (normoxia), hypoxia (5% O2), and hyperoxia (95% O2). Data are means ± 
SEM, n = 3 (3 measurements per replicate). * denotes a significant difference from the control (HL60 
cells without treatments), P < 0.05. 
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It is thought that the cell vitality assay measures mitochondrial dehydrogenase activity 
(Mosmann, 1983). However, under hypoxia the metabolism of normal or cancerous cells shifts 
from the aerobic pathway to lactic fermentation (Warburg, 1956) rather than oxidative 
phosphorylation. Therefore, one might expect that dehydrogenase activity may be affected under 
these conditions, so that under hypoxia (2% O2), the measured cell vitality is decreased. In 
addition to investigating CD38 expression under hypoxia, it was also investigated under 95% O2 
(hyperoxia) at 90 min and 6 h incubation (Fig. 5.8). As expected, there was no effect of 
hyperoxia on CD38 expression. Collectively, these novel data strongly confirmed the effect of 
low oxygen tension on CD38 expression in leukaemia cells. 
The effect of hypoxia on glycolysis activity was evaluated by measuring lactate production in 
both leukaemia cell lines. Figure 5.9 A clearly illustrates that under hypoxia (2% O2, 30 min 
incubation), HL60 cells significantly increased lactate levels compared to RAJI cells or to 
normoxia. These data might suggest a link between hypoxia, CD38 expression and glycolysis 
activity. 
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Figure 5.9 Effect of hypoxia (2% O2) after 30 min incubation in both HL60 and RAJI cells on (A) lactate 
production, n = 3 (2 measurements per replicate), and (B) cell vitality (MTT assay) comparing to each 
untreated control (normoxia), n=2 (3 measurements per replicate). Data are means ± SEM.* denotes a 
significant difference from the related control (HL60 or RAJI cells without treatment), P < 0.05.  
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To further characterize the hypoxic response in the cells, it seemed important to evaluate 
intracellular NAD
+
 levels in addition to evaluating the effects of low O2 tension on cell vitality 
and lactate levels in vitro. Therefore, and also to determine whether NAD
+
 levels might be 
playing a role in the upregulation of CD38 under the hypoxic conditions, the same experiment 
was repeated and NAD
+
 levels were assayed by the routine NAD cycling assay.  
The results show that lower NAD
+
 levels were observed under hypoxic conditions (2% O2) at 30 
min incubation time in HL60 cells compared to the normoxia, while RAJI cells did not show any 
change in NAD
+
 levels (Fig 5.10). The drop in NAD
+
 levels (in HL60) might be mediated by 
CD38 upregulation as confirmed under the same conditions in HL60 cells. However, CD38 
activity might not be regulated at 30 min under hypoxia; there might be other mechanisms 
responsible for the decline in NAD
+ 
levels, such as a high glycolysis activity. Interestingly, the 
decrease in NAD
+
 levels was concomitant with the decrease in the cell vitality (MTT) in HL60 
cells and under hypoxic conditions (Fig. 5.9 B). 
Altogether, the results indicate that the hypoxic response of human leukaemia cells is 
characterized by a rapid but transient increase in CD38 expression and lactate production, but 
with a significant decrease in intracellular NAD
+
 levels and not with a significant decrease in cell 
vitality. Interestingly, the expression of CD38 in CD38
-
 cells (HL60) under hypoxia (2% O2) was 
greater than that of CD38
+
 cells (RAJI) at 30 min incubation time.  
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Figure 5.10 Effect of hypoxia (2% O2) after 30 min incubation both in HL60 and RAJI cells on 
intracellular NAD
+
 levels comparable to the untreated control (normoxia). Data are means ± SEM, n = 3 
(2 measurements per replicate). * denotes a significant difference from the control (HL60 cells without 
treatments), P < 0.05. 
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5.4 Discussion 
Several mechanisms of regulation of CD38 expression that involve transcriptional and post-
transcriptional levels of gene expression have been previously reported. Interestingly, the 
analysis of the human CD38 gene has revealed the presence of a number of response elements, 
for example, the retinoic acid response element (RARE; Tirumurugaan et al., 2008). These make 
this gene responsive to a variety of physiological stimuli, suggesting the complex nature of 
CD38 expression in various types of mammalian cells. For instance, a comparatively rapid 
increase in CD38 expression occurs in response to ATRA in HL60 cells, and the mechanism that 
mediates this regulation has been previously studied (Munshi et al., 2002). Transcriptional 
regulation of CD38 expression was also studied during ATRA-induced HL60 differentiation in 
the work described in this Chapter, but after incubation with kuromanin. It was seen that treating 
the differentiating cells with kuromanin inhibits CD38 mRNA expression compared to the 
untreated control. There are two suggested mechanisms that might explain this attenuation in 
CD38 expression. Firstly, kuromanin inhibition of CD38 cyclase activity might have 
consequences on the inhibition of CD38 expression. Secondly, the elevation in intracellular 
NAD
+
 following inhibition of CD38 cyclase activity might have an impact on CD38 expression, 
since NAD
+
 may affect gene expression through two pathways: (1) through the NAD
+
-
consuming enzymes, PARP-1 and sirtuins, that can affect several transcriptional factors 
(D'Amours et al., 1999; Ford et al., 2006) and (2) through the alterations in NAD levels that 
might modulate an important NAD(H)-dependent transcription co-repressor, the C-terminal 
binding protein (CtBP). The change in NAD levels may regulate the dehydrogenase activity of 
CtBP as well as affect the binding of CtBP to specific repressor complexes (Kumar et al., 2002). 
It is important to note that repressors require an association with corepressors to mediate 
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inhibition of gene transcription (Tyler and Kadonaga, 1999). Hence, the elevation of NAD
+
 
levels might mediate CD38 mRNA inhibition through regulation of CtBP. 
In addition to the kuromanin results, it was investigated whether CD38 expression is regulated 
by NAD
+
 levels by using NAD
+
 application and FK866. It was hypothesized that the elevation in 
intracellular NAD
+
 levels following NAD
+
 application might induce CD38 expression, in order 
to degrade the high NAD
+
 levels and vice versa with FK866. However, the results unexpectedly 
showed that elevation of intracellular NAD
+
 by extracellular NAD
+
 application or inhibition 
intracellular NAD
+
 in all cell lines resulted in attenuation of CD38 expression. One explanation 
is that CD38 might be regulated by specific concentrations of NAD
+
, but not by 100 µM 
extracellular NAD
+
 or by using 100 nM FK866 to diminish NAD
+
 levels. These concentrations 
might be completely different from the normal levels in cells, which are suggested to be around 
the high micromolar range (Yang et al., 2007). Therefore, investigations of CD38 expression in 
cells incubated with a range of concentrations of NAD
+
 are suggested for further studies. It is 
worth mentioning that initial studies found that treatment of the CD38
+
 cells with NAD
+
 was 
shown to induce inactivation of CD38 activities; cyclase, hydrolase (Han et al., 2000) or CD38 
might undergo extensive self-oligomerization in the presence of NAD
+
 (Guida et al., 1995). 
Hence, NAD
+
 application inhibited CD38 activities in previous studies, but the effect of NAD
+
 
application on CD38 mRNA was not investigated. Furthermore, CD38 expression was also 
investigated, in this study, after inhibition of intracellular NAD
+
. NAD
+
 levels were inhibited by 
FK866 through its impact on the NAD biosynthesis enzyme (NAMPT). Interestingly, low 
intracellular NAD
+
 was accompanied by an inhibition of CD38 expression. This downregulation 
of CD38 expression might also be NAD-dependent. One of the possible explanations is that 
limited availability of the substrate NAD for the CD38 enzymatic activities might result in 
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reduction in both NAD-hydrolase and cyclase activities, which further leads to the control of 
CD38 expression. It is important to note that FK866 causes depletion of NAD
+
 levels which 
results in cell death by autophagy as confirmed by Billington et al. (2008b). Thus, cells 
incubated for 24 h with this agent, to ensure that NAD
+
 levels dropped first, and to keep the cells 
viable in order to investigate the effect of inhibiting the NAD recycling pathway on CD38 
expression. 
Previous results (Chapter 3) suggested that NAD levels are CD38-dependent. Intriguingly, this 
study suggests that CD38 expression might also be NAD-dependent. The current findings have 
provided the first in vitro evidence that NAD
+
 metabolism might be a novel target for controlling 
CD38 expression by using FK866 and extracellular NAD
+
 application strategies in addition to 
using kuromanin. Targeting NAD metabolism by using NAD
+
 application might serve as a 
treatment strategy in cancer, Huntington’s disease, multiple sclerosis, and neurodegenerative 
diseases (Khan et al., 2007). Targeting NAD metabolism by using FK866 might also implicated 
in cancer therapy (Hasmann and Schemainda, 2003; Holen et al., 2008). Indeed, regulation of 
CD38 expression via manipulation of NAD levels might serve as a treatment strategy for 
leukemia patients, since CD38 works as a dependable marker of unfavourable prognosis and as 
an indicator of cell proliferation and activation (Malavasi et al., 2011). Moreover, inhibition of 
CD38 expression might reduce the consequences of the CD38-CD31 interaction, and 
supramolecular complex signalling that mediated CLL homing processes and survival. Hence, 
controlling CD38 expression in leukemia patients might affect the unfavourable prognosis and 
consequently inflict on patient survival. 
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Regulation of CD38 expression in leukaemia cells was further investigated under hypoxia 
(similar to in vivo conditions). Hypoxia, a decrease in oxygen levels, plays a major role in many 
pathological processes such as ischemic stroke and tumour progression (Harris, 2002). Under 
hypoxia, cells may survive and adapt to the hypoxic environment. These adaptive responses of 
cells to hypoxia may involve the induction of specific gene expression which may help to 
suppress or limit the effects of hypoxia on these cells (Yun et al., 1997). Several studies have 
showed a significant association between hypoxia and CD38 activity in disease states, in several 
types of cells. For instance, a change in CD38 activity that is associated with hypoxic pulmonary 
vasoconstriction (HPV) has been indicated (Wilson et al., 2001). It was suggested that hypoxia-
mediated vasoconstriction is cADPR dependent and the mechanism was attributed to increase an 
NADH:NAD
+
 ratio (due to increased NADH formation via glycolysis) that appears to favour the 
net production of cADPR probably because of the inhibition of cADPR hydrolase activity of 
CD38 (Wilson et al., 2001; Kotlikoff et al., 2004). cADPR accumulation might also suggest 
activation of ADP-ribosyl cyclase activity. CD38 expression was also found to be changed under 
hypoxia in brain cells from rats (Salmina et al., 2008). It is important to mention that regulation 
of CD38 activities might reflect regulation of its mRNA expression. In addition to that, hypoxia 
attenuated CD38 expression in pancreatic -cells from HIT-T15 hamsters (Ota et al., 2012). 
Recently, an association between CD38 and activation of hypoxia inducible factor (HIF), a 
family of transcription factors extensively involved in the response of mammalian cells to low 
oxygen tension, was shown in allergic airway disease (So Ri et al., 2011). However, regulation 
of CD38 expression under hypoxia and in leukaemia cells is still poorly studied. The current 
novel results successfully demonstrate that hypoxia induces the expression of CD38 in leukaemia 
cells. The data has shown that different leukaemia cells exhibit different levels of sensitivity to 
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hypoxia (2% O2); there was more regulation of CD38 mRNA in HL60 cells in response to 
hypoxia compared to RAJI cells, although CD38 expression in untreated RAJI cells was higher 
than in HL60 cells. Indeed, leukaemia cells in bone marrow are considered physiologically 
hypoxic, with oxygen levels approximately three times lower than that usually applied during in 
vitro cell culture (Harrison et al., 2002). Therefore, the hypoxic condition in a current study was 
within the range for these environments. The reason for using hypoxic conditions was that under 
hypoxia a drop in NAD levels might occur. Hence, and in line with the FK866 results, it was 
hypothesized that the decline in NAD levels (as a consequence of lactic fermentation) might also 
mediate CD38 mRNA downregulation. However, the results unexpectedly showed upregulation 
of CD38 mRNA expression. This might raise the possibility that NAD levels might also be 
involved in this interesting regulation. Another possibility is that tumour cells may require 
increased expression of CD38 to maintain cell survival and resistance to apoptosis under hypoxic 
conditions, and targeting this molecule may be useful for cancer prevention and treatments. 
Other suggested mechanisms might be associated with hypoxia-induced cytokines. For instance, 
the release of TNF-, expected to have occurred under hypoxia as previously shown in retinal 
ganglion cells (Hong et al., 2008), might be linked to CD38 overexpresion, since TNF- has 
been shown to induce CD38 expression (Barata et al., 2004). However, further studies are 
needed to clarify the mechanism of the hypoxia induced upregulation of CD38 in leukaemia 
cells. The consequences of a hypoxic environment on cell physiology, that is reflected by more 
lactate production (from lactic fermentation) with lowered intracellular NAD levels, might cause 
metabolic dysfunction. Thus, the possible reason that CD38 protein is frequently overexpressed 
in a leukemia might be because leukaemia cells, in vivo, exist under constant hypoxic conditions 
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and that this might be participating in the development of poor prognosis and metabolic 
dysfunction in leukaemia cells.  
It is worth noting that under hypoxia (2% O2) for 30 min, CD38 expression levels were greater 
than under all other conditions. Hence, the glycolysis state was investigated by measuring both 
lactate and NAD
+
 levels, and cell vitality only under these particular conditions. Furthermore, 
lactate levels were measured as an indicator of glycolytic activity under hypoxia, thus, there was 
no need to reconfirm the hypoxic conditions by measuring HIF, as most studies do. Ultimately, 
although the mechanism of hypoxia-induced CD38 regulation was not investigated, but it seems 
that NAD levels might be involved in this process (Fig. 5.11). 
 
Figure 5.11 Schematic diagram showing how NAD levels might regulate CD38 expression through 
multiple suggested mechanisms. For instance, elevated NAD levels following kuromanin and NAD
+
 
application might inhibit CD38 mRNA expression. Alternatively, depletion of NAD by using FK866 
might also inhibit CD38 mRNA expression, while decreased NAD levels under hypoxia might upregulate 
CD38 expression. 
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Interestingly, under 95% hyperoxia the results did not show any effect on CD38 regulation 
unlike those seen with hypoxia in leukaemia cells, since it reversed the action of hypoxia on 
CD38 expression. One of the possible explanations of these results is that the leukaemia cell 
lines are adapted to function in hypoxic environments, rather than under hyperoxic conditions, 
and that therefore a hyperoxic environment might not regulate CD38 expression. Indeed, limited 
studies have investigated the effect of hyperoxia in HL60 cells; an earlier report confirmed that 
hyperbaric oxygen induces spontaneous and chemotherapy-induced apoptosis in Jurkat and 
HL60 cells (Ganguly et al., 2002). Other studies have documented the use of hyperoxia as a 
potential anticancer therapeutic (Henk et al., 1977; Watson et al., 1978), while there are no 
studies of the effect of hyperoxia on CD38 expression in human cell lines. 
 
 
 
 
 
 
 
 
Figure 5.12 CD38 regulations in different cell types by hormones, cytokines, and retinoic acid and the 
associated increase in ADP ribosyl cyclase activity. In addition to decreasing cADPR hydrolase activity 
under hypoxia and the consequences of cADPR accumulation, adapted from Kotlikoff et al. (2004). 
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Collectively, regulation of CD38 expression under different stimuli, such as hormones, 
cytokines, ATRA, hypoxia (Fig. 5.12) or by manipulating NAD levels (Fig. 5.11) are key points 
for investigation. This might lead to regulation of CD38 activities, or its products, cADPR and 
NAADP, and their related functions, since the role of CD38 or CD38/cADPR signalling in 
regulating different cellular functions in humans and animal models has been well investigated. 
For instance, cADPR plays an important role in hypoxic pulmonary vasoconstriction; HPV 
(Dipp and Evans, 2001). In diabetes, CD38 plays a distinct regulatory role in the murine model 
with regards to insulin secretion via calcium mobilization of cADPR-sensitive stores (Kato et al., 
1995). The crucial role of CD38 deficiency on prevention of the development of obesity through 
activation of SIRT/PGC1α has also been documented (Baur et al., 2006). Finally, in CLL high 
levels of CD38 expression correlate with both disease stage and poor prognosis (Morabito et al., 
2002). Studies have also confirmed that CD38 is a master regulator of CLL cell homing (Vaisitti 
et al., 2011). Indeed, therapeutic applications that target CD38 have been more explored in 
leukemia. 
Thus, the current study might prove useful to future researchers especially when they are 
investigating mechanisms that regulate CD38 expression as a target in leukemia therapy or in 
other CD38-related diseases. 
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CHAPTER 6 
EFFECT OF LOW NAD LEVELS ON THE 
DNA DAMAGE AND CELL DEATH 
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6.1 Introduction 
In addition to the well-known functions of NAD in metabolism or as a substrate for CD38, it also 
participates in DNA repair and cell death via PARP, a family of enzymes with 17 members of 
which PARP-1 is the founding member (Ying et al., 2005; Hassa and Hottiger 2008). These 
enzymes catalyze the covalent attachment of poly ADP-ribose (PAR) polymers either to 
themselves or to other acceptor proteins, using NAD
+
 as a donor of ADP-ribose units, in addition 
to the release of nicotinamide (Hassa and Hottiger 2008). The poly ADP-ribosylation of specific 
target proteins is crucial for genome stability, DNA repair, telomere maintenance and cell death 
(Khan et al., 2007). PARP-1 activation is critical in determining cellular fate after DNA damage 
has occurred (Pieper et al. 1999) since, through its role in DNA repair, PARP-1 activation may 
serve to rescue damaged cells, preventing them from death (Chatterjee et al., 1999). However, 
extensive DNA damage results in PARP hyperactivation, leading to a rapid depletion of cellular 
NAD
+
 and lowered ATP production, ultimately leading to cell death (Alano et al., 2004; 2010). 
Cell death by autophagy has also observed when intracellular NAD levels are decreased by using 
FK866, a NAD-depleting drug (Billington et al., 2008b). 
Thus, researchers have shown an increased interest in the area of influence of NAD
+
 status on 
genomic stability, DNA repair and apoptotic cell death, specifically in cancer (Schwartz et al., 
1974). The reason for this interest is that cancer cells, which mostly depend on lactic 
fermentation for ATP production, exhibit a particularly high sensitivity to DNA damage and 
PARP-1 activation (Zong et al., 2004). For this, an adequate level of cellular NAD in cancer 
cells is necessary because of a high rate of NAD
+
 turnover due to elevated ADP-ribosylation 
activity (Burkle, 2005). Several studies have drawn attention to the effects of decreases or 
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increases in NAD levels on PARP activity and cell death (Ying et al., 2003; Benavente et al., 
2012). Other cancer therapy studies combined NAD-depleting drugs with chemotherapy and 
radiotherapy (Ekelund et al., 2002; Progrebniak et al., 2006), or combined PARP inhibitors with 
DNA-binding antitumour drugs as a suitable strategy in cancer therapy (Cepeda et al., 2006). 
However, to this author’s knowledge, no research to elucidate the consequences of low NAD 
levels on DNA repair, PARP activity and apoptotic cell death in CD38- expressing leukaemia 
cells, has been carried out to date. Therefore, according to the hypothesis that hyperactivation of 
PARP requires a certain level of cellular NAD to induce cell apoptosis and to decrease cell 
proliferation, it was postulated that in CD38
+
 cells such as leukemia there will be a high demand 
for NAD that might render these cells more resistant to apoptosis.  
The aim of the work described in this chapter was therefore to use a comet assay approach to 
investigate the response to DNA damage induced by UVB in cells expressing CD38 with low 
cellular NAD levels. In addition, the consequences of UVB on PAR production (confirmed by 
western blotting) and finally apoptotic cell death were examined. Whilst the data in this Chapter 
are preliminary, the results showed a significant level of UVB-induced DNA damage in cells 
with low NAD levels, in addition to cell resistance to apoptosis. Finally, these preliminary results 
may help to increase future understanding of the nature of cell resistance to apoptotic death in 
CD38
+
 subsets of leukemia patients, even during chemotherapy or radiotherapy. 
184 
6.2 Material and methods 
6.2.1 Materials 
Low melting point agarose, normal melting point agarose, EDTA, Tris base, Triton X-100, 
DMSO, and Wright-Giemsa stain were all purchased from Sigma (Poole, UK). The PAR 
antibody was purchased from Abcam (Cambridge, UK). 
6.2.2 Comet assay and quantification of DNA damage 
Single-cell gel electrophoresis (the comet assay) is a microelectrophoretic technique for the 
direct visualization of DNA damage in individual cells. The comet assay (outlined in Fig. 6.1) 
was performed as described by Singh et al (1988) on HL60, RAJI and differentiated HL60 cells. 
Cell suspension (100 µl of 1 × 10
5 
cells ml
-1
) were transferred to individual 1.5 ml 
microcentrifuge tubes and centrifuged at 200 × g for 5 min. The supernatants were discarded and 
the pellets were each mixed with 85 µl of low melting-point agarose (0.5% in PBS), which was 
then pipetted onto agarose-coated microscope slides (pre-coated with normal melting-point 
agarose (1% in PBS) and dried at 37 °C). After the cell/ agarose mixture had solidified (4 °C for 
15 min), the slides were then immersed vertically in lysis solution (2.5 M NaCl, 100 mM 
Na2EDTA, 10 mM Tris-base, pH 10, containing freshly added 1% Triton X-100 and 10% 
DMSO) for 24 h at 4 °C. The slides were then washed three times vertically with neutralization 
buffer containing 0.4 M Tris-base, pH 7.5, and then placed into a horizontal electrophoresis 
apparatus (tank) filled with fresh, pre-cooled electrophoresis buffer (1 mM EDTA, 300 mM 
NaOH, pH 13.3). After 20 min of pre-incubation (unwinding of DNA), the electrophoresis was 
run for 20 min at a fixed voltage of 25 V and 300-400 mA, after which the slides were put in a 
tray and washed by adding neutralisation buffer in a drop-wise manner; this process was repeated 
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ten times. The slides were then left to dry at room temperature for 60 min. After drying, the 
slides were kept in a chamber in the dark at room temperature until analysis. 
After 24 h, cells were stained with 20 µl ethidium bromide solution (2 µg ml
-1
), and analysed at 
200 × magnification with a Leica EL6000 fluorescence microscope (Bradford, UK). Assessment 
of DNA damage was based on the analysis of 100 randomly selected comets from each slide 
which were analysed by the comet IV imaging system (Perceptive Instruments, Suffolk, UK). In 
this system, tail DNA is considered to be the parameter most directly related to DNA damage. 
Each experiment was repeated three times with different cell preparations, and statistical analysis 
was carried out using a one-way ANOVA. 
 
Figure 6.1 Schematic representation of the comet assay describing slide preparation, cell lysis, 
electrophoresis, visualisation and scoring steps (adapted from Tice et al., 2000). 
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6.2.3 Validation of the comet assay under in vitro conditions using hydrogen peroxide 
The comet assay was validated using hydrogen peroxide H2O2, as a reference genotoxic agent to 
determine oxidative DNA damage (Tice et al., 2000). This was conducted by in vitro exposure of 
HL60 and differentiated HL60 cells to a range of H2O2 concentrations. The cell pellet was 
incubated with 100 μl of 0-300 μM concentrations of H2O2 for 10 min at 4 °C in the dark. 
Following the incubation, cells were washed with PBS to remove any remaining H2O2, and cell 
viability was determined using trypan blue. Slides were then prepared as described in Section 
6.2.2 and processed for the comet assay. 
6.2.4 UVB radiation of differentiated cells and induction of apoptosis 
HL60, RAJI and 3 day differentiated HL60 cells were irradiated as freshly harvested 
suspensions. The cells were resuspended in PBS after two washes at the desired density (0.2 - 3 
× 10
6
 cells ml
-1
). UVB irradiation was performed using a twin-tube lamp (TL-20W/12RS; 
Philips, Guildford, UK). UVB irradiation was calculated by using a Macam spectroradiometer 
(Macam SR9910, Livingston, UK) using integrated intensity between 280 - 340 nm (peak 
intensity of 310 nm). Irradiation was performed in 24-well plates. The UVB source was 
positioned directly above the cell suspension covered with a filter lid. The dose of UVB was 1.6 
kJ m
-2
 for 560.8 s. In all experiments after exposure to UVB was completed, cells were 
immediately processed for the comet assay, MTT assay, Halo assay, Geimsa staining and 
western blotting (poly ADP-ribose modified protein production). In other samples measuring 
post-irradiation effects on DNA (DNA repair), cell suspensions were maintained at 37 °C for 45 
min, 90 min and 6 h after exposure before processing using the comet assay etc. Cells used as 
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controls were similarly washed, centrifuged, counted, and placed in the 24 well plate, but were 
not exposed to UVB irradiation. 
6.2.5 Halo-Comet assay 
This technique was first described by Vinograd et al. (1965) and it was improved as the alkaline-
halo assay by Sestili et al. (2006). In the normal comet assay, and in response to the electric 
current, charged DNA migrates away from the nucleus. The halo assay, in contrast, does not 
include an electrophoresis step. Also, the intact DNA remains within a residual nucleus-like 
structure called a nucleoid. If the nucleoid DNA contains strand breaks, a halo of DNA extends 
around the original form of the nucleus and may be visualized by fluorescence microscopy. 
In this assay, following cell irradiation, the DNA damage was assessed as described in the 
Section on the comet assay (Section 6.2.2, except for omission of the electrophoresis step), and 
halo cells were visualized using a fluorescence microscope (Nikon Eclipse 80i, Surrey, UK), 
with image analysis software (NIS-Elements BR, Nikon, Surrey, UK). 
6.2.6 Wright-Giemsa staining method 
For morphological assessments of apoptosis, the UVB-exposed cells were stained using the 
Wright-Giemsa staining method. Cells were centrifuged and the pellets were resuspended in 
PBS. Cell suspension (100 µl of 1 × 10
6
 cells ml
-1
) were prepared on slides using a cytospin 
centrifuge (Shandon, Leicester, UK) and fixed with 5 µl methanol before staining with Wright-
Giemsa stain. After 4 min, slides were rinsed in water and air-dried. The morphology of cells 
was examined under a light microscope (× 100; Olympus, Japan). 
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6.2.7 Statistical analysis 
Statistical analysis of the data was assessed using Fisher’s one way analysis of variance 
(Statview 5.0.1; Abacus concepts, USA) or Student’s t-test as appropriate. Data are expressed as 
means ± SEM for three separate experiments in triplicate, unless otherwise stated. A difference 
of P < 0.05 was considered statistically significant. 
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6.3 Results 
6.3.1 Effect of cellular NAD levels on UVB-induce DNA damage 
The induction and repair of UV-induced DNA damage has been previously studied in vitro and 
in several cell lines (Cadet et al., 1997; Ravanat et al., 2001). However, the study in this Chapter 
aimed to induce DNA damage in vitro by using UVB irradiation, and also to investigate DNA 
repair in RAJI, HL60 and differentiated HL60 cells. The alkaline comet assay was used to detect 
the damaged DNA due to its high sensitivity (Collins, 2009). Among all the parameters provided 
by the comet software, the percentage of DNA in the tail (% tail DNA), is considered to be the 
most reliable parameter (Kumaravel and Jha, 2006), and was used in this work to represent 
cellular DNA damage. 
To validate the comet assay, an experiment was conducted with H2O2 exposure to HL60 and 1 
day ATRA-treated cells. DNA damage was clearly seen in the both groups of cells, and was 
similar in cases (Fig. 6.2). The percentage tail DNA data showed an increase in DNA damage 
with concentration in the range 30 to 300 µM H2O2. There was a ≈2.3 fold increase in percentage 
tail DNA with 300 µM H2O2 in HL60 and differentiated HL60 cells, compared to the untreated 
control. Thus, the comet assay proved to be a sensitive technique for the detection of DNA 
damage, and showed that DNA damage by H2O2 was concentration-dependent. 
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Figure 6.2 DNA damage expressed as percentage tail DNA in HL60 (solid line) and 1 day differentiated 
HL60 cells (dashed line) following 10 min in vitro incubation with different concentrations of H2O2 (1-
300 μM). Data are means ± SEM, n = 1 (100 measurements). 
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In order to induce DNA damage, a UVB-irradiation system was used. A UVB meter was used to 
control the irradiation dose and to calculate the irradiation time. The emission spectrum from 
280-340 nm of the lamp is shown in Figure 6.3 with a peak at 310 nm. Thus, to irradiate the cells 
with the desired dosage (1.6 kJ m
-2
); the cells were irradiated for 560.8 s by using a twin-tube 
lamp (TL-20W/12RS; Philips). The irradiation time (t) was measured in seconds and was 
calculated using the formula: D = I × t, where I is the UV radiation density (2.853 W m
-2
 {J s
-1 
m
-
2
} at 310 nm and D is dose of irradiation (1600 J m
-2
). 
In the current study, the induction of the DNA damage by exposure to 1.6 kJ m
-2 
UVB dosages 
was performed on the undifferentiated, 3 day-differentiated HL60 cells and RAJI cells. The 
results (Figure 6.4) showed that the UVB irradiation induced DNA damage in all cell lines, as 
estimated by percentage tail DNA. The DNA damage was more striking in differentiated HL60 
cells and RAJI cells, in comparison to cells not expressing CD38 (undifferentiated HL60 cells), 
which showed relatively low levels of DNA damage. The same results were also confirmed in 
the comet images (Fig. 6.5). There was also no significant loss of cell viability (Figure 6.7) in 
any of the cell lines (cell viability using trypan blue exclusion was 70-80% in all cases). These 
results suggest that the maximum induced DNA damage can be clearly seen in cells that have 
low intracellular NAD levels (CD38
+
 cells) than cells that have a high level of NAD. 
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Figure 6.3 Spectrum of the twin-tube UV lamp with a maximum emission in the UVB region (310 nm). 
The lamp was used to irradiate the cells to induce DNA damage. The data represent a single 
measurement. 
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Figure 6.4 DNA damage expressed as percentage tail DNA in undifferentiated HL60 cells, differentiated 
HL60 cells (3 days) and RAJI cells following the irradiation with 1.6 kJ m
-2
 UVB. Data are means ± 
SEM, n = 3 (100 measurements per replicate). * denotes significant difference from the appropriate 
untreated control (P < 0.05). 
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The DNA damage was also assessed in undifferentiated HL60, RAJI and differentiated HL60 
cells after recovery times of 45 min, 90 min and 6 hours after UVB-irradiation, to evaluate the 
DNA repair process (Fig. 6.6). There was an apparent drop in DNA damage in the all cell lines 
between 45-90 min after irradiation. This might suggest that DNA repair processes were more 
evident in HL60 and RAJI cells than in the differentiating HL60 cells. Interestingly, there was no 
decrease in cell viability at 45 min and 90 min in all cells after irradiation (Figure 6.7). 
Surprisingly, after a clear decline in the DNA damage at 45 and 90 min there was an increase in 
percentage tail DNA in all cells at 6 h post irradiation. No significant difference was observed 
between the different cell types at that time, which might suggest impairment in the DNA repair 
process. Moreover, cell viability results after 6 h recovery time showed a significant loss of 
viability (Figure 6.7) as determined by trypan blue exclusion in all of the cell lines. 
Thus, the above results confirm that a decline in intracellular NAD in CD38 positive cells (3 
days differentiated HL60 cells and RAJI cells) might increase the cell response to UVB-induced 
DNA damage as shown in Figure 6.4. However, these cells showed relatively recovered DNA 
after a short time of irradiation which might be related to PAR accumulation, which initiates the 
repair process in the case of moderate DNA damage (1.6 kJ m
-2
 dosages). 
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Figure 6.5 Representative comet images of undifferentiated HL60, 3 days differentiated HL60 cells and 
RAJI cells, which were exposed to UVB-induced DNA damage (1.6 kJ m
-2
). Cells were stained with 
ethidium bromide before visualization. Magnification = ×200. Scale bars: 50 μm. 
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Figure 6.6 DNA repair of UVB-induced DNA damage (1.6 kJ m-2). Following HL60, ATRA-induced 
HL60 differentiation (3 days) and RAJI cell irradiation, the percentage of DNA damage was assessed 
after recovery times of 45 min, 90 min and 6 hours. Data are means ± SEM, n = 3 (100 measurements per 
replicate). * denotes significant difference from the appropriate control (P < 0.05). 
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Figure 6.7 Cell viability following UVB-induced DNA damaged (1.6 kJ m-2) in HL60, ATRA-induced 
differentiated HL60 and RAJI cells as assessed by trypan blue exclusion over a recovery time of 45 min, 
90 min and 6 h, n = 1 (4 measurements). 
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6.3.2 Effect of UVB on PAR production in CD38
+
/
-
 cells 
Next, the effect of UVB on PAR accumulation in cells expressing CD38 was examined. It is well 
known that PARP-1 is activated upon binding to damaged or abnormal DNA (Durkacz et al., 
1980) and catalyzes the formation of poly(ADP-ribose) polymers (PAR) onto different acceptor 
proteins, including PARP-1 itself (auto PARsylation), using NAD
+
 as substrate. PAR 
accumulation is an immediate response following UV exposure. PARP catalytic activation was 
assessed by detection of its product, PAR-modified proteins, in CD38 negative cells (HL60) and 
CD38 expressing-cells (RAJI, 3 day differentiated HL60 cells) up to 6 h after UVB treatment 
(Fig. 6.8 A). 
Western blotting (Fig. 6.8 A) showed that UVB exposure resulted in an observed decrease in 
PAR hypermodified proteins in HL60 cells, RAJI, and differentiated cells from 0-90 min post 
irradiation compared to the basal levels in each corresponding non-exposed control (Fig. 6.8 B), 
including PARP-1, whose modifications appear clearly between 100-200 kDa (Yu et al., 2002). 
Interestingly, PAR production increases significantly at 6 h post-UVB treatment in all samples 
compared to immediately after treatment (Fig. 6.8 A); this was clearly shown in HL60 cells 
compared to the NAD-restricted cells (RAJI and differentiated HL60 cells) which showed less 
detectable PAR-hypermodified proteins (Fig. 6.8 A). The low PAR levels might reflect low 
availability of the substrate for PARP (NAD), probably restricted by CD38 activity. 
Collectively, Western blotting results for poly ADP-ribose polymer expression might not show clear 
variations in cell response to DNA damage or PAR production which was based on whether or 
not the cells expressed CD38. 
199 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 Western blotting analysis for poly ADP-ribose polymer expression under (A) normal 
conditions,  represented by HL60 cells treated for 3 days with ATRA compared to the controls (RAJI and 
undifferentiated HL60 cells), and (B) PAR production after UVB exposure from 0-6 h for 50 µg cell 
lysate under reducing conditions and 12% SDS PAGE (Chapter 2, section 2.8.4). The figure represents 
one of two separate cultures. 
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6.3.3 Effect of UVB-induced DNA damage on apoptotic cell death in CD38
+ 
and CD38
- 
cells 
In this Section of the work, an attempt was made to examine a possible relationship between 
NAD levels, and effects on DNA-damage and cell death. In previous Sections, a different cell 
response to UVB-induced damage DNA was found. Therefore, it seemed important to further 
confirm these findings by using another method of assessing cell damage or death. Thus, two 
different morphological determination methods- the halo assay and Wright-Giemsa staining- 
were performed to compliment the data already obtained and to further investigate the effect of 
cellular NAD content on either DNA repair or apoptotic cell death. It is worth mentioning that 
radiation therapy is used in cancer treatment via the induction of DNA damage to kill cancer 
cells or to keep them from growing (Lawrence et al., in: DeVita et al., 2008). 
Morphological observation of cell death was performed by two simple, sensitive, and reliable 
assays, the halo assay and Wright-Giemsa staining. These assays were used for the quantification 
of apoptosis in HL60, 3 day differentiated HL60 cells and RAJI cells that had been exposed to 
UVB as a DNA damaging source. Giemsa-stained cells (Fig. 6.9), and cells that were assayed by 
the halo assay (Fig. 6.10) showed morphological changes after UVB irradiation for up to 6 h. 
Typical apoptotic changes, including chromatin condensation, nuclear fragmentation and 
formation of apoptotic bodies, were clearly observed in Giemsa stained cells (Fig. 6.9). Those 
cells exhibiting morphological changes can be easily differentiated from normal cells which, 
under a light microscope, show normal morphology with no apoptotic bodies (Searle et al., 
1982). This was found in the controls for all cell lines. Furthermore, apoptotic cells assayed by 
the halo assay (Fig. 6.10) showed a halo of DNA with a hazy outer boundary that extends around 
the original form of the nucleus. 
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There was variation in cell responses to UVB-induced DNA damage that depended on the cell 
line and the time after irradiation. Thus, apoptosis appeared immediately after irradiation in all 
cell types as detected by Giemsa stain (Fig. 6.9) and halo assays (Fig. 6.10). Interestingly, HL60 
cells showed a greater response to UVB-induced DNA damage with both assays at 0 h, 
compared to the other cells. Also, repair following irradiation was seen at 45 min and 90 min in 
HL60, 3 day differentiated HL60 cells and RAJI cells, respectively, and this observation might 
confirm initiation of the DNA repair process. No characteristics of apoptosis were seen for each 
non-irradiated control, HL60, differentiated HL60 cells and RAJI cells (Fig. 6.9, 6.10). Finally, 
after the recovery time, 6 h, apoptosis was observed in the differentiated HL60 cells and control 
HL60 cells to a greater degree than was observed in RAJI cells (Fig. 6.9, 6.10). These data 
appear to confirm that NAD is a key determinant of apoptotic cell death. Therefore, as NAD 
levels in HL60 cells are higher than those in RAJI cells, these cells were more response to UVB-
induced DNA damage as confirmed by more apoptotic cell death. Importantly, similar results 
were obtained using the two assays (Fig 6.9; 6.10) and these morphological data are concomitant 
with DNA damage results (Fig. 6.6) for the same cells. 
In summary, irradiation of HL60, differentiated HL60 cells and RAJI cells with UVB light 
caused the cells to undergo morphological changes characteristic of apoptosis, and  the level of 
apoptosis differed between cells depending on the levels of CD38 expression, intracellular NAD 
content, PAR production and the time after irradiation. Collectively, these data supported the 
comet results and suggest that leukaemia cells that express CD38 might exhibit a resistance to 
apoptotic cell death that is induced under UVB radiation. 
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Figure 6.9 Photomicrographs showing HL60, 3 day- differentiated HL60 cells and RAJI cells stained 
with Wright-Giemsa stain before, and after irradiation (0-6 h). Cells exhibit features typical of apoptosis 
after UVB-irradiation. Original magnification х100. Scale bars: 50 µm. 
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Figure 6.10 Photomicrographs processed during the halo assay showing HL60, 3 day differentiated HL60 
cells and RAJI cells stained with ethidium bromide as controls or after UVB irradiation (0-6 h). Original 
magnification х 400. Scale bars: 50 µm. 
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6.4 Discussion 
The aim of this study was to evaluate the effect of a CD38-mediated decrease in NAD levels on 
the cellular response to DNA damage (after UVB exposure), both in cells expressing CD38 
(RAJI and 3 day differentiated HL60 cells), compared to undifferentiated HL60 cells, which do 
not express CD38. In the current study, the halo and comet assays were used to assess the DNA 
damage following UVB-induced DNA damage. Ultraviolet B (UVB) causes either direct DNA 
damage, forming cyclobutane pyrimidine dimers (CPD) and 6,4-photoproducts which are 
removed by nucleotide excision repair (NER), or oxidative DNA damage (for example single 
strand breaks), which are removed by base excision repair (BER), and single strand break repair 
(SSBR) (Caldecott, 2003). Interestingly, in order to repair the DNA damage, PARP is known to 
be activated, and it is implicated in both SSBR (Caldecott, 2003) and BER (Le Page et al., 2003) 
of UV-induced oxidative DNA damage (Caldecott, 2003). 
The UVB-induced DNA damage results shown in Fig. 6.4 clearly showed that CD38 negative 
cells (with lower intracellular NAD levels) showed less DNA damage compared to CD38 
positive cells (RAJI and differentiated HL60 cells). Ultimately, these data confirm that the 
decline in NAD levels strongly enhances DNA damage. Furthermore, an important finding is 
that DNA repair was seen from the earliest times after irradiation as confirmed by the less DNA 
damage in HL60 and RAJI cells at 45 min and 90 min compared to differentiated HL60 cells. 
The results suggest that the cellular response to DNA damage is based on the variation in NAD 
levels. Although the differentiated cells expressed high levels of CD38 with lower NAD content, 
they are also showed low DNA damage at 90 min which might relate to the initiation of repair 
processes. A possible explanation for this repair is that the levels of NAD
+
 were suitable to 
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initiate the repair process, and that NAD
+
 might not drop to lower levels after PARP-1 
activation. Also, PARP-1 activation may lead to rapid depletion of the cytosolic pool, but not of 
the mitochondrial pool, of NAD
+
 (Ying et al., 2005). These reasons might contribute to a relative 
DNA repair in the differentiated HL60 cells. Altogether, these results suggest that a repair 
process through PARP activation might occur in response to UVB-induced DNA damage, since 
at low or mild levels of DNA damage, PARP initiates DNA repair processes (for instance, 
recombination, remodelling of chromatin, transcriptional changes at the damaged site, and DNA 
base excision repair, Virag and Szabo, 2002). It is worth noting that an early PARP activation 
(represented by PAR accumulation) has been observed previously at 1 to 2 h after irradiation 
with UVB in mouse fibroblasts (Vodenicharov et al., 2005). However, in the current study, early 
PAR production was observed in HL60 at 90 min after UVB-irradiation, increasing in all cell 
lines after 6 h. Surprisingly, at 6 h, a detectable level of DNA damage was also evident (≈30% 
tail DNA), and it was relatively similar in all cell lines. One possible explanation for these data is 
that PARP activation and PAR production might not be able to participate in the repair of UV-
induced DNA damage, which might reflect the key role of NAD levels in the repair process. In 
addition to the effect of UVB irradiation in inducing DNA damage (Zong et al., 2004), the 
decline in intracellular NAD, probably via CD38, might also participate in increasing this 
damage. CD38 might affect PARP activity by limiting the availability of NAD, ultimately 
mediating DNA damage and some of its consequences (collectively known as genomic 
instability, e.g. chromosomal aberrations, DNA translocations, deletions, and amplifications). In 
the absence of a repair system, probably PARP, genomic instability would rapidly accumulate 
and disturb DNA replication, gene expression and ultimately cellular and tissue homeostasis 
(Burkle, 2001). 
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NAD levels are an important factor in deciding cell fate. In general, two controversial hypotheses 
have been suggested involving NAD as a determinant of cell fate. It was firstly hypothesized that 
NAD depletion increased DNA damage (Winter and Boyer, 1973) and that PARP activation 
causes cell death via apoptosis (Yu et al., 2002), necrosis (Ha and Snyder, 1999) or autophagy 
(Munoz-Gamez et al., 2009). A second hypothesis proposed that NAD-depleted cells are 
resistant to apoptotic cell death, as demonstrated by a study of Wright et al. (1996). This study 
indicated that NAD-deficient cells are resistant to UV light-induced apoptotic cell death. 
Collectively, these two controversial hypotheses might explain that there are two mechanisms by 
which NAD-deficient cells respond when death appears imminent, these being either resistance 
or induced cell death. Importantly, the second hypothesis is strongly confirmed by the results of 
this Chapter. In the current study, it was hypothesized that the decrease in NAD levels might 
increase DNA damage and hence inhibits apoptotic cell death, as it was shown that cells with 
adequate levels of NAD undergo apoptosis, but that cells with restricted or lowered NAD levels 
show a relative resistance to apoptotic cell death. For example, apoptosis was more evident in 
HL60 cells than RAJI cells. It has been shown previously that UVB induced apoptotic cell death 
in HL60 (Lu et al., 1996). The differentiated HL60 cells, unexpectedly, were also found to 
undergo apoptosis, which might be one of the consequences of ATRA-induced terminal 
differentiation of HL60 cells (James et al., 1999). Thus, apoptotic cell death was NAD-
independent in differentiated HL60 cells and NAD-dependent in both HL60 cells and RAJI cells. 
Altogether, cells that are expressing CD38 are expected to have an impaired repair system and 
accumulate DNA damage along with a characteristic resistance to cell death.  
Several approaches have been developed to target NAD
+
 metabolism for both the prevention and 
treatment of cancer (Jacobson et al., 1999). For instance, pharmacological inhibition of PARP-1 
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activity worked as a suitable target to enhance the activity of antitumour drugs through inhibition 
of necrosis and activation of apoptosis (Southan and Szabo, 2003). Furthermore, researchers 
have developed drugs targeting the inhibition of NAMPT (the crucial enzyme in NAD synthesis 
that is overexpressed in human malignancies), that have anticancer properties through depletion 
of cellular NAD
+
 (Van Beijnum et al., 2002), such as using FK866 (Hasmann and Schemainda, 
2003) and CHS828 (now under development as the prodrug GMX1777) either alone (Hjarnaa et 
al., 1999) or in combination with cancer therapy producing DNA damage, the alkylating drugs 
and radiotherapy. For instance, FK866 has been combined with ionizing radiation in a mouse 
tumour model, which shows a delay in tumour growth, with no effect on normal tissues 
(Muruganandham et al., 2005; Kato et al., 2010). Importantly, the results of the current study 
might also be taken into account in cancer therapy while using chemotherapy or radiotherapy in 
combination with inhibitors of NAD biosynthesis, especially in CD38
+
 leukemia subset patients. 
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Figure 6.11 The effects of CD38 expression on NAD depletion and the role of NAD as a metabolic link 
between DNA damage induced by different stimuli or in cancer, and the resistance to cell death via a 
reduction in ATP levels. 
In conclusion, NAD depletion in cells expressing CD38 might induce a resistance to apoptotic 
cell death and promote cell survival in leukaemia cell lines, which might have important 
implications for the pathogenesis and progression of cancer. In terms of leukemia patients, cells 
that are expressing high levels of CD38 (in patients with poor prognosis) would also be expected 
to show a similar relationship. Firstly, according to the results (Chapter 3), the increase in CD38 
expression, concomitant with a decrease in NAD levels, will be linked with reduced glycolytic 
activity which may in turn affect ATP levels, since cells consume ATP to replenish NAD
+
 (Virag 
and Szabo, 2002). Thus, a depletion of ATP might lead to increased resistance to cell death, 
since apoptosis is an energy-dependent process (Kass et al., 1996), Secondly, as suggested by the 
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results presented in this Chapter, low intracellular NAD content may be as a result of CD38 
activities, in addition to PARP activation (following DNA damage under UVB irradiation). 
CD38 activity and low NAD levels might further lead to restricted PARP activity, lowered PAR 
levels, reduction in the repair process and defective induction of apoptosis, since PAR is known 
as an inducer of apoptosis. This may lead to impairment of the repair system and failure to 
control the carcinogenesis. 
Finally, the information presented in this chapter raises the possibility that in leukemia patients 
the combinations of chemotherapy or radiotherapy with CD38 expression might lead to poor 
responsiveness, drug resistance and a worsening of the disease stage. For this reason, DNA-
damaging therapy that uses irradiation or drugs to destroy cancer cells is often accompanied by 
the development of drug resistance and severe side effects (Libura et al., 2005; Mistry et al., 
2005). One possible explanation for this is that CD38 expression is an important regulator of 
intracellular NAD
+
 pools and therefore of metabolic pathways that are related to the availability 
of NAD
+
 rather than glycolysis, such as PARP reactions. This might reduce PAR production 
leading to a delay in apoptotic cell death in preference to cell resistance and survival. Altogether, 
combined CD38 expression with cancer therapy agents or radiotherapy may promote cell 
proliferation (Fig. 6.11), and drug resistance. For these reasons, CD38
+
 patients at a more 
advanced stage of disease show poor responsiveness to chemotherapy and a shorter survival state 
in comparison to CD38
-
 CLL patients (Morabito et al., 2002). Thus, to improve patient therapy, 
one possible suggestion is to avoid the use of DNA-damaging therapy (chemotherapy or 
radiotherapy) in CD38
+
 CLL patients, in order to reduce cell resistance to such treatment. 
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CHAPTER 7 
GENERAL DISCUSSION 
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7.1 Discussion 
Leukaemia is one of the common haematological malignant diseases, and CLL is the most 
frequent leukaemia in Europe and North America. It is a highly heterogeneous, incurable disease 
that ranges from a stable condition, not requiring treatment, to a rapidly progressive disease 
unresponsive to therapy (Hallek et al., 2008). The presence of CD38 on the CLL cell surface has 
prognostic relevance, with high levels being associated with an unfavourable outcome (Damle et 
al., 1999). For these two reasons, CLL was selected as a disease model in the current study to 
investigate the underlying hypothesis. Generally, most studies to date have focused on the role of 
receptor function of CD38 in poor CLL prognosis. This study is the first to describe an important 
role of CD38 enzymatic function in altering NAD levels and of their contribution to leukaemia 
development and progression, in addition to its receptor function. The human leukaemia cell line 
HL60, was predominantly used as an alternative model for leukemia in the current study as a 
model expressing CD38 when differentiated to neutrophil-like cells using ATRA. The current 
findings suggest that CD38 expression plays a key role as a determinant of cell survival, which is 
mediated through consumption of NAD, as a redox cofactor and the substrate for a network of 
NAD-consuming enzymes. Overall, these findings, combined with previous findings, lead to 
three hypotheses describing the synergistic connection between the receptor and enzymatic 
functions of CD38, which might help to explain the poor prognosis in CD38
+
 leukemia subset 
patients. 
Initially, Vaisitti et al. (2011) described two hypotheses in terms of the mechanism by which 
CD38 regulates the homing process and therefore why patients with CD38
+
 CLL clones 
experience a generally more aggressive disease and a worse prognosis. In the first hypothesis, it 
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was suggested that CD38 could transmit its own indirect signals through the generation of Ca
2+
 
active messengers (Vaisitti et al., 2010). Extracellular CD38 catalyses NAD
+
 hydrolysis, 
generating ADPR and, at lower levels, cADPR. These two messengers are transported inside the 
cell by CD38 itself or by active channels, where they could then trigger Ca
2+
 influx from the 
binding to TRPM2 or RyR (Perraud et al., 2001). An increase in Ca
2+
 concentrations may lead to 
direct activation of Ca
2+
-sensitive tyrosine kinases (Schaller, 2010), in addition to direct nuclear 
translocation of Ca
2+
-sensitive transcription factors (Graef et al., 1999). Ultimately, this leads to 
the initiation of a transcriptional program regulating proliferation. 
The second hypothesis suggests that CD38 induces the formation of highly stable supramolecular 
complexes that include surface molecules as well as intracellular signalling adaptors (Deaglio et 
al., 2007). CD38 plays direct role as a molecular amplifier that activates the polymerization of 
actin and nuclear events, specifically in the presence of its non-substrate ligand CD31. In 
addition, the presence of other possible molecules as previously described (Chapter 1) together 
creates a suitable environment for CD38 to work as a master regulator of the CLL cell homing 
process in patients with CD38
+
 CLL clones. 
The current study explores a third hypothesis (Fig. 7.1), which postulates that, in addition to the 
aforementioned role of CD38 as a receptor, CD38 enzymatic functions are also involved in 
CD38-mediated poor prognosis in leukemia patients. Tests of the current hypothesis had two 
major aims, the first was to provide solid confirmation that CD38 is the main NAD consuming 
enzyme, but not its analogue (CD157), nor other NAD consumers (PARP or sirtuin). The 
findings (Chapter 3) supported the hypothesis, confirming the major role of CD38 in altering 
NAD levels to the lower levels concomitant with its expression; this relationship was reversed by 
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the impact of kuromanin in inhibiting CD38 cyclase activity. This study produced results which 
corroborate the findings of Barbosa et al. (2007), who demonstrated that loss of CD38 in CD38 
KO mice had a major effect on NAD homeostasis, since a significant boost in NAD levels were 
shown. 
 
Figure 7.1 Schematic diagram representing the third hypothesis for the functional role of CD38 
enzymatic functions mediated by NAD, combining with its receptor functions in inducing cell 
proliferation and poor prognosis in CD38
+
 leukemia patients. 
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The second aim in testing the current hypothesis was to investigate the consequences of CD38 
enzymatic function (since it has a major role in NAD consumption) on NAD-dependent 
processes, cell physiology and induction of cell proliferation in leukaemia, specifically in chronic 
lymphocytic leukaemia. The results in Chapters 4 and 6 provide positive data that support this 
hypothesis. The results confirmed that many processes were affected by CD38-mediated 
lowering of NAD levels. For example, glycolytic activity, which was reflected by reduced lactate 
production and a relatively constant NAD
+
: NADH ratio. This might directly affect cellular 
energy as the NAD
+
: NADH ratio is a measure of the energy status of a cell (Ying, 2006). 
Moreover, CD38 activity might also restrict NAD-dependent enzyme activities (PARP, sirtuin) 
and their dependent processes in the cells by limiting the substrate availability (NAD). These 
enzymes mediate important roles in modifying cellular functions such as genomic stability, 
apoptosis, cell signalling and stress tolerance (Malavasi et al., 2010). CD38 expression was 
accompanied by elevated lipid peroxidation (as assessed by TBARS) and low total glutathione 
levels, which represents the antioxidant status in the cells, suggesting that an imbalance between 
oxidant/antioxidant status was concomitant with CD38 expression. Collectively, these two 
results using differentiated HL60 cells support the third hypothesis. 
It is worth noting that ATRA-induced CD38 expression in HL60 cells has been shown to induce 
cell apoptosis (Mehta et al., 1996), despite a large decrease in intracellular NAD levels. One of 
the possible explanations for this is that ADP ribosylation of nuclear CD38 may trigger an 
induction of apoptosis in ATRA-treated HL60 cells (Yalcintepe et al., 2005). Similar results 
have been obtained in vivo to the effect of ATRA, in patients with acute promyelocytic 
leukaemia, but with a side effect known as an APL differentiation syndrome (Sanz et al., 2009). 
In other cells, however, CD38 has been attributed to different effects on cell growth; its cellular 
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effects have shown to be ambiguous, since CD38 expression was either a positive or negative 
regulator of induced cell differentiation and growth arrest, depending on the expression level per 
cell (Lamkin et al., 2006). For example, in 3T3 or HeLa cells, it promotes cell cycle progression 
(Zocchi et al., 1998), in B lymphocytes or T lymphocytes it can cause apoptosis (Kumagai et al., 
1995; Tenca et al., 2003), but in CLL, a B cell leukaemia, CD38 is an indicator of poor 
prognosis (Ghia et al., 2003). According to previous studies, CD38
+
 CLL clones show a 
resistance to apoptosis; this might be due to a decline in NAD levels that occur while CD38 
expression is upregulated. Hence, from the current data in differentiated HL60 cells, it is possible 
to suggest that leukemia cell survival might not be affected by NAD-depletion. Instead, cancer 
cells with low cellular ATP levels may show higher resistance to programmed cell death due to 
the high energetic requirements of apoptosis. The findings relating to the current hypothesis 
along with the previous hypotheses may provide a better understanding of the mechanism of 
resistance of leukemiacells to apoptosis. 
In cancer cells, the same basic metabolic pathways are utilized to generate energy as in normal 
cells, but some changes in a tumour microenvironment lead to protective metabolic adaptation 
(DeBerardinis, 2008; Semenza, 2008). For example, the cells in such an environment tend to use 
lactic fermentation in the absence of oxygen, which is a faster way to generate metabolic energy 
(Jones and Thompson, 2009). The main advantage of lactic fermentation is that ATP can be 
obtained at a faster rate through a simpler process (DeBerardini, 2008). Hence, cancer cells 
exhibit a high rate of NAD turnover due to a high glycolytic activity in addition to high levels of 
ADP-ribosylation activity (Gagne et al., 2006), resulting from PARP activation (required for 
DNA repair and genome stability). Thus, in cancer cells, low intracellular NAD levels may lead 
to a resistance to apoptosis and induce cell proliferation. Interestingly, in CD38 negative 
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leukaemia cells one might expect that the replenishment of NAD levels might relatively enhance 
the DNA repair process and control disease progression. However, the same effect might not be 
seen in leukaemia cells that express CD38, since NAD-depletion would have more impact on 
NAD-dependent process and cell survival. Thus, low NAD levels lead to a drop in ATP, the 
level of which is an important factor in the process of apoptosis. Moreover, the metabolic 
pathways that depend on NAD availability such as sirtuin and PARP would also be affected. 
Low intracellular NAD might lead to accumulation of damaged DNA that would further 
decrease NAD levels due to PARP hyperactivation. Altogether, a severe drop in NAD levels 
leads to a similar drop in the determinant factor of apoptotic cell death, ATP. Ultimately, these 
environments create cellular resistance to apoptosis, and also facilitate the cell proliferation 
process. It is worth noting that drug resistance in tumour cells is a common obstacle in cancer 
chemotherapy. Resistance includes decreased drug accumulation, intracellular drug 
detoxification, enhanced DNA repair/ tolerance and failure of apoptotic pathways (Fuertes et al., 
2003). Beyond NAD depletion, it has been suggested that highly resistant tumour cells may 
express different versions of caspases or they may contain endogenous caspase inhibitors that 
limit apoptotic cell death pathways (Schimmer et al., 2003). 
In conclusion, targeting CD38 enzymatic functions in leukemia therapy along with its receptor 
function might serve as a possible solution to apoptotic cell resistance or poor cell metabolism in 
leukemia patients, and that future studies should pay attention to the evaluation of intracellular 
NAD levels as well as CD38 expression levels as a marker for poor prognosis in leukemia 
patients. 
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7.2 Future studies 
One of the current treatments for leukaemia is a drug-based chemotherapy that uses one or more 
drugs to destroy cancer cells and induce apoptosis. However, this may be accompanied by the 
development of drug resistance and severe side effects (Libura et al., 2005; Mistry et al., 2005). 
Chemotherapeutic alkylating agents have been shown to cause miscoding lesions, chromosomal 
aberrations (Veld et al., 1997) and secondary cancer, particularly leukaemia. They may also 
depress NAD
+
 levels (Dreizen et al., 1990). For instance, the chemotherapeutic agents (e.g., 5-
fluorouracil, 6-mercaptopurine) interfere with the conversion of tryptophan to niacin (Stevens et 
al., 1993). Moreover, rat studies have shown that niacin deficiency significantly increases the 
risk of chemotherapeutic induced secondary leukaemia (Kirkland, 2003). Therefore, it is 
imperative to develop other potential therapeutic agents for the treatment of this disease. Thus, 
NAD metabolism has an important position in total cellular metabolism, because it has 
multifunctional roles as a cofactor for individual enzymes and as a substrate for NAD
+
-
consuming enzymes. It could pose an attractive target for the treatment of various pathologies, 
especially in the fields of CD38 biology, linked to the prevention of aging and its related diseases 
like obesity and cancer. The results obtained in the current study might successfully be applied in 
the field of cancer therapy and also open the door for future studies to further characterize the 
functional role of CD38-mediated NAD depletion in the development of leukaemia, for example 
if the observations obtained from a current study using the human leukaemia model (HL60) are 
confirmed in the context of leukaemia cells. If so, therapeutic strategies which target this 
CD38/NAD relationship, such as investigating the effect of manipulating NAD levels on 
prognosis in CD38
+
 leukemia patients, might be effective in fighting leukemia. However, several 
areas still need further investigation to clarify the precise effect of CD38 expression on the 
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nucleotide levels or on other NAD-dependent reactions. One of the important questions to be 
addressed is the levels of NADP in this situation; cADPR levels also need to be measured while 
NAD is consumed. If levels of this messenger decrease concomitantly with NAD levels, this 
raises further questions as to how CD38 induces proliferation signalling since, as previously 
mentioned, cADPR plays a role in the control of cell proliferation via Ca
2+
 signalling (Zupo et 
al., 1994; Hardingham et al., 1997). Similar investigations need to be focus on NAADP as a 
second messenger produced from its precursor, NADP. 
Moreover, according to the results obtained in Chapter 5, CD38 expression can be 
downregulated by adding NAD
+
 to the medium, or using FK866. It would therefore be tempting 
to investigate the mechanism of this inhibitory effect as a future study. It has previously been 
observed that in cancer cells DNA damage can stimulate NAD
+
 biosynthesis (Jacobson et al., 
1999), through upregulation of the expression of NAMPT (Van Beijnum et al., 2002), which is 
the rate-limiting enzyme in the salvage pathway from the breakdown product nicotinamide 
(Revollo et al., 2004). That suggests that NAMPT may be crucial in maintaining cellular NAD
+
 
levels in tumours. For that reason FK866, a potent inhibitor of human NAMPT, is used, and the 
consequent reduction in NAD
+
 levels has been seen to induce apoptosis of tumour cells 
(Hasmann, and Schemainda, 2003; Muruganandham et al., 2005). If a similar mechanism applies 
to the primary leukaemia cells (CD38
+
 cells), and according to the results in Chapter 5, then 
FK866 might serve as a useful therapeutic agent target for leukemia patients. This suggested 
study might succeed in the case of moderate DNA damage in cancer cells, since depletion of 
NAD levels and also CD38 expression by using FK866 might be a useful tool to induce 
apoptotic cell death. Interestingly, downregulation of CD38 expression might reduce its 
signalling effect on proliferation. Furthermore, it would be interesting to determine whether the 
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same process could apply to leukaemia patients by using NAD
+
 supplementation, since applying 
NAD
+
 has also been shown to downregulate CD38 expression (Chapter 5). An elevation of 
intracellular NAD levels through control of NAD homeostasis pathways, either via consuming 
enzyme pathways, or recycling pathways could heavily impact on metabolism, cellular viability 
and signalling pathways. In this situation, repletion of cellular NAD levels by adding NAD
+
 
directly to the culture medium with concomitant inhibition of CD38 expression might also lead 
to apoptotic cell death, since NAD levels are a determinant of cell survival. 
CD38, as a major NAD consumer enzyme in the cells, has developed from a mere marker to a 
disease modifier in leukemia. Thus, it is important to determine the role of other NAD consumers 
in modifying the environment or inducing proliferation signalling in cancer cells. Previously 
published studies observed that inhibition of PARP-1 in cancer cells exposed to DNA-damaging 
drugs would decrease DNA repair and would induce apoptotic cell death, and may also increase 
the sensitivity of tumour cells to DNA damaging antitumour drugs (Munoz-Gamez et al., 2005). 
Interestingly, this was more effective against tumour cells than against normal cells. However, in 
cancer cells that express CD38 the mechanism may be different, since NAD would be consumed 
by CD38 as the main NAD-degrading enzyme rather than PARP, and this might delay apoptotic 
cell death according to the results Chapter 6. Thus, utilizing CD38 inhibitors along with PARP 
inhibitors might elevate intracellular NAD levels and hence might also target apoptotic cell 
death. Furthermore, in the case of severe DNA damage combining intracellular NAD-elevating 
compounds (e.g. nicotinamide or NAD
+
) along with CD38 inhibitors and PARP inhibitors might 
serve as an excellent therapeutic approach for CD38
+ 
leukaemia patients, since elevation of 
intracellular NAD levels might help to induce apoptotic cell death. Indeed, the fact that NAD
+
 
levels could be elevated by selective inhibition of NAD
+
 consumers, PARPs or CD38 might lead 
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to the activation of other NAD
+ 
consumers, such as sirtuin. The latter enzyme has important 
functions such as gene silencing, longevity and genome stability (Zhang, 2003; Pillai et al., 
2005). Nevertheless, blockage or inhibition of one pathway of NAD
+
 consumption might cause 
potential side effects, as, for example, it has been suggested that SIRT1 and 2 are crucial 
antiapoptotic molecules in leukaemia cells and have a role in the development of cancer; thus, 
the SIRT inhibitor, sirtinol, effectively induced cell death and that may be a useful therapeutic 
agent for leukaemia (Peck et al., 2010). Therefore, further studies are still required to evaluate 
whether such a strategy may be of therapeutic value, or whether utilizing inhibitors of DNA 
repair pathways concomitant with the above suggestions could be an efficient strategy for cancer 
therapy. 
One of the fundamental problems of tumour cells is the phenomenon of lactic fermentation; the 
metabolic adaptation of cancer cells in response to hypoxia has been shown to be associated with 
reduced sensitivity to common anti-cancer agents (Xu et al., 2005). Thus, it has previously been 
suggested that targeting the glycolytic pathway might preferentially sensitize cancer cells to 
chemotherapeutic agents without significant toxicity to normal cells (Xu et al., 2005). Hence, in 
combination with the results in Chapter 5, CD38 expression has been seen to be upregulated 
under hypoxic conditions (specifically 2% O2). Therefore, it is worth investigating the role of 
CD38 in inducing cell proliferation under the same in vivo conditions by exposing the cells to a 
range of oxygen levels in order to characterize the enzymatic and receptor functions of CD38 in 
a hypoxic environment similar to that of cancer cells. 
Moreover, it is interesting to note that recently published studies by Vaisitti et al. (2011) found 
that CLL cells taken from patients died easily in culture and appeared to have severe 
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impairments in vital signalling pathways. One possible explanation is that CLL cells from 
patients are more dependent on the external environment and supporting signals from other cells 
in vivo (Vaisitti et al., 2010). This reflects a key role of the host environment in CLL progression 
and suggests that targeting the host might be a valuable therapeutic target. For instance, In 
addition to targeting CD38-mediated NAD depletion and its related processes, it would be 
interesting to target the non-substrate ligand for CD38, CD31. leukemia cells' resistance to 
apoptosis is probably due to CD38/CD31 interaction-mediated anti-apoptotic signals. Thus, 
targeting CD31/CD38 interaction and their proliferation signalling might also be a potential 
target in leukaemia, since CD38 receptor functions have a large signalling effect on proliferation 
in addition to its enzymatic functions. 
Finally, it would be interesting to investigate the role of CD38 expression leading to depletion of 
intracellular NAD and the consequences of this relationship in the development of other diseases 
beyond leukaemia such as obesity. CD38 expression is linked to obesity and it has been 
suggested CD38 deficiency has a key role in preventing the development of obesity following 
NAD elevation (Baur et al., 2006). Thus, future studies might target NAD levels through 
regulation of CD38 expression, such as combining CD38 inhibitors with NAD-elevation 
compounds which is also found to down regulate CD38 expression, as shown in the current 
study. 
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